This invention is directed generally to externally applied neural activation/stimulation for medical purposes.
Nerve disorders may result in loss of control of muscle and other body functions, loss of sensation, or pain. Surgical procedures and medications sometimes treat these disorders but have limitations. This invention pertains to a system for offering other options for treatment and improvement of function.
Inventions are directed to a controller for a patch that is externally applied to a user and activates/stimulates nerves of the user, under control of the controller, to provide improvements to bodily functions, including improvements in urinary voiding behaviors associated with an overactive bladder (“OAB”).
Patch 100 can be any type of device that can be fixedly attached to a user and includes a processor/controller and instructions that are executed by the processor, or a hardware implementation without software instructions, and communication elements to provide communications with the controller disclosed below. Patch 100 can also include additional components that provide topical nerve stimulation on the user to provide benefits to the user, including bladder management for an overactive bladder, such as electrodes, sensors, a battery, adhesive, a control unit, an electronic integrated package, stimulators, etc.
Patch 100 in one example can include a flexible substrate, a malleable dermis conforming bottom surface of the substrate including adhesive and adapted to contact the dermis, a flexible top outer surface of the substrate approximately parallel to the bottom surface, one or more electrodes positioned on the patch proximal to the bottom surface and located beneath the top outer surface and directly contacting the flexible substrate, electronic circuitry embedded in the patch and located beneath the top outer surface and integrated as a system on a chip that is directly contacting the flexible substrate, the electronic circuitry integrated as the system on the chip and including an electrical signal generator integral to the malleable dermis conforming bottom surface configured to electrically activate the one or more electrodes, a signal activator coupled to the electrical signal generator, a nerve stimulation sensor that provides feedback in response to a stimulation of one or more nerves, an antenna configured to communicate with a remote activation device, a power source in electrical communication with the electrical signal generator, and the signal activator, where the signal activator is configured to activate in response to receipt of a communication with the activation device by the antenna and the electrical signal generator configured to generate one or more electrical stimuli in response to activation by the signal activator, and the electrical stimuli configured to activate/stimulate one or more nerves of a user wearing patch 100 at least at one location proximate to patch 100. Additional details of examples of patch 100 are disclosed in U.S. Pat. No. 10,016,600, entitled “Topical Neurological Stimulation”, the disclosure of which is hereby incorporated by reference.
In addition to the above, patch 100 includes one or more of a digital identity 120, a digital serial number 122, and a physical serial number 124 (generally referred to as an “identity”) that provides a unique digital identity.
The user is a person using smart patch 100 by applying it to their left or right ankle according to the instructions for use provided with smart patch 100 in some examples.
Smart patch 100 generates a stimulation event, during which a transcutaneous electrical neurostimulation (“TENS”) signal or other type of electrical signal, or “electrical stimuli”, is sent into the user where smart patch 100 has been applied to the skin, the signal being sent to defer the user's urge to urinate in examples. In one example, the electrical stimuli has a duration of approximately 10 seconds. In another example, the electrical stimuli includes square waves having an amplitude between 10 and 100 volts, pulse widths between 100 and 500 microseconds, and a pulse repetition rate of between 3 and 30 pulses per second. In another example, the electrical stimuli includes voltage-regulated square waves having frequencies between 10 Hz and 50 Hz, and having currents between 20 mA and 200 mA.
A leak event is an occasion in which the user passes some urine after feeling the urge to urinate and failing to suppress that urge through the use of one or more stimulation events.
A no leak event is an occasion in which the user passes no urine after feeling the urge to urinate and succeeding at suppressing that urge through the use of one of more stimulation events.
Stimulation strength is the amplitude of the electrical signal created during a stimulation event, this amplitude being adjustable by the user or automatically adjusted based on feedback.
In examples, recognition signaling is the wireless signaling protocol transmitted and received between device 200 and patch 100 according to the communication protocol selected by the two devices, this protocol being used by smart input device 200 to detect a smart patch 100, in some instances out of multiple available smart patches 100. The communication protocol is also used for the exchange of data between the smart input device 200 and smart patch 100, this protocol being used by smart input device 200 to recognize a smart patch 100, and a smart patch 100 to recognize a smart input device 200.
Activation range is the distance over which the user is able to succeed at connecting smart input device 200 to smart patch 100, this distance being a function of at least the signaling protocol, the physical distance between smart input device 200 and smart patch 100, and materials in between smart input device 200 and smart patch 100, which may impede the signal.
Smart patch power level is the measure of power remaining in smart patch 100.
In some examples, smart input device 200 and smart patch 100 use Bluetooth Low Energy (“BLE”) signaling protocol to communicate. In other examples, other wireless communication methods can be used, such as Bluetooth based communications in all its other variations, Wi-Fi, or other RF means.
In some examples, the communication protocol activates smart input device 200 and smart patch 100 act as controller and peripheral, respectively. Communications are initiated between smart input device 200 and smart patch 100 by smart input device 200, and smart patch 100 responds only when the communication is initiated by smart input device 200, this priority being used to conserve the power used in smart patch 100 over time.
In some examples, smart input device 200 is used by the user to trigger a stimulation event. In some examples, smart input device 200 is used by the user to stop a stimulation event.
The user begins the use of smart patch 100 with smart input device 200 by launching or initiating control machine 300 on smart input device 200, in one example as an app.
In some examples, control machine 300 opens onto display 212, showing start button 310, stop button 312, increase button 314, decrease button 316, connection icon 320, lock icon 322, status display 330 and status indicator 340. In some examples, control machine 300 may include only a status indicator 340 and no separate status display 330.
In some examples, control machine 300 may display only connection icon 320, or only lock icon 322, or neither of these icons, the values for these functions being available to the user by pressing or tapping on menu button 350, and then selecting the option to view the control machine's settings.
In some examples, control machine 300 indicates changes of status to the user by outputting a sound or sounds from speaker 220 or a vibration using an actuator. In some examples, control machine 300 additionally shows leak button 360 and no leak button 362. In some examples, control machine 300 shows intensity slider 370 in place of increase button 314 and decrease button 316.
In some examples, the user creates a communication connection, referred to as an “initialization,” from smart input device 200 to smart patch 100 by placing smart input device 200 within the activation range of smart patch 100. Smart patch 100 detects the recognition signaling from smart input device 200, and smart patch 100 responds by signaling to smart input device 200 with its digital identity 120. Smart input device 200 detects this response signal and checks the digital identity 120. If digital identity 120 matches that of a known type of smart patch 100, then smart input device 200 initiates a connection according to the protocols appropriate to the wireless link between itself and the recognized smart patch 100.
In some examples, each manufactured unit of smart patch 100 includes a unique digital serial number 122, the digital serial number being a sequence of alphanumeric characters or a numerical value in a digitally encoded form. Smart input device 200 identifies smart patch 100 as not only the appropriate device but also checks the smart patch's digital serial number. If more than one smart patch 100 is detected within range by smart input device 200, then smart input device 200 connects to smart patch 100 with the unique digital serial number 122 value matching that of smart patch 100 to which smart input device 200 was most recently connected. If the identification does not match the value of the most recently connected smart patch 100, then smart input device 200 checks the value against the list of digital serial number 122 values for each smart patch 100 to which it had previously been connected, and then connects to the smart patch 100 having digital serial number 122 matched first on the list, sequentially looking further back into its history of connections. If none of the detected smart patch's 100 unique digital serial numbers 122 match the identification value for any previously-connected smart patch 100 for smart input device 200, then smart input device 200 connects to the first smart patch 100 on the list of detected smart patches 100, assuming the first or any subsequent patches are powered up.
In some examples, the identity checking between smart input device 200 and smart patch 100 may allow for multiple values of digital identity 120, such that multiple distinct types of smart patches 100 may interconnect with smart input device 200.
In some examples, variations on the priority scheme for connecting to one of many detected smart patches 100 may be used by smart input device 200. For example, smart input device 200, having estimated the distance to each detected smart patch 100, may attempt to connect to the closest detected smart patch 100, then the next closest, then continuing down the list of detected smart patches 100 until smart input device 200 has attempted to connect to each detected smart patch 100.
If smart input device 200, when placed within activation range of the smart patch 100, fails to detect a response signal from any device within a time limit set in the configuration of smart input device 200, then smart input device 200 indicates to the user this failure to establish a link.
If smart input device 200 is not placed within activation range of any smart patch 100, then smart input device 200 indicates to the user this failure to detect any smart patches 100.
In some examples, smart input device 200 includes a digital identification code that is unique to the one specific smart input device 200, and it sends this digital identification code to smart patch 100 as part of the initialization process, this unique digital identification code being a sequence of alphanumeric characters or a numerical value in a digitally encoded form.
In some examples, smart input device 200 controls the activation range by limiting detection of nearby smart patches 100 to those smart patches 100 within the activation range, even if the signaling protocol recognizes more smart patches 100 with adequate signal to complete the signaling protocol. By limiting the activation range, smart input device 200 prevents smart patches 100 on second and subsequent users near to smart input device 200, but outside the activation range, from being connected inadvertently to the smart input device 200.
In some examples, if smart patch 100 is placed within the activation range of more than one smart input device 200, then control machine 300 running on each of those smart input devices 200 arbitrates for only one smart input device 200 to connect to the smart patch, since a smart patch 100 may be connected to only one smart input device 200 at a time. In some examples, the user on each of smart input devices 200 is prompted on status display 330 to initiate a connection attempt. In some examples, the smart input device 200 closest in distance to smart patch 100 has priority in connecting to smart patch 100. In some examples, the smart input device 200 prioritizes connection to use one of the previously-connected smart patches 100.
In some examples, the indication to the user is a message displayed on the screen of smart input device 200, using one or more of connection icon 320, lock icon 322, and status display 330.
In some examples, the indication to the user is an illumination of status indicator 340, with an illumination pattern or time sequence different from illumination in the connected condition.
In some examples, the indication to the user is an audible signal through speaker 220, with a tone or sequence of tones different from the tone or tones used in the connected condition, or a vibration.
In some examples, smart input device 200 disconnects from smart patch 100 to which smart input device 200 had been connected by moving control machine 300 on smart input device 200 to the background, out of view on display 212.
In some examples, smart input device 200 disconnects from smart patch 100 to which smart input device 200 had been connected by exiting control machine 300 on smart input device 200.
In some examples, smart input device 200 disconnects from smart patch 100 to which smart input device 200 had been connected when power is turned off on smart input device 200 with power button 214.
In some examples, when smart input device 200 disconnects smart patch 100, smart input device 200 saves the settings used with that smart patch 100. The settings may include one or more of the smart patch 100's digital identity 120, the smart patch 100's digital serial number 122, the activation/stimulation strength, and the time at which the last stimulation event was applied.
In some examples, when a smart input device 200 which has saved one or more settings from one connected state to a smart patch 100 is later connected to the same or a different smart patch 100, the smart input device 200 applies one or more of the saved settings to the established connection to a smart patch 100. In such an example, the user may not be required to re-establish a stimulation strength setting for stimulation events, since the smart input device will use the stimulation strength setting saved from the previous connection to a smart patch.
In some examples, smart input device 200 uses previously-saved settings for a connection to a smart patch 100 only when one or more of digital identity 120 and digital serial number 122 of the smart patch in the new connection is identical to the digital identity and digital serial number of the smart patch in the prior connection. In such an example, when the digital identities do not match, the smart input device connects in a mode which requires a new initialization by the user.
In some examples, smart input patch 100 stores a unique digital identification value for each of the one or more smart input devices 200 to which it is or has been connected. When smart patch 100 is disconnected from smart input device 200, then later a new connection is attempted when the smart patch comes into proximity of a smart input device 200, smart patch 100 checks the digital identity received from smart input device 200 with each stored digital identity. If the digital identity of smart input device 200 matches the value of one of the stored digital identities, then smart patch 100 allows the connection request from smart input device 200 to proceed, and a connection is completed. If the digital identity of smart input device 200 does not match any of the values of those stored digital identities in smart patch 100, then smart patch 100 may prevent the connection request from smart input device 200 from succeeding.
A stimulation event requires a stimulation strength adequate to stimulate the nerve through the tissue from the external electrode in smart patch 100. The stimulation strength is increased or decreased to adjust to changes in the impedance of the tissue, or to counter inaccurate placement of the patch on the user's skin. Therefore, the stimulation strength may need to be stronger or weaker when moving from one smart patch to a new smart patch, or from one placement of a smart patch to an adjusted placement of the smart patch, or from one usage on skin of one condition, such as dry skin, to a new usage on skin of a different condition, such as moist skin.
In some examples, smart input device 200 is used by the user to set the stimulation strength of the electrical activation/stimulation for stimulation events. The user presses or taps increase button 314 or decrease button 316 to increase or decrease the stimulation strength, respectively. Smart input device 200 sets an upper maximum limit to the stimulation strength, and a lower minimum limit to the stimulation strength, such that any increase button 314 presses or taps to increase beyond the maximum limit have no effect, and such that any decrease button 316 presses or taps to decrease beyond the minimum limit have no effect.
In some examples, smart input device 200 provides an intensity slider 370 such that the user may increase or decrease the activation/stimulation strength by sliding a finger along intensity slider 370, this function being equivalent to pressing or tapping on increase button 314 or decrease button 316, the stimulation strength being constrained to between a minimum value and a maximum value.
In some examples, the range of stimulation strength is displayed to the user in terms of a minimum and maximum numerical limit. In some examples, the range of stimulation strength is displayed to the user in terms of a percentage of the allowed numerical range, with a minimum percentage limit and a maximum percentage limit. In some examples, smart input device 200 indicates to the user the current stimulation strength on the smart input device's status display 330.
In some examples, the user may lock the stimulation strength setting by pressing or tapping lock icon 322 on smart input device 200, such that subsequent presses or taps on increase button 314 or decrease button 316 have no effect on the stimulation strength until lock icon 322 is used again to unlock the setting.
In some examples, smart input device 200 indicates to the user the lock or unlock state of the settings on the smart input device's status display 330 using one or more of a change of icon, a change of text message, or a change of color. For example, an icon may change from red to green to indicate a change from inactive state represented by that icon to an active state.
In some examples, the user presses or taps start button 310 on smart input device 200 to begin a stimulation event. In some examples, the user presses or taps stop button 312 to end a stimulation event. In some examples, the stimulation event continues from the press or tap the start button 310 until the stimulation event ends at a preset timer value, this preset value being defined in control machine 300.
In some examples, the stimulation event begins when the user presses or taps on increase button 314 or decrease button 316, the stimulation strength for that stimulation event being adjusted to the value indicated by the use of the increase button or the decrease button. In some examples, the stimulation event does not begin with the press or tap of increase button 314 or decrease button 316, but instead begins with the press or tap of start button 310.
In some examples, the stimulation strength used by smart patch 100 is set using the stimulation strength set for the previously-connected smart patch 100, the value of the stimulation strength being saved in one or both of control machine 300 on smart input device 200, and smart patch 100. The user's first use of start button 310 after affixing a new smart patch to the skin and establishing a connection to it from smart input device 200 may initiate a stimulation event with the stimulation strength of the previously-connected smart patch. The use of the previously-set stimulation strength requires fewer user operations such as button presses or taps than requiring the user to adjust the stimulation strength beginning at the default value each time a new smart patch is applied. A change in the condition of the skin or in the positioning of the newly-applied smart patch may cause the previously-connected stimulation strength to be inconsistent with the optimum strength for the newly-attached smart patch.
In some examples, the stimulation strength used by smart patch 100 is set using the default value set in control machine 300. The user's first use of start button 310 after applying a new smart patch 100 and establishing a connection to it from smart input device 200 may initiate a stimulation event with the stimulation strength at the default value. If the skin condition or the position of the newly-attached smart patch differ from the conditions for the previously-connected smart patch, then beginning after affixing a new smart patch to the skin with the use of the default stimulation strength reduces the chance of using a stimulation strength inappropriate for the conditions with the newly-attached smart patch.
In some examples, after the user applies a new smart patch 100, the user may be prompted to choose between to begin use of the new smart patch 100 at the default stimulation strength, or to begin use of the new smart patch 100 at the stimulation strength set by the previously-connected smart patch. In some examples, the user may be able to save this choice as part of the settings within control machine 300.
In some examples, the user presses or taps leak button 360 to indicate to control machine 300 that the user has not successfully suppressed the urge to urinate by applying a stimulation event with smart patch 100. Control machine 300 records/saves this leak event for later review and analysis. In some examples, the user presses or taps no leak button 362 to indicate to control machine 300 that the user has successfully suppressed the urge to urinate by applying a stimulation event with smart patch 100. Control machine 300 records/saves this no leak event for later review and analysis.
In some examples, the indication to the user of a detected smart patch 100 is an illumination of status indicator 340, with an illumination pattern or time sequence different from illumination in the connected condition. In some examples, the indication to the user of a detected smart patch 100 is an audible signal through speaker 220, with a tone or sequence of tones different from the tone or tones used in the connected condition or a vibration.
In some examples, the user begins in control machine 300 at disconnected state 400 at
In some examples, the inactive state of one or more buttons or indicators of control machine 300 is indicated by changing the colors of those user interface elements to a monochrome shading, or to a color designated in the user guide as the color of inactive elements, or by changing the borders or size of the elements.
In some examples, the user presses or taps on start/state button 310 on the disconnected state 400 display. Control machine 300 proceeds to a searching state 440 and the display changes to indicate on state button 310 that the control machine is using its signaling protocol to search for one or more smart patches 100. Control machine 300, on detecting one or more smart patches, proceeds to a found state 450 which changes the display to indicate on state button 310 that one or more smart patches has been found.
In some examples, the user presses or taps on connection icon 320 on disconnected state 400 display. Control machine 300 proceeds to searching state 440 (
In some examples, when the smart input device 200 is in the disconnected state 400, the user may press or tap on connection icon 320 to initiate a new search for nearby smart patches 100.
In some examples, the user presses or taps on state button 310 when the control machine 300 is in found state 450, and state button 310 indicates that one or more smart patches 100 has been detected but not connected (
In some examples, control machine 300 is in the connections state 500 but is unable to connect with any listed smart patch 100, in which case the connection icon 320 is colored or otherwise shown distinctively to indicate that there is no connection to a smart patch. The user may press connection icon 320 to initiate a repeat of the search for nearby smart patches.
In some examples, the connection attempt may be unsuccessful as a result of smart patch 100 failing to identify smart input device 200 using the smart input device's unique digital identification, in the case when smart patch 100 stores the values of the one or more smart digital devices 200 to which it was previously connected, yet it cannot find the digital identification of smart input device 200 currently attempting to connect. When the connection attempt fails for this reason, control machine 300 may move to a rejected state 460 (
In some examples, if the user makes no selection of a smart patch 100, and the user does not press or tap done button 530, and a timer set by control machine 300 expires, then control machine 300 returns to disconnected state 400, leaving the connection icon 320 set to show a disconnected state and state button 310 to indicate no connection.
In the connected state 600, lock icon 322, decrease button 312, increase button 314, state button 310, stop button 312, leak button 360, no leak button 362 are all active and respond to the user's press or tap.
In some examples, control machine 300 in connected state 600 shows the smart patch power level in the connected smart patch 100 using patch power level indicator 330, changing the appearance of that indicator to show when the smart patch power level is low such that the user should remove the connected smart patch 100 from ankle 110, and apply a new smart patch 100.
In some examples, control machine 300 in connected state 600 shows the current stimulation strength and makes active state button 310, stop button 312, increase button 314, decrease button 316, such that the user may press or tap on any of these buttons to initiate that button's function. Control machine 300 indicates a state of readiness to perform a stimulation event by labeling the state button with “start”, or similar label.
In some examples, control machine 300 in the connected state 600 returns to disconnected state 400 when the user initiates a stimulation event and the connection between smart input device 200 and smart patch 100 is interrupted.
In some examples, control machine 300 in connected state 600 shows lock icon 322 to indicate the locked or unlocked state of the stimulation strength in connected smart patch 100.
In some examples, control machine 300 in the connected state 600 makes active leak button 360 and no leak button 362 (as shown in
In some examples, control machine 300 in connected state 600 with smart patch 100 reads data from the smart patch, including one or more of current stimulation strength, current state of the smart patch, such as “stimulating” or “waiting”, and current smart patch power level.
In some examples, instead of using control machine 300 as the remote controller for patch 100, a dedicated fob is used.
In some examples, fob 1200 is used by the user to trigger a stimulation event. In some examples, fob 1200 is used by the user to stop a stimulation event.
The user begins the use of smart patch 100 with fob 1200 by removing battery activation tab 1210 from fob 1200.
In some examples, fob 1200 indicates to the user that the power level inside fob 1200 is insufficient for proper operation, using status indicator 1230 with a distinctive illumination pattern.
In general, fob 1200 interfaces and interacts with smart patch 100 in a similar manner as disclosed above in connection with smart input device 200, and where relevant, the description of functionality of smart input device 200 also applies to the functionality of fob 1200.
If fob 1200, when placed within the activation range of smart patch 100, fails to detect a response signal from any device within a time limit set in the configuration of fob 1200, then fob 1200 indicates to the user this failure to establish a link. In some examples, fob 1200 indicates this failure to link using a distinctive sequence of on and off illuminations of status indicator 1230, or a change in color of status indicator 1230, or a combination of both.
If fob 1200 is not placed within the activation range of any smart patches 100, then fob 1200 indicates to the user this failure to detect any smart patches 100. In some examples, fob 1200 indicates this failure to detect using a distinctive sequence of on and off illuminations of status indicator 1230, or a change in color of status indicator 1230, or a combination of both, this sequence or color change being different from that used to indicate other modes of fob 1200.
In some examples, the user presses pair button 1224 on fob 1200 to initiate an attempt to connect fob 1200 to smart patch 100.
In some examples, when fob 1200 indicates its detection of more than one smart patch 100, the user presses supplemental button 130 on the detected smart patch 100 to which the user wants to connect, this pressing to continue for a length of time at least as specified in the user instructions, such as for four seconds. This pressing action is recognized by the selected smart patch, the smart patch in turn sending this indication to fob 1200. Fob 1200, recognizing one of the many detected smart patches 100 to be the one to which the user wants to connect, continues the connection process with that smart patch 100, ignoring other detected smart patches 100, by requiring a continuous pressing of the supplemental button. The smart patch ignores pressings shorter than the minimum duration such as may occur when the smart patch is being applied to, or removed from the skin.
In some examples, supplemental button 130 is a capacitive button, sealed inside smart patch 100 such that the environmental integrity of the smart patch is not affected by the interior supplemental button circuit.
In some examples, supplemental button 130 has no effect on the smart patch 100 state except when smart patch 100 is both powered on and in the process of completing a connection with fob 1200. Smart patch 100 ignores pressings of supplemental button 130 when smart patch 100 is either powered off or not in the process of completing a connection with fob 1200. Such pressings may occur when the supplemental button is pressed by clothing or other exterior objects.
In connection with pairing either smart input device 200 or fob 1200 (generally referred to as the “controller”), examples determine distance between patch 100 and smart input device 200 or fob 1200. In a fob example (which equally applies to smart input device 200), the distance is determined using BLE and the Received Signal Strength Indicator (“RSSI”). Fob 1200 will attempt to pair with a smart patch 100 it detects with the strongest RSSI signal, only if the smart patch 100 is within 2 feet or some other predefined distance.
After fob 1200 pairs with a smart patch 100, that connection is “latched”. Fob 1200 will pair with no other smart patch 100. Smart patch 100 will pair with no other fob 1200. Each device “remembers” the unique ID of the device with which it is paired.
If the BLE connection is broken, fob 1200 will attempt to pair again, but may only complete a pairing with the patch 100 it had been paired to before the connection was broken. Other patches that may reply to the “ping” of fob 1200 searching for its partner will not be recognized by the fob software in the event of a broken connection.
Fob 1200 pings the patch periodically as a kind of “heartbeat” to make sure that the patch is still there. Therefore, fob 1200 knows within a margin of error that smart patch 100 is still there. This avoids fob 1200 having to initiate a new pairing when the user presses the START button for a stimulation (i.e., when smart patch 100 provides neural stimulation). The stimulation can begin immediately, without the “5 second” delay or other predefined amount of delay needed to complete a pairing sequence. Users do not want a delay of several seconds when they press START and expect the stimulation to start right away.
In some examples, if fob 1200 detects that it has a low battery level, it saves the ID information, state and strength of the connected patch 100. This data is saved into nonvolatile memory in fob 1200. The power for fob 1200 can then be fixed. Fob 1200 can then immediately re-pair with the patch it used before, assumed still to be in range and on the user.
If fob 1200 fails to pair with a smart patch 100, then fob 1200 tries again. This is useful when a patch moves out of range of its fob 1200. This is repeated, but the time between attempts increases slowly, to the point where fob 1200 gives up. This saves power by reducing the number of “pings.” If a ping is successful, then fob 1200 checks the ID of that smart patch 100, and the smart patch 100 checks the ID of fob 1200. If they are as remembered from the most recent paired condition, then the connection is reinstated.
In some examples, fob 1200 when connected with smart patch 100 reads data from smart patch 100, including one or more of current stimulation strength, current state of the smart patch, such as “stimulating” or “waiting”, and current smart patch power level.
In some examples, fob 1200 uses status indicator 1230 that is capable of displaying multiple colors, such that fob 1200 selects timing of illuminations and the selection of color to indicate a set of status conditions, such as flashing red 10 seconds to indicate waiting to connect; solid red 5 seconds to indicate connection failure or no smart patch 100 found; alternating green and red to indicate moving fob 1200 closer to the smart patch 100 to connect; flashing green to indicate negotiating connection; solid green 5 seconds to indicate connection complete/ready to activate; flashing yellow to indicate multiple smart patch devices within activation range; alternating red and yellow to indicate low fob battery; the times for maintaining a color and for alternating colors selected to provide ease of recognition by the user, these times being set by timers in fob 1200.
In some examples, both fob 1200 and smart input device 200 may be connected at the same time to a smart patch 100. This may provide advantages in, for example, a medical care facility where a user and caretaker both have the ability to start/stop stimulation.
In some examples, both fob 1200 and smart input device 200 may records user data that can be saved for later data analytics. The data can include stimulation events, charge levels, time between stimulation events, etc.
Adaptive Circuit and Protocol
In the examples of smart patch 100 disclosed above, when being used for therapeutic treatment such as bladder management for OAB or other medical treatments, there is a need to control the voltage by boosting the voltage to a selected level and providing the same level of charge upon activation to a mammalian nerve. Further, there is a need to conserve battery life by selectively using battery power. Further, there is a need to create a compact electronics package to facilitate mounting the electronics package on a relatively small mammalian dermal patch in the range of the size of an ordinary adhesive bandage. In general, the disclosed voltage levels are peak-to-peak voltage levels. As disclosed, smart input device 200 and/or fob 1200 provide remote control of smart patch 100, including manually controlled start/stop of activation/stimulation, and manual control of the strength of the activation/stimulation. However, in some examples, aspects of the current applied to the nerve are automatically adjusted based on feedback.
To meet the above needs, examples implement a novel boosted voltage circuit a part of smart patch 100 that includes a feedback circuit and a charge application circuit.
Boost voltage circuit 1300 can replace an independent analog-controlled boost regulator by using a digital control loop to create a regulated voltage, output voltage 1350, from the battery source. Output voltage 1350 is provided as an input voltage to charge application circuit 1400. In examples, this voltage provides nerve stimulation currents through the dermis/skin to deliver therapy for an overactive bladder. Output voltage 1350, or “VBoost”, at voltage output node 1350, uses two digital feedback paths 1320, 1330, through controller 1370. In each of these paths, controller 1370 uses sequences of instructions to interpret the measured voltages at voltage monitor 1326, or “VADC”, and current monitor 1334, or “IADC”, and determines the proper output control for accurate and stable output voltage 1350.
Boost voltage circuit 1300 includes an inductor 1312, a diode 1314, a capacitor 1316 that together implement a boosted converter circuit 1310. A voltage monitoring circuit 1320 includes a resistor divider formed by a top resistor 1322, or “RT”, a bottom resistor 1324, or “RB” and voltage monitor 1326. A current monitoring circuit 1330 includes a current measuring resistor 1332, or “RI” and current monitor 1334. A pulse width modulation (“PWM”) circuit 1340 includes a field-effect transistor (“FET”) switch 1342, and a PWM driver 1344. Output voltage 1350 functions as a sink for the electrical energy. An input voltage 1360, or “VBAT”, is the source for the electrical energy.
PWM circuit 1340 alters the “on” time within a digital square wave, fixed frequency signal to change the ratio of time that a power switch is commanded to be “on” versus “off.” In boosted voltage circuit 1300, PWM driver 1344 drives FET switch 1342 to “on” and “off” states.
In operation, when FET switch 1342 is on, i.e., conducting, the drain of FET switch 1342 is brought down to Ground/GND or ground node 1372. FET switch 1342 remains on until its current reaches a level selected by controller 1370 acting as a servo controller. This current is measured as a representative voltage on current measuring resistor 1332 detected by current monitor 1334. Due to the inductance of inductor 1312, energy is stored in the magnetic field within inductor 1312. The current flows through current measuring resistor 1332 to ground until FET switch 1342 is opened by PWM driver 1344.
When the intended pulse width duration is achieved, controller 1370 turns off FET switch 1342. The current in inductor 1312 reroutes from FET switch 1342 to diode 1314, causing diode 1314 to forward current. Diode 1314 charges capacitor 1316. Therefore, the voltage level at capacitor 1316 is controlled by controller 1370.
Output voltage 1350 is controlled using an outer servo loop of voltage monitor 1326 and controller 1370. Output voltage 1350 is measured by the resistor divider using top resistor 1322, bottom resistor 1324, and voltage monitor 1326. The values of top resistor 1322 and bottom resistor 1324 are selected to keep the voltage across bottom resistor 1324 within the monitoring range of voltage monitor 1326. Controller 1370 monitors the output value from voltage monitor 1326.
Charge application circuit 1400 includes a pulse application circuit 1410 that includes an enable switch 1414. Controller 1370 does not allow enable switch 1414 to turn on unless output voltage 1350 is within a desired upper and lower range of the desired value of output voltage 1350. Pulse application circuit 1410 is operated by controller 1370 by asserting an enable signal 1412, or “VSW”, which turns on enable switch 1414 to pass the electrical energy represented by output voltage 1350 through electrodes 1420. At the same time, controller 1370 continues to monitor output voltage 1350 and controls PWM driver 1344 to switch FET switch 1342 on and off and to maintain capacitor 1316 to the desired value of output voltage 1350.
The stability of output voltage 1350 can be increased by an optional inner feedback loop through FET Switch 1342, current measuring resistor 1332, and current monitor 1334. Controller 1370 monitors the output value from current monitor 1334 at a faster rate than the monitoring on voltage monitor 1326 so that the variations in the voltages achieved at the cathode of diode 1314 are minimized, thereby improving control of the voltage swing and load sensitivity of output voltage 1350.
In one example, a voltage doubler circuit is added to boosted voltage circuit 1300 to double the high voltage output or to reduce voltage stress on FET 1342. The voltage doubler circuit builds charge in a transfer capacitor when FET 1342 is turned on and adds voltage to the output of boosted voltage circuit 1300 when FET 1342 is turned off.
As described, in examples, controller 1370 uses multiple feedback loops to adjust the duty cycle of PWM driver 1344 to create a stable output voltage 1350 across a range of values. Controller 1370 uses multiple feedback loops and monitoring circuit parameters to control output voltage 1350 and to evaluate a proper function of the hardware. Controller 1370 acts on the feedback and monitoring values in order to provide improved patient safety and reduced electrical hazard by disabling incorrect electrical functions.
In some examples, controller 1370 implements the monitoring instructions in firmware or software code. In some examples, controller 1370 implements the monitoring instructions in a hardware state machine. The firmware may communicate an electrical hazard to the APP or Fob via a BLE notification of a state change from ON/OFF to DEAD.
In some examples, voltage monitor 1326 is an internal feature of controller 1370. In some examples, voltage monitor 1326 is an external component, which delivers its digital output value to a digital input port of controller 1370.
In some examples, current monitor 1334 is an internal feature of controller 1370. In some examples, current monitor 1334 is an external component, which delivers its digital output value to a digital input port of controller 1370.
An advantage of boosted voltage circuit 1300 over known circuits is decreased component count which may result in reduced costs, reduced circuit board size and higher reliability. Further, boosted voltage circuit 1300 provides for centralized processing of all feedback data which leads to faster response to malfunctions. Further, boosted voltage circuit 1300 controls outflow current from VBAT 1360, which increases the battery's lifetime and reliability.
The pulse width modulation of FET switch 1342 is controlled by one or more pulses for which the setting of each pulse width allows more or less charge to accumulate as a voltage at capacitor 1316 through diode 1314. This pulse width setting is referred to as the ramp strength and it is initialized at 2810. Controller 1370 enables each pulse group in sequence with a pre-determined pulse width, one stage at a time, using a stage index that is initialized at 2812. The desired ramp strength is converted to a pulse width at 2824, which enables and disables FET switch 1342 according to the pulse width. During the intervals when FET switch 1342 is “on”, the current is measured by current monitor 1334 at 2830 and checked against the expected value at 2836. When the current reaches the expected value, the stage is complete and the stage index is incremented at 2840. If the desired number of stages have been applied 2842, then the functionality is complete. Otherwise, the functionality continues to the next stage at 2820.
As a result of the functionality of
An open loop protocol to control current to electrodes in known neural stimulation devices does not have feedback controls. It commands a voltage to be set, but does not check the actual current delivered. A stimulation pulse is sent based on preset parameters and cannot be modified based on feedback from the patient's anatomy. When the device is removed and repositioned, the electrode placement varies. Also the humidity and temperature of the anatomy changes throughout the day. All these factors affect the actual charge delivery if the voltage is preset. Charge control is a patient safety feature and facilitates an improvement in patient comfort, treatment consistency and efficacy of treatment.
In contrast, examples of smart patch 100 includes features that address these shortcomings using controller 1370 to regulate the charge applied by electrodes 1420. Controller 1370 samples the voltage of the stimulation waveform, providing feedback and impedance calculations for an adaptive protocol to modify the stimulation waveform in real time. The current delivered to the anatomy by the stimulation waveform is integrated using a differential integrator and sampled and then summed to determine the actual charge delivered to the user for a treatment, such as Overactive Bladder (“OAB”) treatment. After every pulse in a stimulation event, this data is analyzed and used to modify, in real time, subsequent pulses.
This hardware adaptation allows a firmware protocol to implement the adaptive protocol. This protocol regulates the charge applied to the body by changing output voltage (“VBOOST”) 1350. A treatment is performed by a sequence of periodic pulses, which deliver charge into the body through electrodes 1420. Some of the parameters of the treatment are fixed and some are user adjustable. The strength, duration and frequency may be user adjustable. The user may adjust these parameters as necessary for comfort and efficacy. The strength may be lowered if there is discomfort and raised if nothing is felt. The duration can be increased if the maximum acceptable strength results in an ineffective treatment.
A flow diagram in accordance with one example of the adaptive protocol disclosed above is shown in
The mathematical expression of this protocol is as follows:
Qtarget=Qtarget (A*dS+B*dT), where A is the Strength Coefficient—determined empirically, dS is the user change in Strength, B is the Duration Coefficient—determined empirically, and dT is the user change in Duration.
The adaptive protocol includes two phases in one example: Acquisition phase 501 and Reproduction phase 520. Any change in user parameters places the adaptive protocol in the Acquisition phase. When the first treatment is started, a new baseline charge is computed based on the new parameters. At a new acquisition phase at 502, all data from the previous charge application is discarded. In one example, 502 indicates the first time for the current usage where the user places the patch on a portion of the body and manually adjusts the charge level, which is a series of charge pulses, until it feels suitable, or any time the charge level is changed, either manually or automatically. The treatment then starts. The mathematical expression of this function of the application of a charge is as follows: The charge delivered in a treatment is
Where T is the duration; f is the frequency of “Rep Rate”; Qpulse (i) is the measured charge delivered by Pulse (i) in the treatment pulse train provided as a voltage MON_CURRENT that is the result of a Differential Integrator circuit shown in
As shown in of
In some examples, Analog to Digital Conversion 710 is an internal feature of controller 1370. In some examples, Analog to Digital Conversion 710 is an external component, which delivers its digital output value to a digital input port on Controller 1370.
At 504 and 506, every pulse is sampled. In one example, the functionality of 504 and 506 lasts for 10 seconds with a pulse rate of 20 Hz, which can be considered a full treatment cycle. The result of Acquisition phase 501 is the target pulse charge of Qtarget.
The reproduction phase 520 begins in one example when the user initiates another subsequent treatment after acquisition phase 500 and the resulting acquisition of the baseline charge, Qtarget. For example, a full treatment cycle, as discussed above, may take 10 seconds. After, for example, a two-hour pause as shown at wait period 522, the user may then initiate another treatment. During this phase, the adaptive protocol attempts to deliver Qtarget for each subsequent treatment. The functionality of reproduction phase 520 is needed because, during the wait period 522, conditions such as the impedance of the user's body due to sweat or air humidity may have changed. The differential integrator is sampled at the end of each Pulse in the Treatment. At that point, the next treatment is started and the differential integrator is sampled for each pulse at 524 for purposes of comparison to the acquisition phase Qtarget. Sampling the pulse includes measuring the output of the pulse in terms of total electric charge. The output of the integrator of
NUM_PULSES=(T*f)
After each pulse, the observed charge, Qpulse(i), is compared to the expected charge per pulse.
Qpulse(i)>Qtarget/NUM_PULSES?
The output charge or “VBOOST” is then modified at either 528 (decreasing) or 535 (increasing) for the subsequent pulse by:
dV(i)=G[Qtarget/NUM_PULSES−Qpulse(i)]
where G is the Voltage adjustment Coefficient—determined empirically. The process continues until the last pulse at 532.
A safety feature assures that the VBOOST will never be adjusted higher by more than 10%. If more charge is necessary, then the repetition rate or duration can be increased.
In one example a boost voltage circuit uses dedicated circuits to servo the boost voltage. These circuits process voltage and/or current measurements to control the PWM duty cycle of the boost voltage circuit's switch. In another example, the system controller can set the voltage by adjusting the gain of the feedback loop in the boost voltage circuit. This is done with a digital potentiometer or other digital to analog circuit.
In one example, in general, the current is sampled for every pulse during acquisition phase 500 to establish target charge for reproduction. The voltage is then adjusted via a digital potentiometer, herein referred to as “Pot”, during reproduction phase 520 to achieve the established target_charge, or the duty cycle of a PWM is adjusted.
The digital Pot is calibrated with the actual voltage at startup. A table is generated with sampled voltage for each wiper value. Tables are also precomputed storing the Pot wiper increment needed for 1 v and 5 v output delta at each pot level. This enables quick reference for voltage adjustments during the reproduction phase. The tables may need periodic recalibration due to battery level.
In one example, during acquisition phase 501, the data set=100 pulses and every pulse is sampled and the average is used as the target_charge for reproduction phase 520. In general, fewer pulses provide a weaker data sample to use as a basis for reproduction phase 520.
In one example, during acquisition phase 501, the maximum data set=1000 pulses. The maximum is used to avoid overflow of 32 bit integers in accumulating the sum of samples. Further, 1000 pulses in one example is a sufficiently large data set and collecting more is likely unnecessary.
After 1000 pulses for the above example, the target_charge is computed. Additional pulses beyond 1000 in the acquisition phase do not contribute to the computation of the target charge. In other examples, the maximum data set is greater than 1000 pulses when longer treatment cycle times are desired.
In one example, the first 3-4 pulses are generally higher than the rest so these are not used in acquisition phase 501. This is also accounted for in reproduction phase 520. Using these too high values can result in target charge being set too high and over stimulating on the subsequent treatments in reproduction phase 520. In other examples, more advanced averaging algorithms could be applied to eliminate high and low values.
In an example, there may be a safety concern about automatically increasing the voltage. For example, if there is poor connection between the device and the user's skin, the voltage may auto-adjust at 535 up to the max. The impedance may then be reduced, for example by the user pressing the device firmly, which may result in a sudden high current. Therefore, in one example, if the sample is 500 mv or more higher than the target, it immediately adjusts to the minimum voltage. This example then remains in reproduction phase 520 and should adjust back to the target current/charge level. In another example, the maximum voltage increase is set for a single treatment (e.g., 10V). More than that is not needed to achieve the established target_charge. In another example, a max is set for VBOOST (e.g., 80V).
In various examples, it is desired to have stability during reproduction phase 520. In one example, this is accomplished by adjusting the voltage by steps. However, a relatively large step adjustment can result in oscillation or over stimulation. Therefore, voltage adjustments may be made in smaller steps. The step size may be based on both the delta between the target and sample current as well as on the actual VBOOST voltage level. This facilitates a quick and stable/smooth convergence to the target charge and uses a more gradual adjustments at lower voltages for more sensitive users.
The following are the conditions that may be evaluated to determine the adjustment step.
In other examples, new treatments are started with voltage lower than target voltage with a voltage buffer of approximately 10%. The impedance is unknown at the treatment start. These examples save the target_voltage in use at the end of a treatment. If the user has not adjusted the strength parameter manually, it starts a new treatment with saved target_voltage with the 10% buffer. This achieves target current quickly with the 10% buffer to avoid possible over stimulation in case impedance has been reduced. This also compensates for the first 3-4 pulses that are generally higher.
As disclosed, examples apply an initial charge level, and then automatically adjust based on feedback of the amount of current being applied. The charge amount can be varied up or down while being applied. Therefore, rather than setting and then applying a fixed voltage level throughout a treatment cycle, implementations of the invention measure the amount of charge that is being input to the user, and adjust accordingly throughout the treatment to maintain a target charge level that is suitable for the current environment.
The adaptive circuit described above provides the means to monitor the charge sent through the electrodes to the user's tissue and to adjust the strength and duration of sending charge so as to adapt to changes in the impedance through the electrode-to-skin interface and through the user's tissue such that the field strength at the target nerve is within the bounds needed to overcome the action potential of that nerve at that location and activate a nerve impulse. These changes in impedance may be caused by environmental changes, such as wetness or dryness of the skin or underlying tissue, or by applied lotion or the like; or by tissue changes, such as skin dryness; or by changes in the device's placement on the user's skin, such as by removing the patch and re-applying it in a different location or orientation relative to the target nerve; or by combinations of the above and other factors.
The combined circuits and circuit controls disclose herein generate a charge that is repeated on subsequent uses. The voltage boost conserves battery power by generating voltage on demand. The result is an effective and compact electronics package suitable for mounting on or in a fabric or similar material for adherence to a dermis that allows electrodes to be placed near selected nerves to be activated.
System 10 includes a bus 12 or other communication mechanism for communicating information, and a processor 22 coupled to bus 12 for processing information. Processor 22 may be any type of general or specific purpose processor. System 10 further includes a memory 14 for storing information and instructions to be executed by processor 22. Memory 14 can be comprised of any combination of random access memory (“RAM”), read only memory (“ROM”), static storage such as a magnetic or optical disk, or any other type of computer readable media. System 10 further includes a communication device 20, such as a network interface card, to provide access to a network. Therefore, a user may interface with system 10 directly, or remotely through a network, or any other method.
Computer readable media may be any available media that can be accessed by processor 22 and includes both volatile and nonvolatile media, removable and non-removable media, and communication media. Communication media may include computer readable instructions, data structures, program modules, or other data in a modulated data signal such as a carrier wave or other transport mechanism, and includes any information delivery media.
Processor 22 is further coupled via bus 12 to a display 24, such as a Liquid Crystal Display (“LCD”). A keyboard 26 and a cursor control device 28, such as a computer mouse, are further coupled to bus 12 to enable a user to interface with system 10.
In one embodiment, memory 14 stores software modules that provide functionality when executed by processor 22. The modules include an operating system 15 that provides operating system functionality for system 10. The modules further include a hot socket prediction module 16 that predicts hot sockets for one or more smart meter installations, and all other functionality disclosed herein. System 10 can be part of a larger system. Therefore, system 10 can include one or more additional functional modules 18 to include the additional functionality, such as a smartphone related software. A file storage device or database 17 is coupled to bus 12 to provide centralized storage for modules 16 and 18.
Several examples are specifically illustrated and/or described herein. However, it will be appreciated that modifications and variations of the disclosed examples are covered by the above teachings and within the purview of the appended claims without departing from the spirit and intended scope of the invention.
This application claims priority to U.S. Provisional Pat. Appln. Ser. No. 62/697,692, filed on Jul. 13, 2018, and to U.S. Provisional Pat. Appln. Ser. No. 62/697,702, filed on Jul. 13, 2018. This application is further a continuation-in-part application of U.S. patent application Ser. No. 16/385,361, filed Apr. 16, 2019, which is a continuation application of U.S. patent application Ser. No. 15/650,228, filed Apr. 14, 2017, now U.S. Pat. No. 10,307,591, which is a divisional application of U.S. patent application Ser. No. 14/893,946, filed Nov. 25, 2015, now U.S. Pat. No. 10,016,600, which claims priority to PCT Pat. Appln. Ser. No. PCT/US2014/40240, filed May 30, 2014, which claims priority to U.S. Provisional Pat. Appln. Ser. No. 61/828,981, filed May 30, 2013. The disclosure of each of these applications is hereby incorporated by reference.
Number | Name | Date | Kind |
---|---|---|---|
4277980 | Coats et al. | Jul 1981 | A |
4532930 | Crosby et al. | Aug 1985 | A |
4542753 | Brenman et al. | Sep 1985 | A |
4549556 | Tarjan et al. | Oct 1985 | A |
4553549 | Pope et al. | Nov 1985 | A |
4590949 | Pohndorf | May 1986 | A |
4614395 | Peers-Trevarton | Sep 1986 | A |
4658835 | Pohndorf | Apr 1987 | A |
4677989 | Robblee | Jul 1987 | A |
4690144 | Rise et al. | Sep 1987 | A |
4702254 | Zabara | Oct 1987 | A |
4706682 | Stypulkowski et al. | Nov 1987 | A |
4717581 | Robblee | Jan 1988 | A |
4759228 | Butler et al. | Jul 1988 | A |
4800898 | Hess et al. | Jan 1989 | A |
4817628 | Zealear et al. | Apr 1989 | A |
4881526 | Johnson et al. | Nov 1989 | A |
4883666 | Sabel et al. | Nov 1989 | A |
4919148 | Muccio | Apr 1990 | A |
4940453 | Cadwell | Jul 1990 | A |
4959532 | Owechko | Sep 1990 | A |
5031621 | Grandjean et al. | Jul 1991 | A |
5035242 | Franklin et al. | Jul 1991 | A |
5047005 | Cadwell | Sep 1991 | A |
5092332 | Lee et al. | Mar 1992 | A |
5092835 | Schurig et al. | Mar 1992 | A |
5095905 | Klepinski | Mar 1992 | A |
5211657 | Yamada et al. | May 1993 | A |
5265608 | Lee et al. | Nov 1993 | A |
5381801 | McShane et al. | Jan 1995 | A |
5433737 | Aimone | Jul 1995 | A |
5476494 | Edell et al. | Dec 1995 | A |
5501703 | Holsheimer et al. | Mar 1996 | A |
5569307 | Schulman et al. | Oct 1996 | A |
5575813 | Edell et al. | Nov 1996 | A |
5584869 | Heck et al. | Dec 1996 | A |
5597381 | Rizzo, III | Jan 1997 | A |
5603726 | Schulman et al. | Feb 1997 | A |
5609616 | Schulman et al. | Mar 1997 | A |
5628769 | Saringer | May 1997 | A |
5643330 | Holsheimer et al. | Jul 1997 | A |
5679340 | Chappel | Oct 1997 | A |
5713922 | King | Feb 1998 | A |
5738625 | Gluck | Apr 1998 | A |
5741314 | Daly et al. | Apr 1998 | A |
5792209 | Vamer | Aug 1998 | A |
5795790 | Schinstine et al. | Aug 1998 | A |
5824022 | Zilberman et al. | Oct 1998 | A |
5830651 | Cauley et al. | Nov 1998 | A |
5837236 | Dinsmore | Nov 1998 | A |
5853370 | Chance et al. | Dec 1998 | A |
5871534 | Messick et al. | Feb 1999 | A |
5876425 | Gord et al. | Mar 1999 | A |
5891437 | Pietropaolo et al. | Apr 1999 | A |
5916870 | Lee et al. | Jun 1999 | A |
5921245 | O'Donnell, Jr. | Jul 1999 | A |
5922012 | Sakano | Jul 1999 | A |
5937318 | Warner, Jr. et al. | Aug 1999 | A |
5938691 | Schulman et al. | Aug 1999 | A |
5948428 | Lee et al. | Sep 1999 | A |
5987361 | Mortimer | Nov 1999 | A |
5989445 | Wise et al. | Nov 1999 | A |
5992769 | Wise et al. | Nov 1999 | A |
6002960 | Stemberger, I et al. | Dec 1999 | A |
6011018 | Crabtree et al. | Jan 2000 | A |
6016449 | Fischell et al. | Jan 2000 | A |
6058331 | King | May 2000 | A |
6060048 | Cherksey | May 2000 | A |
6060054 | Staerz | May 2000 | A |
6066084 | Edrich et al. | May 2000 | A |
6067474 | Schulman et al. | May 2000 | A |
6081744 | Loos | Jun 2000 | A |
6085115 | Weaver et al. | Jul 2000 | A |
6096537 | Chappel | Aug 2000 | A |
6119071 | Gorenflo et al. | Sep 2000 | A |
6120538 | Rizzo, III et al. | Sep 2000 | A |
6140116 | Dinsmore | Oct 2000 | A |
6155976 | Sackner et al. | Dec 2000 | A |
6178349 | Kieval | Jan 2001 | B1 |
6203792 | Filbin | Mar 2001 | B1 |
6204053 | Dinsmore | Mar 2001 | B1 |
6258353 | Isacson et al. | Jul 2001 | B1 |
6264950 | Staerz | Jul 2001 | B1 |
6265175 | Gage et al. | Jul 2001 | B1 |
6270831 | Kumar et al. | Aug 2001 | B2 |
6277372 | Fraser et al. | Aug 2001 | B1 |
6284245 | Edge | Sep 2001 | B1 |
6288527 | Sugihara et al. | Sep 2001 | B1 |
6294383 | Isacson et al. | Sep 2001 | B1 |
6304784 | Allee et al. | Oct 2001 | B1 |
6304787 | Kuzma et al. | Oct 2001 | B1 |
6359550 | Brisebois et al. | Mar 2002 | B1 |
6374140 | Rise | Apr 2002 | B1 |
6379393 | Mavroidis et al. | Apr 2002 | B1 |
6392118 | Hammang et al. | May 2002 | B1 |
6392550 | Najor | May 2002 | B1 |
6393327 | Scribner | May 2002 | B1 |
6415186 | Chim et al. | Jul 2002 | B1 |
6421232 | Sallam | Jul 2002 | B2 |
6427083 | Owen et al. | Jul 2002 | B1 |
6444205 | Dinsmore et al. | Sep 2002 | B2 |
6472181 | Mineau-Hanschke | Oct 2002 | B1 |
6510347 | Borkan | Jan 2003 | B2 |
6517833 | Edge | Feb 2003 | B2 |
6533732 | Urmey | Mar 2003 | B1 |
6537200 | Leysieffer et al. | Mar 2003 | B2 |
6546291 | Merfeld et al. | Apr 2003 | B2 |
6561975 | Pool et al. | May 2003 | B1 |
6565503 | Leysieffer et al. | May 2003 | B2 |
6575894 | Leysieffer et al. | Jun 2003 | B2 |
6599695 | Gage et al. | Jul 2003 | B2 |
6640118 | Van Heerden et al. | Oct 2003 | B2 |
6640121 | Telischi et al. | Oct 2003 | B1 |
RE38323 | Sugihara et al. | Nov 2003 | E |
6647297 | Scribner | Nov 2003 | B2 |
6690974 | Archer et al. | Feb 2004 | B2 |
6697674 | Leysieffer | Feb 2004 | B2 |
6727696 | Kruspe et al. | Apr 2004 | B2 |
6744367 | Forster | Jun 2004 | B1 |
6788976 | Gesotti | Sep 2004 | B2 |
6795737 | Gielen et al. | Sep 2004 | B2 |
6807445 | Baumann et al. | Oct 2004 | B2 |
6819956 | DiLorenzo | Nov 2004 | B2 |
6839596 | Nelson et al. | Jan 2005 | B2 |
6850802 | Holsheimer | Feb 2005 | B2 |
6879855 | Schulman et al. | Apr 2005 | B2 |
6884122 | Robinson et al. | Apr 2005 | B2 |
6892097 | Holsheimer | May 2005 | B2 |
6893812 | Woltering et al. | May 2005 | B2 |
6894616 | Forster | May 2005 | B1 |
6902547 | Aves et al. | Jun 2005 | B2 |
6931273 | Groenewegen et al. | Aug 2005 | B2 |
6949251 | Dalal et al. | Sep 2005 | B2 |
6970745 | Scribner | Nov 2005 | B2 |
6976998 | Rizzo et al. | Dec 2005 | B2 |
7001608 | Fishman et al. | Feb 2006 | B2 |
7003335 | Briancon | Feb 2006 | B2 |
7010351 | Firlik et al. | Mar 2006 | B2 |
7027873 | Pajunk et al. | Apr 2006 | B2 |
7030411 | Krulevitch et al. | Apr 2006 | B2 |
7037603 | Lasater | May 2006 | B2 |
7047080 | Palanker et al. | May 2006 | B2 |
7058455 | Huie, Jr. et al. | Jun 2006 | B2 |
7079882 | Schmidt | Jul 2006 | B1 |
7101542 | Vallera et al. | Sep 2006 | B1 |
7106190 | Owens | Sep 2006 | B1 |
7107104 | Keravel et al. | Sep 2006 | B2 |
7115071 | Sunbeck | Oct 2006 | B1 |
7117034 | Kronberg | Oct 2006 | B2 |
7120499 | Thrope et al. | Oct 2006 | B2 |
7127301 | Okandan et al. | Oct 2006 | B1 |
7155278 | King et al. | Dec 2006 | B2 |
7167750 | Knudson et al. | Jan 2007 | B2 |
7174223 | Dalton et al. | Feb 2007 | B2 |
7181288 | Rezai et al. | Feb 2007 | B1 |
7191018 | Gielen et al. | Mar 2007 | B2 |
7193414 | Kruspe et al. | Mar 2007 | B2 |
7206632 | King | Apr 2007 | B2 |
7209787 | DiLorenzo | Apr 2007 | B2 |
7218216 | Uehran | May 2007 | B1 |
7218964 | Hill et al. | May 2007 | B2 |
7228178 | Carroll et al. | Jun 2007 | B2 |
7228727 | Discenzo | Jun 2007 | B2 |
7239918 | Strother et al. | Jul 2007 | B2 |
7249998 | van Esbroeck et al. | Jul 2007 | B2 |
7283867 | Strother et al. | Oct 2007 | B2 |
7297420 | Jiang | Nov 2007 | B2 |
7299034 | Kates | Nov 2007 | B2 |
7308303 | Whitehurst et al. | Dec 2007 | B2 |
7308317 | Okandan et al. | Dec 2007 | B1 |
7333851 | Echauz et al. | Feb 2008 | B2 |
7337004 | Classen et al. | Feb 2008 | B2 |
7349169 | Lee et al. | Mar 2008 | B2 |
RE40209 | Sugihara et al. | Apr 2008 | E |
7376467 | Thrope et al. | May 2008 | B2 |
7384145 | Hetling et al. | Jun 2008 | B2 |
7392093 | Khan | Jun 2008 | B2 |
7398255 | Lauer et al. | Jul 2008 | B2 |
7415309 | McIntyre | Aug 2008 | B2 |
7420760 | Zhang et al. | Sep 2008 | B2 |
7422564 | Parsons et al. | Sep 2008 | B2 |
7435443 | Jiang | Oct 2008 | B2 |
7435585 | Tykocinski et al. | Oct 2008 | B2 |
7437193 | Parramon et al. | Oct 2008 | B2 |
7437196 | Wyler et al. | Oct 2008 | B2 |
7483747 | Gliner et al. | Jan 2009 | B2 |
7499745 | Littrup et al. | Mar 2009 | B2 |
7499748 | Moffitt et al. | Mar 2009 | B2 |
7502652 | Gaunt et al. | Mar 2009 | B2 |
7519419 | Jiang et al. | Apr 2009 | B2 |
7529582 | DiLorenzo | May 2009 | B1 |
7553307 | Bleich et al. | Jun 2009 | B2 |
7555343 | Bleich | Jun 2009 | B2 |
7561919 | Shalev et al. | Jul 2009 | B2 |
7565199 | Sheffield et al. | Jul 2009 | B2 |
7565200 | Wyler et al. | Jul 2009 | B2 |
7571002 | Thrope et al. | Aug 2009 | B2 |
7571006 | Gordon et al. | Aug 2009 | B2 |
7578819 | Bleich et al. | Aug 2009 | B2 |
7584004 | Caparso et al. | Sep 2009 | B2 |
7587238 | Moffitt et al. | Sep 2009 | B2 |
7598031 | Liew | Oct 2009 | B2 |
7599737 | Yomtov et al. | Oct 2009 | B2 |
7616988 | Stahmann et al. | Nov 2009 | B2 |
7620456 | Gliner et al. | Nov 2009 | B2 |
7622303 | Soykan et al. | Nov 2009 | B2 |
7636597 | Gross et al. | Dec 2009 | B2 |
7643874 | Nitzan et al. | Jan 2010 | B2 |
7657308 | Miles et al. | Feb 2010 | B2 |
7658707 | Topolev | Feb 2010 | B2 |
7662558 | Liew | Feb 2010 | B2 |
7676274 | Hung et al. | Mar 2010 | B2 |
7680526 | McIntyre et al. | Mar 2010 | B2 |
7684866 | Fowler et al. | Mar 2010 | B2 |
7689285 | Garabet | Mar 2010 | B2 |
D613868 | Lhuillery et al. | Apr 2010 | S |
7699768 | Kishawi et al. | Apr 2010 | B2 |
7704740 | Schindler et al. | Apr 2010 | B2 |
7706888 | Jolly | Apr 2010 | B2 |
7706893 | Hung et al. | Apr 2010 | B2 |
7711416 | Akkin et al. | May 2010 | B1 |
7715919 | Osorio et al. | May 2010 | B2 |
7715924 | Rezai et al. | May 2010 | B2 |
7725196 | Machado et al. | May 2010 | B2 |
7732407 | Hunter | Jun 2010 | B2 |
7738968 | Bleich | Jun 2010 | B2 |
7738969 | Bleich | Jun 2010 | B2 |
7740631 | Bleich et al. | Jun 2010 | B2 |
7747318 | John et al. | Jun 2010 | B2 |
7756583 | Demarais et al. | Jul 2010 | B2 |
7756584 | Sheffield et al. | Jul 2010 | B2 |
7769462 | Meadows et al. | Aug 2010 | B2 |
7769470 | Rezai et al. | Aug 2010 | B1 |
7798982 | Zets et al. | Sep 2010 | B2 |
7799021 | Leung et al. | Sep 2010 | B2 |
7801603 | Westlund et al. | Sep 2010 | B2 |
7813809 | Strother et al. | Oct 2010 | B2 |
7819801 | Miles et al. | Oct 2010 | B2 |
7819869 | Godara et al. | Oct 2010 | B2 |
7831305 | Gliner | Nov 2010 | B2 |
7844340 | Pawlowicz, III | Nov 2010 | B2 |
7877136 | Moffitt et al. | Jan 2011 | B1 |
7887493 | Stahmann et al. | Feb 2011 | B2 |
7892180 | Epley | Feb 2011 | B2 |
7894911 | Greenberg et al. | Feb 2011 | B2 |
7894914 | Stahmann et al. | Feb 2011 | B2 |
7899542 | Cowan et al. | Mar 2011 | B2 |
7914842 | Greenberg et al. | Mar 2011 | B1 |
7917231 | Farah et al. | Mar 2011 | B2 |
7918802 | Urmey | Apr 2011 | B2 |
7922676 | Daskal et al. | Apr 2011 | B2 |
7943632 | Katzman et al. | May 2011 | B2 |
7945330 | Gliner et al. | May 2011 | B2 |
7947448 | Couillard-Despres et al. | May 2011 | B2 |
RE42449 | Forster | Jun 2011 | E |
7959577 | Schmitz et al. | Jun 2011 | B2 |
7963915 | Bleich | Jun 2011 | B2 |
7967751 | Goscha et al. | Jun 2011 | B2 |
7974689 | Volpe et al. | Jul 2011 | B2 |
7981144 | Geist et al. | Jul 2011 | B2 |
7988688 | Webb et al. | Aug 2011 | B2 |
7991475 | Tang et al. | Aug 2011 | B1 |
7991480 | Stahmann et al. | Aug 2011 | B2 |
7992521 | Bocquier | Aug 2011 | B2 |
8000782 | Gharib et al. | Aug 2011 | B2 |
8000796 | Tass et al. | Aug 2011 | B2 |
8000804 | Wessendorf et al. | Aug 2011 | B1 |
8010202 | Shah et al. | Aug 2011 | B2 |
8014868 | Greenberg et al. | Sep 2011 | B2 |
8014878 | Greenberg et al. | Sep 2011 | B2 |
8025632 | Einarsson | Sep 2011 | B2 |
8027716 | Gharib et al. | Sep 2011 | B2 |
8033996 | Behar | Oct 2011 | B2 |
8060210 | Carroll | Nov 2011 | B1 |
8065012 | Firlik et al. | Nov 2011 | B2 |
8067173 | Liew | Nov 2011 | B2 |
8073526 | Graham et al. | Dec 2011 | B2 |
8073546 | Sheffield et al. | Dec 2011 | B2 |
8075556 | Betts | Dec 2011 | B2 |
8078252 | Kipke et al. | Dec 2011 | B2 |
8090446 | Fowler et al. | Jan 2012 | B2 |
8092398 | Weinberg et al. | Jan 2012 | B2 |
8095209 | Flaherty | Jan 2012 | B2 |
8101358 | Liew | Jan 2012 | B2 |
8110358 | Liew | Feb 2012 | B2 |
8114019 | Miles et al. | Feb 2012 | B2 |
8114597 | Liew | Feb 2012 | B2 |
8116875 | Osypka et al. | Feb 2012 | B2 |
8126562 | Fowler et al. | Feb 2012 | B2 |
8131376 | Faraji et al. | Mar 2012 | B1 |
8133674 | Liew | Mar 2012 | B2 |
8133675 | Liew | Mar 2012 | B2 |
8135472 | Fowler et al. | Mar 2012 | B2 |
8137258 | Dennis et al. | Mar 2012 | B1 |
8137284 | Miles et al. | Mar 2012 | B2 |
8140152 | John et al. | Mar 2012 | B2 |
8140162 | Jiang et al. | Mar 2012 | B1 |
8140170 | Rezai et al. | Mar 2012 | B2 |
8148072 | Liew | Apr 2012 | B2 |
8155757 | Neisz et al. | Apr 2012 | B1 |
8160713 | Greenberg et al. | Apr 2012 | B2 |
8162846 | Epley | Apr 2012 | B2 |
8165685 | Knutson et al. | Apr 2012 | B1 |
8170676 | Greenberg et al. | May 2012 | B2 |
8174371 | Schwieger | May 2012 | B2 |
8180453 | Greenberg et al. | May 2012 | B2 |
8180460 | Nevsmith et al. | May 2012 | B2 |
8192357 | Miles et al. | Jun 2012 | B2 |
8195300 | Gliner et al. | Jun 2012 | B2 |
8195307 | Vilims | Jun 2012 | B2 |
8200338 | Grennberg et al. | Jun 2012 | B2 |
8215773 | Gibson-Horn et al. | Jul 2012 | B2 |
8216135 | Goscha et al. | Jul 2012 | B2 |
8226661 | Balling et al. | Jul 2012 | B2 |
8228202 | Buchner et al. | Jul 2012 | B2 |
8239036 | Shah et al. | Aug 2012 | B2 |
8255044 | Miles et al. | Aug 2012 | B2 |
8257922 | Liew | Sep 2012 | B2 |
8260428 | Fink et al. | Sep 2012 | B2 |
8260439 | DiUbaldi et al. | Sep 2012 | B2 |
8280516 | Graupe | Oct 2012 | B2 |
8301266 | Zilberman et al. | Oct 2012 | B1 |
8303516 | Schmitz et al. | Nov 2012 | B2 |
8308665 | Harry et al. | Nov 2012 | B2 |
8313443 | Tom | Nov 2012 | B2 |
8323320 | Lowry et al. | Dec 2012 | B2 |
8328354 | Li et al. | Dec 2012 | B2 |
8332037 | Imran | Dec 2012 | B2 |
8332044 | McIntyre | Dec 2012 | B2 |
8346367 | Carroll | Jan 2013 | B2 |
8352022 | Akkin et al. | Jan 2013 | B2 |
8359083 | Clark et al. | Jan 2013 | B2 |
8364257 | Van Den Eerenbeemd et al. | Jan 2013 | B2 |
8364258 | Della Rocca et al. | Jan 2013 | B2 |
8374698 | Ok et al. | Feb 2013 | B2 |
8374701 | Hyde et al. | Feb 2013 | B2 |
8382656 | Brown | Feb 2013 | B1 |
8386032 | Bachinski | Feb 2013 | B2 |
8386053 | Komet | Feb 2013 | B2 |
8388678 | Singhal et al. | Mar 2013 | B2 |
8391970 | Tracey et al. | Mar 2013 | B2 |
8391986 | Graupe et al. | Mar 2013 | B2 |
8391987 | Faraji et al. | Mar 2013 | B2 |
8396556 | Libbus et al. | Mar 2013 | B2 |
8403841 | Miles et al. | Mar 2013 | B2 |
8406886 | Gaunt et al. | Mar 2013 | B2 |
8412328 | Whelan et al. | Apr 2013 | B2 |
8412335 | Gliner et al. | Apr 2013 | B2 |
8417345 | Machado et al. | Apr 2013 | B2 |
8419653 | Bleich et al. | Apr 2013 | B2 |
8428732 | Nishida et al. | Apr 2013 | B2 |
8428738 | Valencia | Apr 2013 | B2 |
8428739 | Ahuja et al. | Apr 2013 | B2 |
8430882 | Lowry et al. | Apr 2013 | B2 |
8444640 | Demarais et al. | May 2013 | B2 |
8457764 | Ramachandran et al. | Jun 2013 | B2 |
8460167 | Chornenky et al. | Jun 2013 | B2 |
8463383 | Sakai et al. | Jun 2013 | B2 |
8473048 | Greenberg et al. | Jun 2013 | B2 |
8494640 | Peterson et al. | Jul 2013 | B2 |
8494642 | Cowan et al. | Jul 2013 | B2 |
8498698 | Donofrio et al. | Jul 2013 | B2 |
8498717 | Lee et al. | Jul 2013 | B2 |
8498720 | Pellinen et al. | Jul 2013 | B2 |
8506613 | Webb et al. | Aug 2013 | B2 |
8509903 | York et al. | Aug 2013 | B2 |
8512235 | Miles et al. | Aug 2013 | B2 |
8515533 | Rofougaran | Aug 2013 | B2 |
8515543 | Greenberg et al. | Aug 2013 | B2 |
8517961 | Imran et al. | Aug 2013 | B2 |
8532776 | Greenberg et al. | Sep 2013 | B2 |
8538537 | Hulvershorn et al. | Sep 2013 | B2 |
8543210 | Sharma | Sep 2013 | B2 |
8548600 | Deem et al. | Oct 2013 | B2 |
8554328 | Faraji et al. | Oct 2013 | B2 |
8554337 | Barolat | Oct 2013 | B2 |
8556838 | Moutray | Oct 2013 | B2 |
8560041 | Flaherty et al. | Oct 2013 | B2 |
8562521 | Miles et al. | Oct 2013 | B2 |
8565894 | Vetter et al. | Oct 2013 | B2 |
8568331 | Bertagnoli et al. | Oct 2013 | B2 |
8571665 | Moffitt et al. | Oct 2013 | B2 |
8579837 | Makower et al. | Nov 2013 | B1 |
8583238 | Heldman et al. | Nov 2013 | B1 |
8588918 | Bighetti | Nov 2013 | B2 |
8594798 | Osorio et al. | Nov 2013 | B2 |
8600514 | Carroll | Dec 2013 | B1 |
8608664 | Kunitake et al. | Dec 2013 | B2 |
8612002 | Faltys et al. | Dec 2013 | B2 |
8615308 | Hung et al. | Dec 2013 | B2 |
8617808 | Braesch-Andersen et al. | Dec 2013 | B2 |
8626265 | Hempel et al. | Jan 2014 | B2 |
8626305 | Nielsen et al. | Jan 2014 | B2 |
8628469 | Miles et al. | Jan 2014 | B2 |
8634930 | Dalal et al. | Jan 2014 | B2 |
8634932 | Ye et al. | Jan 2014 | B1 |
8639344 | Greenberg et al. | Jan 2014 | B2 |
8644900 | Balberg et al. | Feb 2014 | B2 |
8644937 | Greenberg et al. | Feb 2014 | B2 |
8644938 | Craggs | Feb 2014 | B2 |
8647346 | Bleich et al. | Feb 2014 | B2 |
8649845 | McIntyre et al. | Feb 2014 | B2 |
8649868 | Greenberg et al. | Feb 2014 | B2 |
8652129 | Wu et al. | Feb 2014 | B2 |
8652187 | Wells et al. | Feb 2014 | B2 |
8655455 | Mann et al. | Feb 2014 | B2 |
8657756 | Stahmann et al. | Feb 2014 | B2 |
8660655 | Peterson et al. | Feb 2014 | B2 |
8666500 | Greenberg et al. | Mar 2014 | B2 |
8667971 | Makkar et al. | Mar 2014 | B2 |
8667972 | Makkar et al. | Mar 2014 | B2 |
8669058 | Liew | Mar 2014 | B2 |
8670837 | Daneshvar et al. | Mar 2014 | B2 |
8674838 | Konishi et al. | Mar 2014 | B2 |
8676274 | Li | Mar 2014 | B2 |
8682443 | Faraji et al. | Mar 2014 | B2 |
8688190 | Libbus et al. | Apr 2014 | B2 |
8698637 | Raichman | Apr 2014 | B2 |
8702685 | Schwartz et al. | Apr 2014 | B2 |
8706241 | Firlik et al. | Apr 2014 | B2 |
8708899 | Miles et al. | Apr 2014 | B2 |
8712517 | Jolly | Apr 2014 | B2 |
8712538 | Greenberg et al. | Apr 2014 | B2 |
8712549 | Zdeblick et al. | Apr 2014 | B2 |
8721637 | Zarins et al. | May 2014 | B2 |
8725251 | Della Rocca et al. | May 2014 | B2 |
8734339 | Rao et al. | May 2014 | B2 |
8740783 | Gharib et al. | Jun 2014 | B2 |
8740896 | Zarins et al. | Jun 2014 | B2 |
8744570 | Lee et al. | Jun 2014 | B2 |
8750957 | Tang et al. | Jun 2014 | B2 |
8753271 | Miles et al. | Jun 2014 | B1 |
8755896 | Humayun et al. | Jun 2014 | B2 |
8761889 | Wingeier et al. | Jun 2014 | B2 |
8774922 | Zarins et al. | Jul 2014 | B2 |
8774937 | Mercanzini et al. | Jul 2014 | B2 |
8777942 | Wu et al. | Jul 2014 | B2 |
8781603 | Ye et al. | Jul 2014 | B2 |
8784461 | Webb et al. | Jul 2014 | B2 |
8788064 | Mercanzini et al. | Jul 2014 | B2 |
8788065 | Rezai et al. | Jul 2014 | B2 |
8790338 | Asirvatham et al. | Jul 2014 | B2 |
8798756 | McClure et al. | Aug 2014 | B2 |
8801589 | Peterchev et al. | Aug 2014 | B2 |
8805467 | Yobas et al. | Aug 2014 | B2 |
8805517 | Radivojevic et al. | Aug 2014 | B2 |
8805521 | Carroll | Aug 2014 | B2 |
8821396 | Miles et al. | Sep 2014 | B1 |
8831750 | Ramachandran et al. | Sep 2014 | B2 |
8834545 | Stafford et al. | Sep 2014 | B2 |
8835163 | Zhao et al. | Sep 2014 | B2 |
8843201 | Heldman et al. | Sep 2014 | B1 |
8843204 | Gamham et al. | Sep 2014 | B2 |
8843210 | Simon et al. | Sep 2014 | B2 |
8849412 | Perryman et al. | Sep 2014 | B2 |
8855767 | Faltys et al. | Oct 2014 | B2 |
8862236 | Wolpaw et al. | Oct 2014 | B2 |
8864665 | Rotondo et al. | Oct 2014 | B2 |
8864759 | Godara et al. | Oct 2014 | B2 |
8866621 | Wolfe et al. | Oct 2014 | B2 |
8868164 | Kabakov et al. | Oct 2014 | B2 |
8868172 | Leyde et al. | Oct 2014 | B2 |
8868216 | Dunagan | Oct 2014 | B2 |
8870857 | Seymour et al. | Oct 2014 | B2 |
8874216 | Kim et al. | Oct 2014 | B2 |
8874239 | Greenberg et al. | Oct 2014 | B2 |
8880189 | Lipani | Nov 2014 | B2 |
8886324 | Beuter et al. | Nov 2014 | B2 |
8888773 | Chang et al. | Nov 2014 | B2 |
8892215 | Lipani | Nov 2014 | B2 |
8903494 | Goldwasser et al. | Dec 2014 | B2 |
8903501 | Perryman | Dec 2014 | B2 |
8909343 | Towe | Dec 2014 | B2 |
8909344 | Arle et al. | Dec 2014 | B2 |
8909345 | Danilov et al. | Dec 2014 | B1 |
8912149 | Rawat et al. | Dec 2014 | B1 |
8915846 | Miles et al. | Dec 2014 | B2 |
8915867 | Imran et al. | Dec 2014 | B2 |
8918178 | Simon et al. | Dec 2014 | B2 |
8921473 | Hyman | Dec 2014 | B1 |
8926959 | Deisseroth et al. | Jan 2015 | B2 |
8929990 | Moffitt et al. | Jan 2015 | B2 |
8932196 | Chornenky et al. | Jan 2015 | B2 |
8942797 | Bartol et al. | Jan 2015 | B2 |
8942812 | Machado et al. | Jan 2015 | B2 |
8942821 | Barolat | Jan 2015 | B2 |
8945004 | Miles et al. | Feb 2015 | B2 |
8945216 | Parker et al. | Feb 2015 | B2 |
8948884 | Ramachandran et al. | Feb 2015 | B2 |
8951193 | Ong et al. | Feb 2015 | B2 |
8954144 | Anderson et al. | Feb 2015 | B2 |
8954150 | Swanson et al. | Feb 2015 | B2 |
8954157 | Faraji et al. | Feb 2015 | B2 |
8954167 | Zarembo et al. | Feb 2015 | B2 |
8956387 | Naghavi et al. | Feb 2015 | B2 |
8958862 | Hetke et al. | Feb 2015 | B2 |
8958883 | Mueller et al. | Feb 2015 | B2 |
8958890 | Kipke et al. | Feb 2015 | B2 |
8965513 | Wingeier et al. | Feb 2015 | B2 |
8969532 | DeFrees et al. | Mar 2015 | B2 |
8972026 | Kipke et al. | Mar 2015 | B2 |
8974402 | Oddsson et al. | Mar 2015 | B2 |
8983593 | Bartol et al. | Mar 2015 | B2 |
8983601 | Fukamachi et al. | Mar 2015 | B2 |
8983628 | Simon et al. | Mar 2015 | B2 |
8983629 | Simon et al. | Mar 2015 | B2 |
8985057 | Woodward | Mar 2015 | B2 |
8986294 | Demarais et al. | Mar 2015 | B2 |
8992522 | Pellegrino et al. | Mar 2015 | B2 |
8996131 | Owen et al. | Mar 2015 | B1 |
8998894 | Mauch et al. | Apr 2015 | B2 |
9002458 | Pal et al. | Apr 2015 | B2 |
9002477 | Burnett | Apr 2015 | B2 |
9005191 | Azamian et al. | Apr 2015 | B2 |
9008784 | Chan et al. | Apr 2015 | B2 |
9014810 | Sauter-Starace et al. | Apr 2015 | B2 |
9014811 | Pal et al. | Apr 2015 | B2 |
9014823 | Simon et al. | Apr 2015 | B2 |
9019106 | Alameh et al. | Apr 2015 | B2 |
9020598 | Simon et al. | Apr 2015 | B2 |
9020612 | Danilov et al. | Apr 2015 | B1 |
9023037 | Zarins et al. | May 2015 | B2 |
9034640 | Matos et al. | May 2015 | B2 |
9037268 | Knight | May 2015 | B2 |
9042958 | Karmarkar et al. | May 2015 | B2 |
9043001 | Simon et al. | May 2015 | B2 |
9044596 | Mahadevan-Jansen et al. | Jun 2015 | B2 |
9044611 | Zhao et al. | Jun 2015 | B2 |
9056197 | Kishawi et al. | Jun 2015 | B2 |
9061097 | Holt et al. | Jun 2015 | B2 |
9061134 | Askin, III et al. | Jun 2015 | B2 |
9061135 | Keller et al. | Jun 2015 | B1 |
9072886 | Gaunt et al. | Jul 2015 | B2 |
9072889 | Guarraia et al. | Jul 2015 | B1 |
9072891 | Rao | Jul 2015 | B1 |
9084550 | Bartol et al. | Jul 2015 | B1 |
9084610 | Goshgarian et al. | Jul 2015 | B2 |
9084895 | Greenberg et al. | Jul 2015 | B2 |
9084900 | Hershey et al. | Jul 2015 | B2 |
9089341 | Chomas et al. | Jul 2015 | B2 |
9089687 | Lee, II et al. | Jul 2015 | B2 |
9089691 | Libbus et al. | Jul 2015 | B2 |
9095267 | Halpern et al. | Aug 2015 | B2 |
9095320 | Littrup et al. | Aug 2015 | B2 |
9095538 | Yu et al. | Aug 2015 | B2 |
9101279 | Ritchey et al. | Aug 2015 | B2 |
9113912 | Mehta et al. | Aug 2015 | B1 |
9114261 | Yonce | Aug 2015 | B2 |
9119628 | Mehta et al. | Sep 2015 | B1 |
9119964 | Marnfeldt | Sep 2015 | B2 |
9126197 | Orwar et al. | Sep 2015 | B2 |
9132058 | Imboden et al. | Sep 2015 | B2 |
9138579 | Wolpaw et al. | Sep 2015 | B2 |
9144677 | Gamham et al. | Sep 2015 | B2 |
9155887 | Miller, III et al. | Oct 2015 | B2 |
9158890 | Meredith et al. | Oct 2015 | B2 |
9162010 | Lenarz et al. | Oct 2015 | B2 |
9162064 | Faltys et al. | Oct 2015 | B2 |
9173585 | Tsampazis et al. | Nov 2015 | B2 |
9179850 | Wingeier et al. | Nov 2015 | B2 |
9179875 | Hua | Nov 2015 | B2 |
9189613 | Tuthill et al. | Nov 2015 | B1 |
9192757 | Seymour | Nov 2015 | B2 |
9192767 | Mercanzini et al. | Nov 2015 | B2 |
9199089 | Perryman et al. | Dec 2015 | B2 |
9205275 | Pan et al. | Dec 2015 | B2 |
9220897 | Perryman et al. | Dec 2015 | B2 |
9220899 | Cattaneo et al. | Dec 2015 | B2 |
9220900 | Libbus et al. | Dec 2015 | B2 |
9221177 | Herr et al. | Dec 2015 | B2 |
9227051 | Fisk et al. | Jan 2016 | B1 |
9227056 | Heldman et al. | Jan 2016 | B1 |
9254382 | Ahmad et al. | Feb 2016 | B2 |
9855427 | Bennett et al. | Jan 2018 | B2 |
9895546 | Jiang et al. | Feb 2018 | B2 |
10016600 | Creasey et al. | Jul 2018 | B2 |
10118040 | Zhu | Nov 2018 | B2 |
10342977 | Raghunathan | Jul 2019 | B2 |
10412828 | Tamakawa | Sep 2019 | B1 |
10737096 | Klee | Aug 2020 | B1 |
20010034477 | Mansfield et al. | Oct 2001 | A1 |
20010055776 | Greenwait | Dec 2001 | A1 |
20020009461 | Isacson et al. | Jan 2002 | A1 |
20020019652 | Silva et al. | Feb 2002 | A1 |
20020031497 | Fraser et al. | Mar 2002 | A1 |
20020034819 | Smith et al. | Mar 2002 | A1 |
20020055779 | Andrews | May 2002 | A1 |
20020090722 | Dominko et al. | Jul 2002 | A1 |
20020136705 | Dinsmore | Sep 2002 | A1 |
20020176849 | Slepian | Nov 2002 | A1 |
20030002297 | Nemtsev | Jan 2003 | A1 |
20030004547 | Owen et al. | Jan 2003 | A1 |
20030049328 | Dalal et al. | Mar 2003 | A1 |
20030088274 | Gliner et al. | May 2003 | A1 |
20030097161 | Firlik et al. | May 2003 | A1 |
20030100367 | Cooke | May 2003 | A1 |
20030104993 | Rueger et al. | Jun 2003 | A1 |
20030109901 | Greatbatch | Jun 2003 | A1 |
20030125786 | Gliner et al. | Jul 2003 | A1 |
20030149450 | Mayberg | Aug 2003 | A1 |
20030157712 | Daniel et al. | Aug 2003 | A1 |
20030195441 | Firouzgar | Oct 2003 | A1 |
20030198664 | Sullivan et al. | Oct 2003 | A1 |
20030232055 | Medzhitov | Dec 2003 | A1 |
20040005291 | Rogers et al. | Jan 2004 | A1 |
20040014662 | Lindquist et al. | Jan 2004 | A1 |
20040028613 | Quay | Feb 2004 | A1 |
20040030365 | Rubin | Feb 2004 | A1 |
20040038888 | Mercer et al. | Feb 2004 | A1 |
20040048279 | Olek et al. | Mar 2004 | A1 |
20040048373 | Gage et al. | Mar 2004 | A1 |
20040049134 | Tosaya et al. | Mar 2004 | A1 |
20040049241 | Campos | Mar 2004 | A1 |
20040054300 | Hung et al. | Mar 2004 | A1 |
20040062755 | Smith et al. | Apr 2004 | A1 |
20040064052 | Chance et al. | Apr 2004 | A1 |
20040081652 | Zack et al. | Apr 2004 | A1 |
20040093093 | Andrews | May 2004 | A1 |
20040097401 | Datta | May 2004 | A1 |
20040097839 | Epley | May 2004 | A1 |
20040102525 | Kozachuk | May 2004 | A1 |
20040106966 | Scribner et al. | Jun 2004 | A1 |
20040121464 | Rathjen et al. | Jun 2004 | A1 |
20040133164 | Funderburk et al. | Jul 2004 | A1 |
20040143170 | DuRousseau | Jul 2004 | A1 |
20040147975 | Popovic et al. | Jul 2004 | A1 |
20040156826 | Dangond et al. | Aug 2004 | A1 |
20040162583 | Bingham et al. | Aug 2004 | A1 |
20040172100 | Humayun et al. | Sep 2004 | A1 |
20040172102 | Leysieffer | Sep 2004 | A1 |
20040185557 | Smith et al. | Sep 2004 | A1 |
20040199235 | Younis | Oct 2004 | A1 |
20040212504 | Forcier et al. | Oct 2004 | A1 |
20040219184 | Brown et al. | Nov 2004 | A1 |
20040228831 | Belinka et al. | Nov 2004 | A1 |
20040229702 | Cooke | Nov 2004 | A1 |
20040230226 | Bingham et al. | Nov 2004 | A1 |
20040243021 | Murphy et al. | Dec 2004 | A1 |
20050003998 | Bertilsson et al. | Jan 2005 | A1 |
20050015133 | Ibrahim et al. | Jan 2005 | A1 |
20050020519 | Albiston et al. | Jan 2005 | A1 |
20050020945 | Tosaya et al. | Jan 2005 | A1 |
20050038473 | Tamarkin et al. | Feb 2005 | A1 |
20050054096 | Piniella | Mar 2005 | A1 |
20050054907 | Page et al. | Mar 2005 | A1 |
20050070819 | Poux et al. | Mar 2005 | A1 |
20050073649 | Spector | Apr 2005 | A1 |
20050107859 | Daglow et al. | May 2005 | A1 |
20050125044 | Tracey | Jun 2005 | A1 |
20050165323 | Montgomery et al. | Jul 2005 | A1 |
20050203366 | Donoghue et al. | Sep 2005 | A1 |
20050203601 | Palanker et al. | Sep 2005 | A1 |
20050222631 | Dalal et al. | Oct 2005 | A1 |
20050226852 | Toda et al. | Oct 2005 | A1 |
20050234370 | Beal et al. | Oct 2005 | A1 |
20050267552 | Conquergood et al. | Dec 2005 | A1 |
20050272097 | Calenoff | Dec 2005 | A1 |
20050273890 | Flaherty et al. | Dec 2005 | A1 |
20050277918 | Shah et al. | Dec 2005 | A1 |
20060034767 | Lum et al. | Feb 2006 | A1 |
20060047326 | Wheeler | Mar 2006 | A1 |
20060049950 | Lockhart | Mar 2006 | A1 |
20060049957 | Surgenor et al. | Mar 2006 | A1 |
20060058627 | Flaherty et al. | Mar 2006 | A1 |
20060118035 | Lasater | Jun 2006 | A1 |
20060122458 | Bleich | Jun 2006 | A1 |
20060122529 | Tsau | Jun 2006 | A1 |
20060122864 | Gottesman et al. | Jun 2006 | A1 |
20060140930 | Rodriguez et al. | Jun 2006 | A1 |
20060149345 | Boggs et al. | Jul 2006 | A1 |
20060161225 | Sormann et al. | Jul 2006 | A1 |
20060167498 | DiLorenzo | Jul 2006 | A1 |
20060167564 | Flaherty et al. | Jul 2006 | A1 |
20060171933 | Short | Aug 2006 | A1 |
20060184219 | Pajunk et al. | Aug 2006 | A1 |
20060190056 | Fowler et al. | Aug 2006 | A1 |
20060195146 | Tracey et al. | Aug 2006 | A1 |
20060195153 | Diubaldi et al. | Aug 2006 | A1 |
20060206167 | Flaherty et al. | Sep 2006 | A1 |
20060206178 | Kim | Sep 2006 | A1 |
20060234376 | Mistry et al. | Oct 2006 | A1 |
20060263336 | Caplan | Nov 2006 | A1 |
20060265037 | Kuzma | Nov 2006 | A1 |
20060281130 | Bock et al. | Dec 2006 | A1 |
20070005106 | Adducci | Jan 2007 | A1 |
20070021803 | Deem et al. | Jan 2007 | A1 |
20070043591 | Meretei et al. | Feb 2007 | A1 |
20070049814 | Muccio | Mar 2007 | A1 |
20070049842 | Hill et al. | Mar 2007 | A1 |
20070067004 | Boveja et al. | Mar 2007 | A1 |
20070073361 | Goren et al. | Mar 2007 | A1 |
20070088335 | Jolly | Apr 2007 | A1 |
20070100393 | Whitehurst et al. | May 2007 | A1 |
20070102009 | Wong et al. | May 2007 | A1 |
20070107071 | Couillard-Despres | May 2007 | A1 |
20070123778 | Kantorovich | May 2007 | A1 |
20070129769 | Bourget et al. | Jun 2007 | A1 |
20070134657 | Poznansky et al. | Jun 2007 | A1 |
20070135846 | Knudson et al. | Jun 2007 | A1 |
20070165322 | Strom et al. | Jul 2007 | A1 |
20070173893 | Pitts | Jul 2007 | A1 |
20070173903 | Goren et al. | Jul 2007 | A1 |
20070179558 | Gliner et al. | Aug 2007 | A1 |
20070180542 | Brinster et al. | Aug 2007 | A1 |
20070192881 | Brinster et al. | Aug 2007 | A1 |
20070203533 | Goren et al. | Aug 2007 | A1 |
20070208212 | DiLorenzo | Sep 2007 | A1 |
20070208385 | Carroll et al. | Sep 2007 | A1 |
20070219074 | Pride | Sep 2007 | A1 |
20070239211 | Lorincz et al. | Oct 2007 | A1 |
20070249952 | Rubin et al. | Oct 2007 | A1 |
20070276449 | Gunter et al. | Nov 2007 | A1 |
20070282396 | Overstreet et al. | Dec 2007 | A1 |
20070287613 | Adducci | Dec 2007 | A1 |
20070293893 | Stolen et al. | Dec 2007 | A1 |
20070299483 | Strother et al. | Dec 2007 | A1 |
20080002276 | Strom et al. | Jan 2008 | A1 |
20080027507 | Bijelic et al. | Jan 2008 | A1 |
20080033520 | Jolly | Feb 2008 | A1 |
20080040951 | Kates | Feb 2008 | A1 |
20080057028 | Alitalo et al. | Mar 2008 | A1 |
20080064946 | Greenberg et al. | Mar 2008 | A1 |
20080071321 | Boggs et al. | Mar 2008 | A1 |
20080074794 | Lee et al. | Mar 2008 | A1 |
20080077192 | Harry et al. | Mar 2008 | A1 |
20080095747 | Rutishauser et al. | Apr 2008 | A1 |
20080097530 | Muccio et al. | Apr 2008 | A1 |
20080120029 | Zelek et al. | May 2008 | A1 |
20080125870 | Carmichael et al. | May 2008 | A1 |
20080133016 | Heinz | Jun 2008 | A1 |
20080139907 | Rao et al. | Jun 2008 | A1 |
20080149102 | Kim et al. | Jun 2008 | A1 |
20080154335 | Thrope et al. | Jun 2008 | A1 |
20080161879 | Firlik et al. | Jul 2008 | A1 |
20080161882 | Firlik et al. | Jul 2008 | A1 |
20080161887 | Hagen | Jul 2008 | A1 |
20080170234 | Kim | Jul 2008 | A1 |
20080170316 | Kim | Jul 2008 | A1 |
20080195163 | Scharmer | Aug 2008 | A1 |
20080200967 | Ponomarev et al. | Aug 2008 | A1 |
20080208280 | Lindenthaler et al. | Aug 2008 | A1 |
20080215112 | Firlik et al. | Sep 2008 | A1 |
20080221653 | Agrawal et al. | Sep 2008 | A1 |
20080241208 | Shanley et al. | Oct 2008 | A1 |
20080242607 | DeFrees | Oct 2008 | A1 |
20080243218 | Bottomley et al. | Oct 2008 | A1 |
20080248959 | DeFrees | Oct 2008 | A1 |
20080249439 | Tracey et al. | Oct 2008 | A1 |
20080253992 | DeFrees et al. | Oct 2008 | A1 |
20080255582 | Harris | Oct 2008 | A1 |
20080262557 | Brown | Oct 2008 | A1 |
20080262584 | Bottomley et al. | Oct 2008 | A1 |
20080274958 | DeFrees | Nov 2008 | A1 |
20080275546 | Storey et al. | Nov 2008 | A1 |
20080280818 | DeFrees | Nov 2008 | A1 |
20080312538 | Shahar et al. | Dec 2008 | A1 |
20080318314 | Fulga et al. | Dec 2008 | A1 |
20090012586 | Kepecs | Jan 2009 | A1 |
20090012590 | Inman et al. | Jan 2009 | A1 |
20090029912 | Gronthos et al. | Jan 2009 | A1 |
20090036938 | Shipley et al. | Feb 2009 | A1 |
20090036945 | Chancellor et al. | Feb 2009 | A1 |
20090054800 | Martinerie et al. | Feb 2009 | A1 |
20090054950 | Stephens | Feb 2009 | A1 |
20090076421 | Grant | Mar 2009 | A1 |
20090076444 | Machado et al. | Mar 2009 | A1 |
20090086015 | Larsen et al. | Apr 2009 | A1 |
20090105149 | Albrechtsen et al. | Apr 2009 | A1 |
20090112278 | Wingeier et al. | Apr 2009 | A1 |
20090112279 | Wingeier et al. | Apr 2009 | A1 |
20090118777 | Iki et al. | May 2009 | A1 |
20090118788 | Firlik et al. | May 2009 | A1 |
20090124965 | Greenberg et al. | May 2009 | A1 |
20090131995 | Sloan et al. | May 2009 | A1 |
20090132018 | DiUbaldi et al. | May 2009 | A1 |
20090149782 | Cohen | Jun 2009 | A1 |
20090149900 | Moffitt et al. | Jun 2009 | A1 |
20090149912 | Dacey, Jr. et al. | Jun 2009 | A1 |
20090157091 | Buysman | Jun 2009 | A1 |
20090171381 | Schmitz et al. | Jul 2009 | A1 |
20090182393 | Bachinski | Jul 2009 | A1 |
20090201671 | Huntley | Aug 2009 | A1 |
20090214474 | Jennings | Aug 2009 | A1 |
20090215896 | Morseman et al. | Aug 2009 | A1 |
20090220466 | Ratajczak et al. | Sep 2009 | A1 |
20090226598 | Feng et al. | Sep 2009 | A1 |
20090227025 | Nichols et al. | Sep 2009 | A1 |
20090227831 | Burnett et al. | Sep 2009 | A1 |
20090227965 | Wijesiriwardana | Sep 2009 | A1 |
20090234265 | Reid et al. | Sep 2009 | A1 |
20090258048 | Ward et al. | Oct 2009 | A1 |
20090270958 | Greenberg et al. | Oct 2009 | A1 |
20090292338 | Gordon et al. | Nov 2009 | A1 |
20090299439 | Mire et al. | Dec 2009 | A1 |
20090306728 | Wright et al. | Dec 2009 | A1 |
20090306745 | Parker et al. | Dec 2009 | A1 |
20090326612 | Distler | Dec 2009 | A1 |
20100004654 | Schmitz et al. | Jan 2010 | A1 |
20100010550 | Ponomarev et al. | Jan 2010 | A1 |
20100016732 | Wells et al. | Jan 2010 | A1 |
20100035299 | DeFrees et al. | Feb 2010 | A1 |
20100037755 | McMillen et al. | Feb 2010 | A1 |
20100042180 | Mueller et al. | Feb 2010 | A1 |
20100042185 | Curtis | Feb 2010 | A1 |
20100045595 | Bakke | Feb 2010 | A1 |
20100047915 | Soykan et al. | Feb 2010 | A1 |
20100092983 | Liew | Apr 2010 | A1 |
20100092984 | Liew | Apr 2010 | A1 |
20100094311 | Jolly et al. | Apr 2010 | A1 |
20100099786 | Dias et al. | Apr 2010 | A1 |
20100112026 | Karp et al. | May 2010 | A1 |
20100114195 | Burnes et al. | May 2010 | A1 |
20100124745 | Liew | May 2010 | A1 |
20100124746 | Liew | May 2010 | A1 |
20100145427 | Gliner et al. | Jun 2010 | A1 |
20100168739 | Wu et al. | Jul 2010 | A1 |
20100179284 | Ward et al. | Jul 2010 | A1 |
20100185042 | Schneider et al. | Jul 2010 | A1 |
20100189712 | Heureux et al. | Jul 2010 | A1 |
20100203520 | Liew | Aug 2010 | A1 |
20100204538 | Burnett et al. | Aug 2010 | A1 |
20100204777 | Storey et al. | Aug 2010 | A1 |
20100211172 | Bellamkonda et al. | Aug 2010 | A1 |
20100222630 | Mangrum et al. | Sep 2010 | A1 |
20100222844 | Troosters et al. | Sep 2010 | A1 |
20100241195 | Meadows et al. | Sep 2010 | A1 |
20100249637 | Walter et al. | Sep 2010 | A1 |
20100268055 | Jung et al. | Oct 2010 | A1 |
20100268125 | Epley | Oct 2010 | A9 |
20100280570 | Sturm et al. | Nov 2010 | A1 |
20100280571 | Sloan | Nov 2010 | A1 |
20100286067 | DeFrees | Nov 2010 | A1 |
20100292759 | Hahn et al. | Nov 2010 | A1 |
20100298916 | Rabischong et al. | Nov 2010 | A1 |
20100304864 | Johnson et al. | Dec 2010 | A1 |
20100305674 | Zarembo et al. | Dec 2010 | A1 |
20100310529 | Aizman | Dec 2010 | A1 |
20100324355 | Spitaels et al. | Dec 2010 | A1 |
20100324626 | Lefkovitz | Dec 2010 | A1 |
20110009959 | Tiedtke | Jan 2011 | A1 |
20110014189 | Soula et al. | Jan 2011 | A1 |
20110022105 | Owen et al. | Jan 2011 | A9 |
20110022131 | Giuliano | Jan 2011 | A1 |
20110028345 | Fang et al. | Feb 2011 | A1 |
20110040204 | Ivorra et al. | Feb 2011 | A1 |
20110040349 | Graupe | Feb 2011 | A1 |
20110059447 | Liew | Mar 2011 | A1 |
20110060266 | Streeter et al. | Mar 2011 | A1 |
20110082531 | Swanson et al. | Apr 2011 | A1 |
20110092863 | Kim et al. | Apr 2011 | A1 |
20110098777 | Silverstone | Apr 2011 | A1 |
20110106207 | Cauller et al. | May 2011 | A1 |
20110106219 | Cauller et al. | May 2011 | A1 |
20110112352 | Pilla et al. | May 2011 | A1 |
20110118556 | Siegel et al. | May 2011 | A1 |
20110124959 | Murison | May 2011 | A1 |
20110137189 | Kuo et al. | Jun 2011 | A1 |
20110158444 | Waldmann | Jun 2011 | A1 |
20110177029 | DeFrees | Jul 2011 | A1 |
20110184269 | Sauter-Starace et al. | Jul 2011 | A1 |
20110190882 | Parker et al. | Aug 2011 | A1 |
20110195106 | McMurtrey | Aug 2011 | A1 |
20110196454 | Strand et al. | Aug 2011 | A1 |
20110202120 | Ball et al. | Aug 2011 | A1 |
20110208226 | Fatone et al. | Aug 2011 | A1 |
20110218593 | Rubinstein et al. | Sep 2011 | A1 |
20110224565 | Ong et al. | Sep 2011 | A1 |
20110224754 | Wei | Sep 2011 | A1 |
20110257501 | Huys et al. | Oct 2011 | A1 |
20110257504 | Hendricks et al. | Oct 2011 | A1 |
20110262501 | Webster et al. | Oct 2011 | A1 |
20110264178 | Mehregany et al. | Oct 2011 | A1 |
20110268776 | Schapira et al. | Nov 2011 | A1 |
20110270345 | Johnston et al. | Nov 2011 | A1 |
20110270361 | Borsody | Nov 2011 | A1 |
20110295156 | Arturi | Dec 2011 | A1 |
20110301662 | Bar-Yoseph et al. | Dec 2011 | A1 |
20110313270 | Neves et al. | Dec 2011 | A1 |
20110319703 | Wiskerke et al. | Dec 2011 | A1 |
20120016431 | Paul et al. | Jan 2012 | A1 |
20120016440 | Muccio | Jan 2012 | A1 |
20120022616 | Gamham et al. | Jan 2012 | A1 |
20120035684 | Thompson et al. | Feb 2012 | A1 |
20120045487 | Lahann et al. | Feb 2012 | A1 |
20120046702 | Gibson | Feb 2012 | A1 |
20120059389 | Larson et al. | Mar 2012 | A1 |
20120064628 | Blick et al. | Mar 2012 | A1 |
20120076830 | Sitharaman et al. | Mar 2012 | A1 |
20120078327 | Sloan et al. | Mar 2012 | A1 |
20120089047 | Ryba et al. | Apr 2012 | A1 |
20120095166 | Ward et al. | Apr 2012 | A1 |
20120095524 | Nelson et al. | Apr 2012 | A1 |
20120101326 | Simon et al. | Apr 2012 | A1 |
20120101413 | Beetel et al. | Apr 2012 | A1 |
20120109233 | Lee et al. | May 2012 | A1 |
20120123508 | Wentz et al. | May 2012 | A1 |
20120124470 | West et al. | May 2012 | A1 |
20120130360 | Buckley et al. | May 2012 | A1 |
20120134965 | Kim et al. | May 2012 | A1 |
20120136232 | Jeong et al. | May 2012 | A1 |
20120143293 | Mauch et al. | Jun 2012 | A1 |
20120158095 | Jolly | Jun 2012 | A1 |
20120158104 | Huynh et al. | Jun 2012 | A1 |
20120158113 | Jolly et al. | Jun 2012 | A1 |
20120158114 | Debruyne et al. | Jun 2012 | A1 |
20120179076 | Bavelier et al. | Jul 2012 | A1 |
20120185173 | Yamamoto et al. | Jul 2012 | A1 |
20120191052 | Rao | Jul 2012 | A1 |
20120191086 | Moll et al. | Jul 2012 | A1 |
20120197092 | Luo et al. | Aug 2012 | A1 |
20120197252 | Deem et al. | Aug 2012 | A1 |
20120197374 | Vogt et al. | Aug 2012 | A1 |
20120214737 | Marchionni | Aug 2012 | A1 |
20120221072 | Fukamachi et al. | Aug 2012 | A1 |
20120226331 | Banna et al. | Sep 2012 | A1 |
20120237557 | Lewitus et al. | Sep 2012 | A1 |
20120238924 | Avni | Sep 2012 | A1 |
20120239363 | Durrani et al. | Sep 2012 | A1 |
20120244503 | Neveldine | Sep 2012 | A1 |
20120245534 | Jolly | Sep 2012 | A1 |
20120253236 | Snow et al. | Oct 2012 | A1 |
20120259255 | Tomlinson et al. | Oct 2012 | A1 |
20120259390 | Canion | Oct 2012 | A1 |
20120277825 | Mawson et al. | Nov 2012 | A1 |
20120277842 | Kunis | Nov 2012 | A1 |
20120282228 | Bhasin | Nov 2012 | A1 |
20120283800 | Perryman et al. | Nov 2012 | A1 |
20120296191 | McGrath et al. | Nov 2012 | A1 |
20120296230 | Davis et al. | Nov 2012 | A1 |
20120296444 | Greenberg et al. | Nov 2012 | A1 |
20120302856 | Chang et al. | Nov 2012 | A1 |
20120310140 | Kramer et al. | Dec 2012 | A1 |
20120323288 | Anderson et al. | Dec 2012 | A1 |
20130006322 | Tai | Jan 2013 | A1 |
20130012831 | Schmitz et al. | Jan 2013 | A1 |
20130018240 | McCoy | Jan 2013 | A1 |
20130018444 | Glenn et al. | Jan 2013 | A1 |
20130035745 | Ahmed et al. | Feb 2013 | A1 |
20130041432 | Tucker et al. | Feb 2013 | A1 |
20130052712 | Cha et al. | Feb 2013 | A1 |
20130053853 | Schmitz et al. | Feb 2013 | A1 |
20130053934 | Gluckman et al. | Feb 2013 | A1 |
20130066147 | Brown | Mar 2013 | A1 |
20130066216 | Park | Mar 2013 | A1 |
20130066391 | Hulvershorn et al. | Mar 2013 | A1 |
20130066392 | Simon et al. | Mar 2013 | A1 |
20130066395 | Simon et al. | Mar 2013 | A1 |
20130072808 | Neves et al. | Mar 2013 | A1 |
20130072835 | Harry et al. | Mar 2013 | A1 |
20130090542 | Kipke et al. | Apr 2013 | A1 |
20130090711 | Ramachandran et al. | Apr 2013 | A1 |
20130101635 | Park et al. | Apr 2013 | A1 |
20130116685 | Deem et al. | May 2013 | A1 |
20130116744 | Blum et al. | May 2013 | A1 |
20130122528 | Tyrell et al. | May 2013 | A1 |
20130123568 | Hamilton et al. | May 2013 | A1 |
20130123570 | Ly et al. | May 2013 | A1 |
20130131743 | Yamasaki et al. | May 2013 | A1 |
20130131753 | Simon et al. | May 2013 | A1 |
20130137955 | Kong et al. | May 2013 | A1 |
20130144143 | Kim et al. | Jun 2013 | A1 |
20130144369 | Elias et al. | Jun 2013 | A1 |
20130144370 | Debruyne et al. | Jun 2013 | A1 |
20130150653 | Borsody | Jun 2013 | A1 |
20130154838 | Alameh et al. | Jun 2013 | A1 |
20130157229 | Laurilzen et al. | Jun 2013 | A1 |
20130178765 | Mishelevich | Jul 2013 | A1 |
20130184792 | Simon et al. | Jul 2013 | A1 |
20130184795 | Kipke et al. | Jul 2013 | A1 |
20130184799 | Kipke et al. | Jul 2013 | A1 |
20130204122 | Hendler et al. | Aug 2013 | A1 |
20130204317 | Sauter-Starace et al. | Aug 2013 | A1 |
20130210041 | Anderberg et al. | Aug 2013 | A1 |
20130218456 | Zelek et al. | Aug 2013 | A1 |
20130231725 | Williams et al. | Sep 2013 | A1 |
20130238066 | Joseph et al. | Sep 2013 | A1 |
20130238074 | Zimmerling | Sep 2013 | A1 |
20130245480 | Crockford | Sep 2013 | A1 |
20130245486 | Simon et al. | Sep 2013 | A1 |
20130245711 | Simon et al. | Sep 2013 | A1 |
20130245712 | Simon et al. | Sep 2013 | A1 |
20130245717 | Stohl et al. | Sep 2013 | A1 |
20130245765 | Lowry et al. | Sep 2013 | A1 |
20130248226 | Sime et al. | Sep 2013 | A1 |
20130253299 | Weber et al. | Sep 2013 | A1 |
20130274540 | Pilla et al. | Oct 2013 | A1 |
20130274658 | Steinke et al. | Oct 2013 | A1 |
20130274842 | Gaunt et al. | Oct 2013 | A1 |
20130280233 | Kahn et al. | Oct 2013 | A1 |
20130282001 | Hezi-Yamit et al. | Oct 2013 | A1 |
20130282090 | Decréet al. | Oct 2013 | A1 |
20130288233 | Murray | Oct 2013 | A1 |
20130289659 | Nelson et al. | Oct 2013 | A1 |
20130289678 | Clark et al. | Oct 2013 | A1 |
20130289686 | Masson et al. | Oct 2013 | A1 |
20130296767 | Zarins et al. | Nov 2013 | A1 |
20130309278 | Peyman | Nov 2013 | A1 |
20130310909 | Simon et al. | Nov 2013 | A1 |
20130317400 | Ferezy | Nov 2013 | A1 |
20130317580 | Simon et al. | Nov 2013 | A1 |
20130324994 | Pellegrino et al. | Dec 2013 | A1 |
20130331869 | Runge et al. | Dec 2013 | A1 |
20130338729 | Spector | Dec 2013 | A1 |
20130341185 | Collaert et al. | Dec 2013 | A1 |
20140003696 | Taghva | Jan 2014 | A1 |
20140018792 | Gang et al. | Jan 2014 | A1 |
20140022162 | Yu et al. | Jan 2014 | A1 |
20140023999 | Greder | Jan 2014 | A1 |
20140024981 | Chun et al. | Jan 2014 | A1 |
20140025301 | Storm et al. | Jan 2014 | A1 |
20140030735 | Merali et al. | Jan 2014 | A1 |
20140046423 | Rajguru et al. | Feb 2014 | A1 |
20140051938 | Goldstein et al. | Feb 2014 | A1 |
20140058481 | Perryman et al. | Feb 2014 | A1 |
20140058483 | Zao et al. | Feb 2014 | A1 |
20140066924 | Azamian et al. | Mar 2014 | A1 |
20140073883 | Rao et al. | Mar 2014 | A1 |
20140074186 | Faltys et al. | Mar 2014 | A1 |
20140081682 | Perlmuter | Mar 2014 | A1 |
20140094674 | Nurmikko et al. | Apr 2014 | A1 |
20140099352 | Matheny | Apr 2014 | A1 |
20140107397 | Simon et al. | Apr 2014 | A1 |
20140107398 | Simon et al. | Apr 2014 | A1 |
20140114168 | Block et al. | Apr 2014 | A1 |
20140127171 | Nocera et al. | May 2014 | A1 |
20140128939 | Embrey et al. | May 2014 | A1 |
20140135607 | Lee et al. | May 2014 | A1 |
20140135680 | Peyman | May 2014 | A1 |
20140142374 | Makower et al. | May 2014 | A1 |
20140148649 | Miles et al. | May 2014 | A1 |
20140148871 | Southwell et al. | May 2014 | A1 |
20140148872 | Goldwasser et al. | May 2014 | A1 |
20140155811 | Gibson | Jun 2014 | A1 |
20140155973 | Grigsby et al. | Jun 2014 | A1 |
20140163580 | Tischendorf et al. | Jun 2014 | A1 |
20140163641 | Yao et al. | Jun 2014 | A1 |
20140163658 | Faraji et al. | Jun 2014 | A1 |
20140171807 | Akkin et al. | Jun 2014 | A1 |
20140180036 | Bukkapatnam et al. | Jun 2014 | A1 |
20140180196 | Stone et al. | Jun 2014 | A1 |
20140180365 | Perryman et al. | Jun 2014 | A1 |
20140187872 | Stivoric et al. | Jul 2014 | A1 |
20140194951 | Gong et al. | Jul 2014 | A1 |
20140197937 | Huang et al. | Jul 2014 | A1 |
20140200432 | Banerji et al. | Jul 2014 | A1 |
20140200466 | Sereno et al. | Jul 2014 | A1 |
20140200496 | Hyde et al. | Jul 2014 | A1 |
20140200681 | Kennedy et al. | Jul 2014 | A1 |
20140206947 | Isserow et al. | Jul 2014 | A1 |
20140207292 | Ramagem et al. | Jul 2014 | A1 |
20140213842 | Simon et al. | Jul 2014 | A1 |
20140213971 | Dolan et al. | Jul 2014 | A1 |
20140220555 | Chen et al. | Aug 2014 | A1 |
20140222125 | Glenn et al. | Aug 2014 | A1 |
20140225763 | Kavaler et al. | Aug 2014 | A1 |
20140228901 | Vogt | Aug 2014 | A1 |
20140228926 | Santina et al. | Aug 2014 | A1 |
20140235950 | Miles et al. | Aug 2014 | A1 |
20140236249 | Rao et al. | Aug 2014 | A1 |
20140236847 | Hamilton | Aug 2014 | A1 |
20140243616 | Johnson | Aug 2014 | A1 |
20140243932 | Libbus et al. | Aug 2014 | A1 |
20140249395 | Zhou et al. | Sep 2014 | A1 |
20140255461 | McMurtrey | Sep 2014 | A9 |
20140257063 | Ong et al. | Sep 2014 | A1 |
20140257437 | Simon et al. | Sep 2014 | A1 |
20140267123 | Ludwig | Sep 2014 | A1 |
20140275737 | Shore et al. | Sep 2014 | A1 |
20140276718 | Turovskiy et al. | Sep 2014 | A1 |
20140276760 | Bonyak et al. | Sep 2014 | A1 |
20140277031 | Ballakur et al. | Sep 2014 | A1 |
20140277033 | Taylor et al. | Sep 2014 | A1 |
20140277220 | Brennan et al. | Sep 2014 | A1 |
20140277237 | Maskara et al. | Sep 2014 | A1 |
20140277271 | Chan et al. | Sep 2014 | A1 |
20140277310 | Beetel et al. | Sep 2014 | A1 |
20140277582 | Leuthardt et al. | Sep 2014 | A1 |
20140288379 | Miles et al. | Sep 2014 | A1 |
20140296646 | Wingeier et al. | Oct 2014 | A1 |
20140300490 | Kotz et al. | Oct 2014 | A1 |
20140303525 | Sitharaman | Oct 2014 | A1 |
20140303548 | Jolly et al. | Oct 2014 | A1 |
20140304773 | Woods et al. | Oct 2014 | A1 |
20140309548 | Merz et al. | Oct 2014 | A1 |
20140316398 | Kelly et al. | Oct 2014 | A1 |
20140320289 | Raichman | Oct 2014 | A1 |
20140324120 | Bogie et al. | Oct 2014 | A1 |
20140330337 | Linke et al. | Nov 2014 | A1 |
20140336631 | Wu et al. | Nov 2014 | A1 |
20140336722 | Lima et al. | Nov 2014 | A1 |
20140350041 | Fun et al. | Nov 2014 | A1 |
20140350633 | Gustafson et al. | Nov 2014 | A1 |
20140357453 | Tamanaha | Dec 2014 | A1 |
20140357933 | Lee et al. | Dec 2014 | A1 |
20140360511 | Mohler | Dec 2014 | A1 |
20140371547 | Gartenberg et al. | Dec 2014 | A1 |
20140371564 | Anikeeva et al. | Dec 2014 | A1 |
20140371622 | Hausman et al. | Dec 2014 | A1 |
20140375457 | Diaz | Dec 2014 | A1 |
20140378779 | Freeman et al. | Dec 2014 | A1 |
20140378789 | McKinley et al. | Dec 2014 | A1 |
20140378946 | Thompson et al. | Dec 2014 | A1 |
20140379045 | Rahimi et al. | Dec 2014 | A1 |
20140379049 | Mashiach et al. | Dec 2014 | A1 |
20150005607 | Cui et al. | Jan 2015 | A1 |
20150005680 | Lipani | Jan 2015 | A1 |
20150005840 | Pal et al. | Jan 2015 | A1 |
20150005841 | Pal et al. | Jan 2015 | A1 |
20150005851 | Bradley | Jan 2015 | A1 |
20150010607 | Francis et al. | Jan 2015 | A1 |
20150012079 | Goroszeniuk et al. | Jan 2015 | A1 |
20150016647 | Martinez et al. | Jan 2015 | A1 |
20150017140 | Bhatia et al. | Jan 2015 | A1 |
20150018659 | Ware et al. | Jan 2015 | A1 |
20150032044 | Peyman | Jan 2015 | A9 |
20150032178 | Simon et al. | Jan 2015 | A1 |
20150032184 | Muccio | Jan 2015 | A1 |
20150038886 | Snow | Feb 2015 | A1 |
20150039055 | Wagner et al. | Feb 2015 | A1 |
20150049325 | Curtis | Feb 2015 | A1 |
20150051439 | Hillbralt et al. | Feb 2015 | A1 |
20150051684 | Greenberg et al. | Feb 2015 | A1 |
20150057736 | Zachar | Feb 2015 | A1 |
20150059390 | Hayes | Mar 2015 | A1 |
20150062018 | Naidu et al. | Mar 2015 | A1 |
20150066126 | Marx et al. | Mar 2015 | A1 |
20150067422 | Hamilton | Mar 2015 | A1 |
20150073232 | Ahmad et al. | Mar 2015 | A1 |
20150073520 | Strahl et al. | Mar 2015 | A1 |
20150080709 | Chaturvedi | Mar 2015 | A1 |
20150080926 | Emery | Mar 2015 | A1 |
20150088030 | Taylor | Mar 2015 | A1 |
20150088223 | Blum et al. | Mar 2015 | A1 |
20150088224 | Goldwasser et al. | Mar 2015 | A1 |
20150088225 | Noble et al. | Mar 2015 | A1 |
20150102925 | Foldyna et al. | Apr 2015 | A1 |
20150105794 | Dhanasingh et al. | Apr 2015 | A1 |
20150105795 | Lenarz et al. | Apr 2015 | A1 |
20150112234 | McCaffrey et al. | Apr 2015 | A1 |
20150112321 | Cadouri | Apr 2015 | A1 |
20150112359 | Gillbe | Apr 2015 | A1 |
20150112360 | Pellinen et al. | Apr 2015 | A1 |
20150112404 | Holding et al. | Apr 2015 | A1 |
20150112405 | Brown et al. | Apr 2015 | A1 |
20150112408 | Kals | Apr 2015 | A1 |
20150119673 | Pellinen et al. | Apr 2015 | A1 |
20150119790 | Moffitt et al. | Apr 2015 | A1 |
20150119954 | Bhadra et al. | Apr 2015 | A2 |
20150119989 | Pimenta et al. | Apr 2015 | A1 |
20150126997 | Beetel et al. | May 2015 | A1 |
20150133761 | Vetter et al. | May 2015 | A1 |
20150133956 | Dayan et al. | May 2015 | A1 |
20150135840 | Sato et al. | May 2015 | A1 |
20150148643 | Small et al. | May 2015 | A1 |
20150148644 | Vaidyanathan et al. | May 2015 | A1 |
20150148736 | Jolly et al. | May 2015 | A1 |
20150148869 | Alan et al. | May 2015 | A1 |
20150148878 | Yoo et al. | May 2015 | A1 |
20150150508 | Glenn et al. | Jun 2015 | A1 |
20150157398 | Zarins et al. | Jun 2015 | A1 |
20150157851 | Sefkow et al. | Jun 2015 | A1 |
20150157854 | Hetke et al. | Jun 2015 | A1 |
20150157862 | Greenberg et al. | Jun 2015 | A1 |
20150164360 | Kipke et al. | Jun 2015 | A1 |
20150164401 | Toth | Jun 2015 | A1 |
20150173673 | Toth et al. | Jun 2015 | A1 |
20150173918 | Herr et al. | Jun 2015 | A1 |
20150174403 | Pal et al. | Jun 2015 | A1 |
20150174418 | Tyler et al. | Jun 2015 | A1 |
20150182753 | Harris et al. | Jul 2015 | A1 |
20150190635 | Neuvonen et al. | Jul 2015 | A1 |
20150190636 | Simon et al. | Jul 2015 | A1 |
20150190637 | Simon et al. | Jul 2015 | A1 |
20150196767 | Ahmed | Jul 2015 | A1 |
20150201855 | Pellinen et al. | Jul 2015 | A1 |
20150202331 | Blumenfeld et al. | Jul 2015 | A1 |
20150202437 | Franke et al. | Jul 2015 | A1 |
20150209104 | Tran et al. | Jul 2015 | A1 |
20150209577 | Golestanirad et al. | Jul 2015 | A1 |
20150209586 | Silva et al. | Jul 2015 | A1 |
20150217125 | Chornenky et al. | Aug 2015 | A1 |
20150223731 | Sahin | Aug 2015 | A1 |
20150224300 | Hagr et al. | Aug 2015 | A1 |
20150224330 | Kaib et al. | Aug 2015 | A1 |
20150230749 | Gharib et al. | Aug 2015 | A1 |
20150231396 | Burdick et al. | Aug 2015 | A1 |
20150235529 | Deschamps | Aug 2015 | A1 |
20150238104 | Tass | Aug 2015 | A1 |
20150238253 | Wu et al. | Aug 2015 | A1 |
20150238764 | Franke | Aug 2015 | A1 |
20150246072 | Bhatia et al. | Sep 2015 | A1 |
20150248470 | Coleman et al. | Sep 2015 | A1 |
20150251004 | Imran et al. | Sep 2015 | A1 |
20150254992 | Sethi | Sep 2015 | A1 |
20150257824 | Mauch | Sep 2015 | A1 |
20150272805 | Burnett et al. | Oct 2015 | A1 |
20150273206 | Monteiro | Oct 2015 | A1 |
20150283365 | Dacey et al. | Oct 2015 | A1 |
20150284416 | Zhao | Oct 2015 | A1 |
20150290439 | Eldredge et al. | Oct 2015 | A1 |
20150290450 | Kolb et al. | Oct 2015 | A1 |
20150290464 | Monteiro | Oct 2015 | A1 |
20150290472 | Maguire et al. | Oct 2015 | A1 |
20150297104 | Chen et al. | Oct 2015 | A1 |
20150297444 | Tass | Oct 2015 | A1 |
20150297914 | Hamid et al. | Oct 2015 | A1 |
20150305667 | Durand | Oct 2015 | A1 |
20150305686 | Coleman et al. | Oct 2015 | A1 |
20150310762 | Seim et al. | Oct 2015 | A1 |
20150313498 | Coleman et al. | Nov 2015 | A1 |
20150313512 | Hausman et al. | Nov 2015 | A1 |
20150314017 | Zhao | Nov 2015 | A1 |
20150320560 | Mulliken et al. | Nov 2015 | A1 |
20150320588 | Connor | Nov 2015 | A1 |
20150321000 | Rosenbluth et al. | Nov 2015 | A1 |
20150321010 | Marnfeldt | Nov 2015 | A1 |
20150321017 | Perryman et al. | Nov 2015 | A1 |
20150322155 | Zhao | Nov 2015 | A1 |
20150328454 | Lambert | Nov 2015 | A1 |
20150328455 | Meadows et al. | Nov 2015 | A1 |
20150335288 | Toth et al. | Nov 2015 | A1 |
20150335876 | Jeffery et al. | Nov 2015 | A1 |
20150335877 | Jeffery et al. | Nov 2015 | A1 |
20150335883 | Halpern et al. | Nov 2015 | A1 |
20150335888 | Demers et al. | Nov 2015 | A1 |
20150343196 | Vasapollo | Dec 2015 | A1 |
20150343215 | Ridder | Dec 2015 | A1 |
20150343242 | Tyler et al. | Dec 2015 | A1 |
20150354922 | Carriere | Dec 2015 | A1 |
20150359704 | Imboden et al. | Dec 2015 | A1 |
20150364018 | Mirov et al. | Dec 2015 | A1 |
20150374515 | Meijer et al. | Dec 2015 | A1 |
20150379880 | Sethi | Dec 2015 | A1 |
20160015962 | Maragheh et al. | Jan 2016 | A1 |
20160235982 | Toong et al. | Aug 2016 | A1 |
20170001003 | Pivonka et al. | Jan 2017 | A1 |
20170080216 | Pham | Mar 2017 | A1 |
20170209693 | An et al. | Jul 2017 | A1 |
20170215745 | Felix et al. | Aug 2017 | A1 |
20170224990 | Goldwasser et al. | Aug 2017 | A1 |
20170312512 | Creasey et al. | Nov 2017 | A1 |
20170312526 | Steinke et al. | Nov 2017 | A1 |
20170333695 | Kaplan et al. | Nov 2017 | A1 |
20180020951 | Kaifosh et al. | Jan 2018 | A1 |
20180116877 | Ineichen | May 2018 | A1 |
20180133479 | Bennett et al. | May 2018 | A1 |
20180140859 | Meir | May 2018 | A1 |
20180154147 | Izvorski et al. | Jun 2018 | A1 |
20180161586 | Beyer et al. | Jun 2018 | A1 |
20180214054 | Soltani et al. | Aug 2018 | A1 |
20180318585 | Pfeifer | Nov 2018 | A1 |
20180350451 | Ohnemus et al. | Dec 2018 | A1 |
20190114766 | Song et al. | Apr 2019 | A1 |
20190117976 | Belson et al. | Apr 2019 | A1 |
20190134391 | Druke et al. | May 2019 | A1 |
20190189253 | Kartoun et al. | Jun 2019 | A1 |
20190198144 | Blackley et al. | Jun 2019 | A1 |
20190282822 | Freeman et al. | Sep 2019 | A1 |
20190313934 | Lee et al. | Oct 2019 | A1 |
20190336763 | Spurling et al. | Nov 2019 | A1 |
20200069941 | Campean et al. | Mar 2020 | A1 |
20200069942 | Campean et al. | Mar 2020 | A1 |
20200338333 | Toong et al. | Oct 2020 | A1 |
20200338334 | Toong et al. | Oct 2020 | A1 |
20200376266 | Toong et al. | Dec 2020 | A1 |
Number | Date | Country |
---|---|---|
101868279 | Oct 2010 | CN |
107362447 | Nov 2017 | CN |
2211977 | Aug 2010 | EP |
2646779 | Jul 1993 | FR |
2011502707 | Jan 2011 | JP |
2012512682 | Jun 2012 | JP |
2013500080 | Jan 2013 | JP |
2013512076 | Apr 2013 | JP |
2009064641 | May 2009 | WO |
2011011748 | Jan 2011 | WO |
2011053607 | May 2011 | WO |
2012129574 | Sep 2012 | WO |
2015183620 | Apr 2016 | WO |
Entry |
---|
US 8,398,630 B2, 03/2013, Demarais et al. (withdrawn) |
US 8,613,701 B2, 12/2013, Rao et al. (withdrawn) |
US 8,652,133 B2, 02/2014, Zarins et al. (withdrawn) |
Gupta, P, et al.; Percutaneous tibial nerve stimulation and sacral neuromodulation: an update; Curr Urol Rep; 2015; 4; 16. |
Guys, JM, et al.; [Neurogenic bladder in children: basic principles in diagnosis and treatment]; Ann Urol (Paris); 2006; 15-27; 40;Abstract. |
Guys, JM, et al.; Sacral neuromodulation for neurogenic bladder dysfunction in children; J Urol; 2004; 1673-1676; 172. |
Haddad, M, et al.; Sacral neuromodulation in children with urinary and fecal incontinence: a multicenter, open label, randomized, crossover study; J Urol; 2010; 696-701; 184. |
Hamann, MF, et al.; [Urinary incontinence in men and women. Diagnostics and conservative therapy]; Urologe A; 2014; 1073-1084; quiz 1085-1076; 53. |
Hartmann, KE, et al.; Treatment of overactive bladder in women; Evid Rep Technol Assess (Full Rep); 2009; 1-120, v. |
Hasan, ST, et al.; Neuromodulation in bladder dysfunction; Curr Opin Obstet Gynecol; 1998; 395-399; 10. |
Hasan, ST, et al.; Surface localization of sacral foramina for neuromodulation of bladder function. An anatomical study; Eur Urol; 1996; 90-98; 29;Abstract. |
Hasan, ST, et al.; Transcutaneous electrical nerve stimulation and temporary S3 neuromodulation in idiopathic detrusor instability; J Urol; 1996; 2005-2011; 155. |
Hashim, H, et al.; Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations; Drugs; 2004; 1643-1656; 64. |
Hashim, H, et al.; Novel uses for antidiuresis; Int J Clin Pract Suppl; 2007; 32-36; ;Abstract. |
Hashim, H, et al.; Patient preferences for treating refractory overactive bladder in the UK; Int Urol Nephrol; 2015; 1619-1627; 47. |
Hassouna, M, et al.; Dog as an animal model for neurostimulation; Neurourol Urodyn; 1994; 159-167; 13. |
Hassouna, M, et al.; Update on sacral neuromodulation: indications and outcomes; Curr Urol Rep; 2003; 391-398; 4. |
Hassouna, M; Sacral neuromodulation for overactive bladder: Is it worth it?; Can Urol Assoc J; 2013; E454; 7. |
Hassouna, MM, et al.; Economic evaluation of sacral neuromodulation in overactive bladder: A Canadian perspective; Can Urol Assoc J; 2015; 242-247; 9. |
Hedlund, H, et al.; Sacral neuromodulation in Norway: clinical experience of the first three years; Scand J Urol Nephrol Suppl; 2002; 87-95; ;Abstract. |
Heinze, K, et al.; [Neuromodulation—new techniques]; Urologe A; 2015; 373-377; 54. |
Hellstrom, PA, et al.; Sacral nerve stimulation lead implantation using the O-arm; BMC Urol; 2013; 48; 13. |
Herbison, GP, et al.; Sacral neuromodulation with implanted devices for urinary storage and voiding dysfunction in adults; Cochrane Database Syst Rev; 2009; Cd004202. |
Hersh, L, et al.; Clinical management of urinary incontinence in women; Am Fam Physician; 2013; 634-640; 87. |
Hijaz, A, et al.; Complications and troubleshooting of two-stage sacral neuromodulation therapy: a single-institution experience; Urology; 2006; 533-537; 68. |
Hill, AJ, et al.; Resolution of Chronic Vulvar Pruritus With Replacement of a Neuromodulation Device; J Minim Invasive Gynecol; 2015; 889-891; 22. |
Hindley, RG, et al.; The 2-year symptomatic and urodynamic results of a prospective randomized trial of interstitial radiofrequency therapy vs transurethral resection of the prostate; BJU Int; 2001; 217-220; 88. |
Hoag, N, et al.; Underactive Bladder: Clinical Features, Urodynamic Parameters, and Treatment; Int Neurourol J; 2015; 185-189; 19. |
Hoch, M, et al.; [Chemical destruction of sacral nerve roots by alcohol injection for the treatment of overactive bladder]; Prog Urol; 2006; 584-587; 16;Abstract. |
Hoda, MR, et al.; [Sacral neuromodulation in urology. The emperor's new clothes or effective high-tech medicine?]; Urologe A; 2010; 1254-1259; 49. |
Hoebeke, P, et al.; Transcutaneous neuromodulation for the urge syndrome in children: a pilot study; J Urol; 2001; 2416-2419; 166. |
Hohenfellner, M, et al.; [Sacral neuromodulation of the urinary bladder]; Urologe A; 2000; 55-63; 39. |
Hohenfellner, M, et al.; Bilateral chronic sacral neuromodulation for treatment of lower urinary tract dysfunction; J Urol; 1998; 821-824; 160. |
Hohenfellner, M, et al.; Chronic sacral neuromodulation for treatment of neurogenic bladder dysfunction: long-term results with unilateral implants; Urology; 2001; 887-892; 58. |
Hohenfellner, M, et al.; Sacral neuromodulation for treatment of lower urinary tract dysfunction; BJU Int; 2000; 10-19; discussion 22-13; 85 Suppl 3. |
Hoque, T, et al.; Validation of internal controls for gene expression analysis in the intestine of rats infected with Hymenolepis diminuta; Parasitol Int; 2007; 325-329; 56. |
Horrocks, EJ, et al.; Double-blind randomised controlled trial of percutaneous tibial nerve stimulation versus sham electrical stimulation in the treatment of faecal incontinence: CONtrol of Faecal Incontinence using Distal NeuromodulaTion (the CONFIDeNT trial); Health Technol Assess; 2015; 1-164; 19. |
Hotouras, A, et al.; Prospective clinical audit of two neuromodulatory treatments for fecal incontinence: sacral nerve stimulation (SNS) and percutaneous tibial nerve stimulation (PTNS); Surg Today; 2014; 2124-2130; 44. |
Hoyle, CH, et al.; Ethylcholine mustard aziridinium ion (AF64A) impairs cholinergic neuromuscular transmission in the guinea-pig ileum and urinary bladder, and cholinergic neuromodulation in the enteric nervous system of the guinea-pig distal colon; Gen Pharmacol; 1986; 543-548; 17. |
Hubsher, CP, et al.; Sacral nerve stimulation for neuromodulation of the lower urinary tract; Can J Urol; 2012; 6480-6484; 19. |
Hull, T, et al.; Long-term durability of sacral nerve stimulation therapy for chronic fecal incontinence; Dis Colon Rectum; 2013; 234-245; 56. |
Hull, TL; Sacral neuromodulation stimulation in fecal incontinence; Int Urogynecol J; 2010; 1565-1568; 21. |
Humphreys, MR, et al.; Preliminary results of sacral neuromodulation in 23 children; J Urol; 2006; 2227-2231; 176. |
Hyun, SJ, et al.; Comparative analysis between thoracic spinal cord and sacral neuromodulation in a rat spinal cord injury model: a preliminary report of a rat spinal cord stimulation model; Korean J Spine; 2013; 14-18; 10. |
Iarumov, N, et al.; [Anal incontinence-new methods of surgical treatment using artificial bowel sphincter and sacral nerve stimulation]; Khirurgiia (Sofiia); 2007; 40-45; Abstract. |
Indar, A, et al.; A dual benefit of sacral neuromodulation; Surg Innov; 2008; 219-222; 15. |
Indinnimeo, M, et al.; Sacral neuromodulation for the treatment of fecal incontinence: analysis of cost-effectiveness; Dis Colon Rectum; 2010; 1661-1669; 53. |
Ingber, MS, et al.; Neuromodulation and female sexual function: does treatment for refractory voiding symptoms have an added benefit?; Int Urogynecol J Pelvic Floor Dysfunct; 2009; 1055-1059; 20. |
Iqbal, F, et al.; Bilateral transcutaneous tibial nerve stimulation for chronic constipation; Colorectal Dis; 2016; 173-178; 18. |
Ishigooka, M, et al.; Sacral nerve stimulation and diurnal urine volume; Eur Urol; 1999; 421-426; 36;Abstract. |
J. Groen and J.L.H.R. Bosch; Neuromodulation techniques in the treatment of the overactive bladder; BJU International (2001), 87, 723-731. |
Jacobs, SA, et al.; Randomized prospective crossover study of interstim lead wire placement with curved versus straight stylet; Neurourol Urodyn; 2014; 488-492; 33. |
Jadav, AM, et al.; Does sacral nerve stimulation improve global pelvic function in women?; Colorectal Dis; 2013; 848-857; 15. |
Nambiar, A, et al.; Chapter 4: Guidelines for the diagnosis and treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO); Neurourol Urodyn; 2014; S21-25; 33 Suppl 3. |
Natalin, R, et al.; Management of OAB in those over age 65; Curr Urol Rep; 2013; 379-385; 14. |
Ng, CK, et al.; Refractory overactive bladder in men: update on novel therapies; Curr Urol Rep; 2006; 456-461; 7. |
Nijman, RJ; Classification and treatment of functional incontinence in children; BJU Int; 2000; 37-42; discussion 45-36; 85 Suppl 3. |
Nijman, RJ; Role of antimuscarinics in the treatment of nonneurogenic daytime urinary incontinence in children; Urology; 2004; 45-50; 63. |
Nilsson, KF, et al.; Estimation of endogenous adenosine activity at adenosine receptors in guinea-pig ileum using a new pharmacological method; Acta Physiol (Oxf); 2010; 231-241; 199. |
Nitti, VW; Urodynamics, Incontinence, and Neurourology: Highlights from the Society for Urodynamics and Female Urology Annual Winter Meeting, Feb. 28-Mar. 2, 2008, Miami, FL; Rev Urol; 2008; 229-231; 10. |
Noblett, K, et al.; Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder; Neurourol Urodyn; 2016; 246-251;35. |
Noblett, KL, et al.; Sacral nerve stimulation for the treatment of refractory voiding and bowel dysfunction; Am J Obstet Gynecol; 2014; 99-106; 210. |
Nordling, J; Surgical treatment of painful bladder syndrome/interstitial cystitis; Womens Health (Lond Engl); 2006; 233-238; 2. |
Nyarangi-Dix, JN, et al.; [Overactive bladder syndrome. Are there indications for surgical therapy?]; Urologe A; 2006; 1289-1290, 1292; 45. |
Occhino, JA, et al.; Sacral nerve modulation in overactive bladder; Curr Urol Rep; 2010; 348-352; 11. |
Oerlemans, DJ, et al.; Is on-demand sacral neuromodulation in patients with OAB syndrome a feasible therapy regime?; Neurourol Urodyn; 2011; 1493-1496; 30. |
Oerlemans, DJ, et al.; Sacral nerve stimulation for neuromodulation of the lower urinary tract; Neurourol Urodyn; 2008; 28-33; 27. |
Offiah, I, et al.; Interstitial cystitis/bladder pain syndrome: diagnosis and management; Int Urogynecol J; 2013; 1243-1256; 24. |
Oliver, S, et al.; Measuring the sensations of urge and bladder filling during cystometry in urge incontinence and the effects of neuromodulation; Neurourol Urodyn; 2003; 42567; 22. |
Oliver_et_al-2003-Neurourology_and_Urodynamics. |
Olivera, CK, et al.; Non-antimuscarinic treatment for overactive bladder: a systematic review; Am J Obstet Gynecol; 2016;Abstract. |
Olujide, LO, et al.; Female voiding dysfunction; Best Pract Res Clin Obstet Gynaecol; 2005; 807-828; 19. |
Oom, DM, et al.; Anterior sphincteroplasty for fecal incontinence: a single center experience in the era of sacral neuromodulation; Dis Colon Rectum; 2009; 1681-1687; 52. |
Oom, DM, et al.; Is sacral neuromodulation for fecal incontinence worthwhile in patients with associated pelvic floor Injury?; Dis Colon Rectum; 2010; 422-427; 53. |
Ordia, JI, et al.; Continuous intrathecal baclofen infusion delivered by a programmable pump for the treatment of severe spasticity following traumatic brain injury; Neuromodulation; 2002; 103-107; 5. |
O'Reilly, BA, et al.; A prospective randomised double-blind controlled trial evaluating the effect of trans-sacral magnetic stimulation in women with overactive bladder; Int Urogynecol J Pelvic Floor Dysfunct; 2008; 497-502; 19. |
Osman, NI, et al.; Fowler's syndrome—a cause of unexplained urinary retention in young women?; Nat Rev Urol; 2014; 87-98; 11;Abstract. |
Osman, NI, et al.; Overactive bladder syndrome: Current pathophysiological concepts and therapeutic approaches; Arab J Urol; 2013; 313-318; 11. |
Otto, W, et al.; [Sacral neuromodulation as second-line treatment strategy for lower urinary tract symptoms of various aetiologies: experience of a German high-volume clinic]; Aktuelle Urol; 2012; 162-166; 43;Abstract. |
Ozyalcin, NS, et al.; [Sacral nerve stimulation in fecal incontinence; efficacy and safety]; Agri; 2004; 35-44; 16; Abstract. |
Panicker, JN, et al.; Lower urinary tract dysfunction in the neurological patient: clinical assessment and management; Lancet Neurol; 2015; 720-732; 14. |
Pannek, J, et al.; [Initial results of Stoller peripheral neuromodulation in disorders of bladder function]; Urologe A; 2003; 1470-1476; 42. |
Parija, SC, et al.; Adenosine- and alpha,beta-methylene ATP-induced differential inhibition of cholinergic and non-cholinergic neurogenic responses in rat urinary bladder; Br J Pharmacol; 1991; 396-400; 102. |
Park, SH, et al.; Overactive bladder: treatment options for the aging woman; Int J Fertil Womens Med; 2005; 37-44; 50;Abstract. |
Parnell, BA, et al.; The effect of sacral neuromodulation on pudendal nerve function and female sexual function; Neurourol Urodyn; 2015; 456-460; 34. |
Pascual, I, et al.; Sacral nerve stimulation for fecal incontinence; Rev Esp Enferm Dig; 2011; 355-359; 103. |
Patidar, N, et al.; Transcutaneous posterior tibial nerve stimulation in pediatric overactive bladder: A preliminary report; J Pediatr Urol; 2015; 351.e351-356; 11. |
Pauls, RN, et al.; Effects of sacral neuromodulation on female sexual function; Int Urogynecol J Pelvic Floor Dysfunct; 2007; 391-395; 18. |
Peeters, K, et al.; Long-term follow-up of sacral neuromodulation for lower urinary tract dysfunction; BJU Int; 2014; 789-794; 113. |
Peirce, C, et al.; Central representation of the inferior rectal nerve of the rat; Dis Colon Rectum; 2010; 315-320; 53. |
Pelaez, E, et al.; [Epidural spinal cord stimulation for interstitial cystitis]; Rev Esp Anestesiol Reanim; 2004; 549-552; 51;Abstract. |
Pelliccioni, G, et al.; External anal sphincter responses after S3 spinal root surface electrical stimulation; Neurourol Urodyn; 2006; 788-791; 25. |
Pena, G, et al.; Cholinergic regulatory lymphocytes re-establish neuromodulation of innate immune responses in sepsis; J Immunol; 2011; 718-725; 187. |
Peng, CW, et al.; Pudendal neuromodulation with a closed-loop control strategy to improve bladder functions in the animal study; Conf Proc IEEE Eng Med Biol Soc; 2013; 3626-3629; 2013. |
Penson, DF; Re: Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin a treatment for patients with idiopathic overactive bladder; J Urol; 2012; 2157-2158; 187. |
Penson, DF; Re: Physician Use of Sacral Neuromodulation among Medicare Beneficiaries with Overactive Bladder and Urinary Retention; J Urol; 2016; 689; 195. |
Perissinotto et al.; Transcutaneous Tibial Nerve Stimulation in the Treatment of Lower UrinaryTract Symptoms and Its Impact on Health-Related Quality of Life in Patients With ParkinsonDisease; J Wound, Ostomy and Continence Nurses Society; 2015; 94-99; 42. |
Perrigot, M, et al.; [Perineal electrical stimulation and rehabilitation in urinary incontinence and other symptoms of non-neurologic origin]; Ann Readapt Med Phys; 2008; 479-490; 51;Abstract. |
Pescatori, LC, et al.; Sphincteroplasty for anal incontinence; Gastroenterol Rep (Oxf); 2014; 92-97; 2. |
Peters, KM, et al.; Characterization of a clinical cohort of 87 women with interstitial cystitis/painful bladder syndrome; Urology; 2008; 634-640; 71. |
Peters, KM, et al.; Chronic pudendal neuromodulation: expanding available treatment options for refractory urologic symptoms; Neurourol Urodyn; 2010; 1267-1271; 29. |
Peters, KM, et al.; Clinical outcomes of sacral neuromodulation in patients with neurologic conditions; Urology; 2013; 738-743; 81. |
Peters, KM, et al.; Does patient age impact outcomes of neuromodulation?; Neurourol Urodyn; 2013; 30-36; 32. |
Jarrett, ME; Neuromodulation for constipation and fecal incontinence; Urol Clin North Am; 2005; 79-87; 32. |
Jarvis, JC, et al.; Functional electrical stimulation for control of internal organ function; Neuromodulation; 2001; 155-164; 4. |
Jesus, LE, et al.; Psychosocial and respiratory disease related to severe bladder dysfunction and non-monosymptomatic enuresis; J Pediatr Urol; 2015;Abstract. |
Jezernik, S, et al.; Electrical stimulation for the treatment of bladder dysfunction: current status and future possibilities; Neurol Res; 2002; 413-430; 24;Abstract. |
Jiang, CH; Modulation of the micturition reflex pathway by intravesical electrical stimulation: an experimental study in the rat; Neurourol Urodyn; 1998; 543-553; 17. |
Jimenez-Toscano, M, et al.; Efficacy and quality of life after transcutaneous posterior tibial neuromodulation for faecal incontinence; Colorectal Dis; 2015; 718-723; 17. |
Jin, H, et al.; Electrical neuromodulation at acupoint ST36 normalizes impaired colonic motility induced by rectal distension in dogs; Am J Physiol Gastrointest Liver Physiol; 2015; G368-376; 309. |
Johnsen, NV, et al.; The role of electrical stimulation techniques in the management of the male patient with urgency incontinence; Curr Opin Urol; 2014; 560-565; 24. |
Johnston, TE, et al.; Implantable FES system for upright mobility and bladder and bowel function for individuals with spinal cord injury; Spinal Cord; 2005; 713-723; 43. |
Joussain, C, et al.; Electrical management of neurogenic lower urinary tract disorders; Ann Phys Rehabil Med; 2015; 245-250; 58. |
Julius, F, et al.; Catheter tip granuloma associated with sacral region intrathecal drug administration Neuromodulation; 2003; 225-228; 6. |
Kachur, JF, et al.; Neuromodulation of guinea pig intestinal electrolyte transport by cholecystokinin octapeptide; Gastroenterology; 1991; 344-349; 100;Abstract. |
Kacker, R, et al.; Electrical and mechanical office-based neuromodulation; Urol Clin North Am; 2013; 581-589; 40. |
Kacker, R, et al.; Selection of ideal candidates for neuromodulation in refractory overactive bladder; Curr Urol Rep; 2010; 372-378; 11. |
Kantartizis, K, et al.; Sacral neuromodulation and intravesical botulinum toxin for refractory overactive bladder; Curr Opin Obstet Gynecol; 2012; 331-336; 24. |
Kantartzis, KL, et al.; Cost-effectiveness of test phase implantation strategies for InterStim(R) sacral neuromodulation; Female Pelvic Med Reconstr Surg; 2013; 322-327; 19;Abstract. |
Kapoor, DS, et al.; Combined urinary and faecal incontinence; Int Urogynecol J Pelvic Floor Dysfunct; 2005; 321-328; 16. |
Karademir, K, et al.; A peripheric neuromodulation technique for curing detrusor overactivity: Stoller afferent neurostimulation; Scand J Urol Nephrol; 2005; 230-233; 39. |
Karam, R, et al.; Real-Time Classification of Bladder Events for Effective Diagnosis and Treatment of Urinary Incontinence; IEEE Trans Biomed Eng; 2015. |
Karmarkar, R, et al.; Emerging drugs for overactive bladder; Expert Opin Emerg Drugs; 2015; 613-624; 20;Abstract. |
Karram, MM; Sacral neuromodulation: emerging technology with expanding indications; Int Urogynecol J; 2010; 1443; 21. |
Karsenty, G, et al.; Botulinum toxin type a injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux; J Urol; 2007; 1011-1014; 177. |
Karsenty, G, et al.; Understanding detrusor sphincter dyssynergia—significance of chronology; Urology; 2005; 763-768; 66. |
Katsuragi, T, et al.; Cholinergic neuromodulation by ATP, adenosine and its N6-substituted analogues in guinea-pig ileum; Clin Exp Pharmacol Physiol; 1985; 73-78; 12;Abstract. |
Katsuragi, T, et al.; Involvement of dihydropyridine-sensitive Ca2+ channels in adenosine-evoked inhibition of acetylcholine release from guinea pig ileal preparation; J Neurochem; 1990; 363-369; 55. |
Katsuragi, T, et al.; Possible transsynaptic cholinergic neuromodulation by ATP released from ileal longitudinal muscles of guinea pigs; Life Sci; 1993; 911-918; 53. |
Kaufmann, S, et al.; Unilateral vs bilateral sacral neuromodulation in pigs with formalin-induced detrusor hyperactivity; BJU Int; 2009; 260-263; 103. |
Kavia, R, et al.; A functional magnetic resonance imaging study of the effect of sacral neuromodulation on brain responses in women with Fowler's syndrome; BJU Int; 2010; 366-372; 105. |
Kavia, R, et al.; Overactive bladder; J R Soc Promot Health; 2005; 176-179; 125;Abstract. |
Kenefick, NJ; Sacral nerve neuromodulation for the treatment of lower bowel motility disorders; Ann R Coll Surg Engl; 2006; 617-623; 88. |
Keppene, V, et al.; [Neuromodulation in the management of neurogenic lower urinary tract dysfunction]; Prog Urol; 2007; 609-615; 17;Abstract. |
Kessler, TM, et al.; [Sacral neuromodulation for neurogenic bladder dysfunction]; Urologe A; 2012; 179-183; 51. |
Kessler, TM, et al.; [Urodynamic phenomena in the aging bladder]; Urologe A; 2004; 542-546; 43. |
Kessler, TM, et al.; Prolonged sacral neuromodulation testing using permanent leads: a more reliable patient selection method?; Eur Urol; 2005; 660-665; 47. |
Kessler, TM, et al.; Sacral neuromodulation for refractory lower urinary tract dysfunction: results of a nationwide registry in Switzerland; Eur Urol; 2007; 1357-1363; 51. |
Kessler, TM, et al.; Urologists' referral attitude for sacral neuromodulation for treating refractory idiopathic overactive bladder syndrome: discrete choice experiment; Neurourol Urodyn; 2014; 1240-1246; 33. |
Killinger, KA, et al.; Secondary changes in bowel function after successful treatment of voiding symptoms with neuromodulation; Neurourol Urodyn; 2011; 133-137; 30. |
Kim, JH, et al.; Sacral nerve stimulation for treatment of intractable pain associated with cauda equina syndrome; J Korean Neurosurg Soc; 2010; 473-476; 47. |
Kinder, MV, et al.; Neuronal circuitry of the lower urinary tract; central and peripheral neuronal control of the micturition cycle; Anat Embryol (Berl); 1995; 195-209; 192. |
Kirkham, AP, et al.; Neuromodulation through sacral nerve roots 2 to 4 with a Finetech-Brindley sacral posterior and anterior root stimulator; Spinal Cord; 2002; 272-281; 40. |
Kirkham, AP, et al.; The acute effects of continuous and conditional neuromodulation on the bladder in spinal cord injury; Spinal Cord; 2001; 420-428; 39. |
Klingler, HC, et al.; Use of peripheral neuromodulation of the S3 region for treatment of detrusor overactivity: a urodynamic-based study; Urology; 2000; 766-771; 56. |
Knowles, CH, et al.; Percutaneous tibial nerve stimulation versus sham electrical stimulation for the treatment of faecal incontinence in adults (CONFIDeNT): a double-blind, multicentre, pragmatic, parallel-group, randomised controlled trial; Lancet; 2015; 1640-1648; 386. |
Knupfer, S, et al.; [Therapy-refractory overactive bladder: alternative treatment approaches]; Urologe A; 2011; 806-809; 50. |
Knupfer, SC, et al.; Protocol for a randomized, placebo-controlled, double-blind clinical trial investigating sacral neuromodulation for neurogenic lower urinary tract dysfunction; BMC Urol; 2014; 65; 14. |
Kocjancic, E, et al.; Sacral neuromodulation for urinary retention in a kidney-transplant patient; Urol Int; 2005; 187-188; 75. |
Kohli, N, et al.; InterStim Therapy: A Contemporary Approach to Overactive Bladder; Rev Obstet Gynecol; 2009; 18-27; 2. |
Kohli, N, et al.; Neuromodulation techniques for the treatment of the overactive bladder; Clin Obstet Gynecol; 2002; 218-232; 45. |
Koldewijn, EL; [What to do if pills do not work for urge incontinence—still many questions and ambiguities]; Ned Tijdschr Geneeskd; 2012; A5099; 156;Abstract. |
Kosan, M, et al.; Alteration in contractile responses in human detrusor smooth muscle from obstructed bladders with overactivity; Urol Int; 2008; 193-200; 80. |
Bernstein, AJ, et al.; Expanding indications for neuromodulation; Urol Clin North Am; 2005; 59-63; 32. |
Bertapelle, MP, et al.; Sacral neuromodulation and Botulinum toxin A for refractory idiopathic overactive bladder: a cost-utility analysis in the perspective of Italian Healthcare System; World J Urol; 2015; 1109-1117; 33. |
Beusterien, K, et al.; Use of best-worst scaling to assess patient perceptions of treatments for refractory overactive bladder; Neurourol Urodyn; 2015;Abstract. |
Biemans, JM, et al.; Efficacy and effectiveness of percutaneous tibial nerve stimulation in the treatment of pelvic organ disorders: a systematic review; Neuromodulation; 2013; 25-33; discussion 33; 16. |
Bleier, JI, et al.; Surgical management of fecal incontinence; Gastroenterol Clin North Am; 2013; 815-836; 42. |
Blok, BF, et al.; Different brain effects during chronic and acute sacral neuromodulation in urge incontinent patients with implanted neurostimulators; BJU Int; 2006; 1238-1243; 98. |
Bolton, JF, et al.; Neuromodulation 10 years on: how widely should we use this technique in bladder dysfunction? Curr Opin Urol; 2009; 375-379; 19. |
Bosch, JL, et al.; Neuromodulation: urodynamic effects of sacral (S3) spinal nerve stimulation in patients with detrusor instability or detrusor hyperflexia; Behav Brain Res; 1998; 141-150; 92. |
Bosch, JL, et al.; Sacral nerve neuromodulation in the treatment of patients with refractory motor urge incontinence long-term results of a prospective longitudinal study; J Urol; 2000; 1219-1222; 163. |
Bosch, JL, et al.; What treatment should we use if drugs fail for OAB; and, what really works after drugs?; Neurourol Urodyn; 2010; 658-661; 29. |
Bosch, JL; An update on sacral neuromodulation: where do we stand with this in the management of lower urinary tract dysfunction in 2010?; BJU Int; 2010; 1432-1442; 106. |
Bosch, JL; Sacral neuromodulation in the treatment of the unstable bladder; Curr Opin Urol; 1998; 287-291; 8. |
Bosch, JL; Sacral neuromodulation: treatment success is not just a matter of optimal electrode position; BJU Int; 2000; 20-21; discussion 22-23; 85 Suppl 3. |
Bouchelouche, K, et al.; Recent developments in the management of interstitial cystitis; Curr Opin Urol; 2003; 309-313; 13. |
Bouguen, G, et al.; Effects of transcutaneous tibial nerve stimulation on anorectal physiology in fecal incontinence: a double-blind placebo-controlled cross-over evaluation; Neurogastroenterol Motil; 2014; 247-254; 26. |
Bower, WF, et al.; A pilot study of the home application of transcutaneous neuromodulation in children with urgency or urge incontinence; J Urol; 2001; 2420-2422; 166. |
Bower, WF, et al.; A review of non-invasive electro neuromodulation as an intervention for non-neurogenic bladder dysfunction in children; Neurourol Urodyn; 2004; 63-67; 23. |
Bower, WF, et al.; A urodynamic study of surface neuromodulation versus sham in detrusor instability and sensory urgency; J Urol; 1998; 2133-2136; 160. |
Braun, PM, et al.; [Chronic sacral bilateral neuromodulation. Using a minimal invasive implantation technique in patients with disorders of bladder function]; Urologe A; 2002; 44-47; 41. |
Braun, PM, et al.; Alterations of cortical electrical activity in patients with sacral neuromodulator; Eur Urol; 2002; 562-566; discussion 566-567; 41. |
Braun, PM, et al.; Stimulation signal modification in a porcine model for suppression of unstable detrusor contractions; Urology; 2003; 839-844; 61. |
Braun, PM, et al.; Tailored laminectomy: a new technique for neuromodulator implantation; J Urol; 1999; 1607-1609; 162. |
Brink, TS, et al.; A Chronic, Conscious Large Animal Platform to Quantify Therapeutic Effects of Sacral Neuromodulation on Bladder Function; J Urol; 2015; 252-258; 194. |
Bristow, SE, et al.; TENS: a treatment option for bladder dysfunction; Int Urogynecol J Pelvic Floor Dysfunct; 1996; 185-190; 7. |
Brooks, DR, et al.; The Caenorhabditis elegans orthologue of mammalian puromycin-sensitive aminopeptidase has roles in embryogenesis and reproduction; J Biol Chem; 2003; 42795-42801; 278. |
Brosa, M, et al.; Cost-effectiveness analysis of sacral neuromodulation (SNM) with Interstim for fecal incontinence patients in Spain; Curr Med Res Opin; 2008; 907-918; 24. |
Bross, S, et al.; [Sacral neuromodulation in patients with nonobstructive, chronic urinary retention: relevance of the carbachol test and influence of associated nerve lession]; Aktuelle Urol; 2003; 157-161; 34;Abstract. |
Bross, S, et al.; The role of the carbachol test and concomitant diseases in patients with nonobstructive urinary retention undergoing sacral neuromodulation; World J Urol; 2003; 346-349; 20. |
Brouwer, R, et al.; Sacral nerve neuromodulation is effective treatment for fecal incontinence in the presence of a sphincter defect, pudendal neuropathy, or previous sphincter repair; Dis Colon Rectum; 2010; 273-278; 53. |
Brown, DR, et al.; Delta-opioid receptor mRNA expression and immunohistochemical localization in porcine ileum; Dig Dis Sci; 1998; 1402-1410; 43. |
Brown, ET, et al.; New evidence in the treatment of overactive bladder; Curr Opin Obstet Gynecol; 2015; 366-372; 27. |
Brown, SR, et al.; Surgery for faecal incontinence in adults; Cochrane Database Syst Rev; 2013; Cd001757; 7. |
Buback, D; The use of neuromodulation for treatment of urinary incontinence; Aorn j; 2001; 176-178, 181-177, 189-190; quiz 191-176; 73;Abstract. |
Bugbee, M, et al.; An implant for chronic selective stimulation of nerves; Med Eng Phys; 2001; 29-36; 23. |
Buhmann, H, et al.; [Update on fecal incontinence]; Praxis (Bern 1994); 2014; 1313-1321; 103. |
Burks, FN, et al.; Neuromodulation and the neurogenic bladder; Urol Clin North Am; 2010; 559-565; 37. |
Burks, FN, et al.; Neuromodulation versus medication for overactive bladder: the case for early intervention; Curr Urol Rep; 2009; 342-346; 10. |
Burnstock, G, et al.; P2X receptors in health and disease; Adv Pharmacol; 2011; 333-372; 61;Abstract. |
Burnstock, G; Innervation of bladder and bowel; Ciba Found Symp; 1990; 2-18; discussion 18-26; 151;Abstract. |
Burnstock, G; Introduction and perspective, historical note; Front Cell Neurosci; 2013; 227; 7. |
Burnstock, G; Introductory overview of purinergic signalling; Front Biosci (Elite Ed); 2011; 896-900; 3;Abstract. |
Burnstock, G; Purinergic cotransmission; F1000 Biol Rep; 2009; 46; 1. |
Burnstock, G; Purinergic signalling in the gastrointestinal tract and related organs in health and disease; Purinergic Signal; 2014; 18323; 10. |
Burnstock, G; Purinergic signalling: Its unpopular beginning, its acceptance and its exciting future; Bioessays 2012; 218-225; 34. |
Burnstock, G; Purinergic signalling: past, present and future; Braz J Med Biol Res; 2009; 42437; 42. |
Burnstock, G; The journey to establish purinergic signalling in the gut; Neurogastroenterol Motil; 2008; 42601; 20 Suppl 1. |
Cadish, LA, et al.; Stimulation latency and comparison of cycling regimens in women using sacral neuromodulation Neurourol Urodyn; 2016;Abstract. |
Cameron, AP, et al.; Battery explantation after sacral neuromodulation in the Medicare population; Neurourol Urodyn; 2013; 238-241; 32. |
Campbell, JD, et al.; Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence; BMC Urol; 2009; 18; 9. |
Campin, L, et al.; [Urinary functional disorders bound to deep endometriosis and to its treatment: review of the literature]; J Gynecol Obstet Biol Reprod (Paris); 2014; 431-442; 43;Abstract. |
Findlay, JM, et al.; Peripheral neuromodulation via posterior tibial nerve stimulation—a potential treatment for faecal incontinence?; Ann R Coll Surg Engl; 2010; 385-390; 92. |
Firoozi, F, et al.; Increasing patient preparedness for sacral neuromodulation improves patient reported outcomes despite leaving objective measures of success unchanged; J Urol; 2013; 594-597; 190. |
Fjorback, MV, et al.; A portable device for experimental treatment of neurogenic detrusor overactivity; Neuromodulation; 2003; 158-165; 6. |
Foditsch, EE, et al.; Laparoscopic placement of a tined lead electrode on the pudendal nerve with urodynamic monitoring of bladder function during electrical stimulation: an acute experimental study in healthy female pigs; Springerplus; 2014; 309; 3. |
Foon, R, et al.; The overactive bladder; Ther Adv Urol; 2010; 147-155; 2. |
Ford, AP, et al.; P2X3 receptors and sensitization of autonomic reflexes; Auton Neurosci; 2015; 16-24; 191. |
Fowler, CJ; The perspective of a neurologist on treatment-related research in fecal and urinary incontinence; Gastroenterology; 2004; S172-174; 126. |
Franzen, K, et al.; Surgery for urinary incontinence in women 65 years and older: a systematic review; Int Urogynecol J; 2015; 1095-1102; 26. |
Fraser, MO, et al.; Neural control of the urethra and development of pharmacotherapy for stress urinary incontinence; BJU Int; 2003; 743-748; 91. |
Freeman, RM, et al.; Overactive bladder; Best Pract Res Clin Obstet Gynaecol; 2005; 829-841; 19. |
French, JS, et al.; What do spinal cord injury consumers want? A review of spinal cord injury consumer priorities and neuroprosthesis from the 2008 neural interfaces conference; Neuromodulalion; 2010; 229-231; 13. |
Frokjaer, JB, et al.; Modulation of vagal tone enhances gastroduodenal motility and reduces somatic pain sensitivity; Neurogastroenterol Motil; 2016. |
Fu, G, et al.; [Neuromodulation for treatment for neurogenic bowel dysfunction]; Zhonghua Wai Ke Za Zhi; 2009; 128-131; 47. |
Gaj, F, et al.; [Chronic pelvic pain treatment with posterior tibial nerve stimulation]; Clin Ter; 2011; e111-114; 162; Abstract. |
Gajewski, JB, et al.; The long-term efficacy of sacral neuromodulation in the management of intractable cases of badder pain syndrome: 14 years of experience in one centre; BJU Int; 2011; 1258-1264; 107. |
Game, X, et al.; [Alternative treatments for interstitial cystitis]; Prog Urol; 2009; 357-363; 19;Abstract. |
Game, X, et al.; Outcome after treatment of detrusor-sphincter dyssynergia by temporary stent; Spinal Cord; 2008; 74-77; 46. |
Game, X; [Sacral neuromodulation and sexuality]; Prog Urol; 2008; 167; 18;Abstract. |
Ganio, E, et al.; Neuromodulation for fecal incontinence: outcome in 16 patients with definitive implant. The initial Italian Sacral Neurostimulation Group (GINS) experience; Dis Colon Rectum; 2001; 965-970; 44. |
George, E, et al.; Use of combined anticholinergic medication and sacral neuromodulation in the treatment of refractory overactive bladder; Female Pelvic Med Reconstr Surg; 2011; 97-99; 17;Abstract. |
Ghazwani, YQ, et al.; Efficacy of sacral neuromodulation in treatment of bladder pain syndrome: long-term follow-up; Neurourol Urodyn; 2011; 1271-1275; 30. |
Ghiselli, R, et al.; Nitric oxide synthase expression in rat anorectal tissue after sacral neuromodulation; J Surg Res; 2012; 29-33; 176. |
Giarenis, I, et al.; Management of refractory overactive bladder; Minerva Ginecol; 2013; 41-52; 65;Abstract. |
Giarenis, I, et al.; Managing urinary incontinence: what works?; Climacteric; 2014; 26-33; 17 Suppl 2;Abstract. |
Gibbons, SJ, et al.; Review article: carbon monoxide in gastrointestinal physiology and its potential in therapeutics; Aliment Pharmacol Ther; 2013; 689-702; 38. |
Gill, BC, et al.; Improved sexual and urinary function in women with sacral nerve stimulation; Neuromodulation; 2011; 436-443; discussion 443; 14. |
Gill, BC, et al.; Improvement of bowel dysfunction with sacral neuromodulation for refractory urge urinary incontinence; Int Urogynecol J; 2012; 735-741; 23. |
Gleason, JL, et al.; Sacral neuromodulation effects on periurethral sensation and urethral sphincter activity; Neurourol Urodyn; 2013; 476-479; 32. |
Glinski, RW, et al.; Refractory overactive bladder: Beyond oral anticholinergic therapy; Indian J Urol; 2007; 166-173; 23. |
Gonzalez-Chamorro, F, et al.; [Current status of neurostimulation and neuromodulation for vesicourethral dysfunction]; Arch Esp Urol; 1997; 687-694; 50;Abstract. |
Gonzalez-Chamorro, F, et al.; [Neurostimulation and neuromodulation in urinary incontinence]; Rev Med Univ Navarra; 2004; 75-84; 48;Abstract. |
Gormley, EA, et al.; Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment; J Urol; 2015; 1572-1580; 193. |
Gottwald, T, et al.; [Sex differences in neuromodulation of mucosal mast cells in the rat jejunum]; Langenbecks Arch Chir; 1997; 157-163; 382;Abstract. |
Govaert, B, et al.; Neuromodulation for functional bowel disorders; Best Pract Res Clin Gastroenterol; 2009; 545-553; 23. |
Govier, FE, et al.; Percutaneous afferent neuromodulation for the refractory overactive bladder: results of a multicenter study; J Urol; 2001; 1193-1198; 165. |
Green, BT, et al.; Neuromodulation of enteropathogen internalization in Peyer's patches from porcine jejunum; J Neuroimmunol; 2003; 74-82; 141. |
Griffin, KM, et al.; Sacral nerve stimulation increases activation of the primary somatosensory cortex by anal canal stimulation in an experimental model; Br J Surg; 2011; 1160-1169; 98. |
Grill, WM; Electrical activation of spinal neural circuits: application to motor-system neural prostheses; Neuromodulation; 2000; 97-106; 3. |
Groen, J, et al.; Chronic pudendal nerve neuromodulation in women with idiopathic refractory detrusor overactivity incontinence: results of a pilot study with a novel minimally invasive implantable mini-stimulator; Neurourol Urodyn; 2005; 226-230; 24. |
Groen, J, et al.; Computerized assessment of detrusor instability in patients treated with sacral neuromodulation; J Urol; 2001; 169-173; 165. |
Groen, J, et al.; Neuromodulation techniques in the treatment of the overactive bladder; BJU Int; 2001; 723-731; 87. |
Groen, J, et al.; Sacral neuromodulation in women with idiopathic detrusor overactivity incontinence: decreased overactivity but unchanged bladder contraction strength and urethral resistance during voiding; J Urol; 2006; 1005-1009; discussion 1009; 175. |
Groen, LA, et al.; Sacral neuromodulation with an implantable pulse generator in children with lower urinary tract symptoms: 15-year experience; J Urol; 2012; 1313-1317; 188. |
Groenendijk, PM, et al.; Five-Year Follow-up After Sacral Neuromodulation: Single Center Experience Neuromodulation; 2007; 363-368; 10. |
Groenendijk, PM, et al.; Urodynamic evaluation of sacral neuromodulation for urge urinary incontinence; BJU Int; 2008; 325-329; 101. |
Gross, T, et al.; Transcutaneous Electrical Nerve Stimulation for Treating Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review; Eur Urol; 2016;Abstract. |
Grossi, U, et al.; Sacral neuromodulation for anorectal dysfunction secondary to congenital imperforate anus: report of two cases; Int J Colorectal Dis; 2014; 889-890; 29. |
Grunewald, V; Neuromodulation/neurostimulation; World J Urol; 1998; 299-300; 16. |
Guerci, B, et al.; Gastric electrical stimulation for the treatment of diabetic gastroparesis; Diabetes Metab; 2012; 393-402; 38. |
Gulur, DM, et al.; Management of overactive bladder; Nat Rev Urol; 2010; 572-582; 7. |
Abdel Raheem, A, et al.; Voiding dysfunction in women: Howto manage it correctly; Arab J Urol; 2013; 319-330; 11. |
Abraham, N, et al.; Urgency aftera sling: review of the management; Curr Urol Rep; 2014; 400; 15. |
Abrams, P, et al.; The role of neuromodulation in the management of urinary urge incontinence; BJU Int; 2003; 355-359; 91. |
Abrams, P; The role of neuromodulation in the management of urinary urge incontinence; BJU Int; 2004; 1116; 93. |
Allahdin, S, et al.; An overview of treatment of overactive bladder syndrome in women; J Obstet Gynaecol; 2012; 217-221; 32. |
Alo, KM, et al.; Sacral nerve root stimulation for the treatment of urge incontinence and detrusor dysfunction utilizing a cephalocaudal intraspinal method of lead insertion: a case report; Neuromodulation; 2001; 53-58; 4. |
Alo, KM, et al.; Selective Nerve Root Stimulation (SNRS) for the Treatment of Intractable Pelvic Pain and Motor Dysfunction: A Case Report; Neuromodulation; 2001; 19-23; 4. |
Al-Shaiji, TF, et al.; Pelvic electrical neuromodulation for the treatment of overactive bladder symptoms; Adv Urol; 2011; 757454; 2011. |
Al-Zahrani, AA, et al.; Long-term outcome and surgical interventions after sacral neuromodulation implant for lower urinary tract symptoms: 14-year experience at 1 center; J Urol; 2011; 981-986; 185. |
Amarenco, G, et al.; Urodynamic effect of acute transcutaneous posterior tibial nerve stimulation in overactive bladder; J Urol; 2003; 2210-2215; 169. |
Amend, B, et al.; [Second-line therapy of idiopathic detrusor overactivity. Sacral neuromodulation and botulinum toxin A]; Urologe A; 2010; 245-252; 49. |
Amend, B, et al.; Prolonged percutaneous SNM testing does not cause infection-related explanation; BJU Int; 2013; 485-491; 111. |
Amoroso, L, et al.; Sacral-neuromodulation CT-guided; Radiol Med; 2005; 421-429; 109;Abstract. |
Amundsen, CL, et al.; Sacral neuromodulation for intractable urge incontinence: are there factors associated with cure?; Urology; 2005; 746-750; 66. |
Amundsen, CL, et al.; Sacral neuromodulation in an older, urge-incontinent population; Am J Obstet Gynecol; 2002; 1462-1465; discussion 1465; 187. |
Amundsen, CL, et al.; The Refractory Overactive Bladder: Sacral NEuromodulation vs. BoTulinum Toxin Assessment: Rosetta trial; Contemp Clin Trials; 2014; 272-283; 37. |
Anger, JT, et al.; The effect of sacral neuromodulation on anticholinergic use and expenditures in a privately insured population; Neuromodulation; 2014; 72-74; discussion 74; 17. |
Antolak, SJ, Jr., et al.; Therapeutic pudendal nerve blocks using corticosteroids cure pelvic pain after failure of sacral neuromodulation; Pain Med; 2009; 186-189; 10. |
Antolak, SJ, Jr.; Re: Sacral neuromodulation for the symptomatic treatment of refractory interstitial cystitis: a prospective study; J Urol; 2003; 1956; author reply 1956; 170. |
Anton, PA; Stress and mind-body impact on the course of inflammatory bowel diseases; Semin Gastrointest Dis; 1999; 14-19; 10;Abstract. |
Aoun, F, et al.; [Lower urinary tract dysfunction following radical hysterectomy]; Prog Urol; 2015; 1184-1190; 25;Abstract. |
Apostolidis, A; Neuromodulation for intractable OAB; Neurourol Urodyn; 2011; 766-770; 30. |
Arlandis, S, et al.; Cost-effectiveness of sacral neuromodulation compared to botulinum neurotoxin a or continued medical management in refractory overactive bladder; Value Health; 2011; 219-228; 14. |
Arnold, J, et al.; Overactive bladder syndrome—management and treatment options; Aust Fam Physician; 2012; 878-883; 41. |
Arrabal-Polo, MA, et al.; Clinical efficacy in the treatment of overactive bladder refractory to anticholinergics by posterior tibial nerve stimulation; Korean J Urol; 2012; 483-486; 53. |
Atiemo, HO, et al.; Evaluation and management of refractory overactive bladder; Curr Urol Rep; 2006; 370-375; 7. |
Atnip, S, et al.; A unique approach to severe constipation; Urol Nurs; 2011; 348-350; 31. |
Badawi, JK, et al.; [Current diagnostics and therapy of the overactive bladder and urge incontinence]; Dtsch Med Wochenschr; 2005; 1503-1506; 130;Abstract. |
Badlani, GH; Update on lower urinary tract symptoms; ScientificWorldJournal; 2009; 499-500; 9. |
Baeten, CG; Status of sacral neuromodulation for refractory constipation; Colorectal Dis; 2011; 19-22; 13 Suppl 2. |
Balchandra, P, et al.; Women's perspective: intra-detrusor botox versus sacral neuromodulation for overactive bladder symptoms after unsuccessful anticholinergic treatment; Int Urogynecol J; 2014; 1059-1064; 25. |
Banakhar, M, et al.; Effect of sacral neuromodulation on female sexual function and quality of life: Are they correlated?; Can Urol Assoc J; 2014; E762-767; 8. |
Banakhar, M, et al.; Sacral Neuromodulation for Genitourinary Problems; Prog Neurol Surg; 2015; 192-199; 29; Abstract. |
Banakhar, MA, et al.; Sacral neuromodulation and refractory overactive bladder: an emerging tool for an old problem; Ther Adv Urol; 2012; 179-185; 4. |
Bannowsky, A, et al.; [Sacral neuromodulation in treatment of functional disorders of the lower urinary tract. An overview of basic principles, indications, outcomes]; Urologe A; 2003; 1357-1365; 42. |
Bannowsky, A, et al.; Urodynamic changes and response rates in patients treated with permanent electrodes compared to conventional wire electrodes in the peripheral nerve evaluation test; World J Urol; 2008; 623-626; 26. |
Banyo, T; [The role of electrical neuromodulation in the therapy of chronic lower urinary tract dysfunction]; Ideggyogy Sz; 2003; 68-71; 56;Abstract. |
Barnett, G, et al.; Re: Cost of neuromodulation therapies for overactive bladder: percutaneous tibial nerve stimulation versus sacral nerve stimulation: M. Martinson, S. MacDiarmid and E. Black J Urol 2013; 189:210-216; J Urol; 2013; 1444-1445; 190. |
Baron, M, et al.; [Does urinary sacral neuromodulation improve bowel symptoms other than fecal incontinence: A systematic review]; Prog Urol; 2016;Abstract. |
Barroso U Jr et al.; Electrical nerve stimulation for overactive bladder in children;Nature Reviews Urology; 2011; 402-407; 8. |
Barroso, U, Jr., et al.; Posterior tibial nerve stimulation vs parasacral transcutaneous neuromodulation for overactive bladder in children; J Urol; 2013; 673-677; 190. |
Bartley, J, et al.; Neuromodulation for overactive bladder; Nat Rev Urol; 2013; 513-521; 10. |
Bartley, JM, et al.; Understanding clinic options for overactive bladder; Curr Urol Rep; 2013; 541-548; 14. |
Batla, A, et al.; Lower urinary tract dysfunction in patients with functional movement disorders; J Neurol Sci; 2016; 192-194; 361. |
Bayrak, O, et al.; Botulinum toxin injections for treating neurogenic detrusor overactivity; Turk J Urol; 2015; 221-227; 41. |
Bemelmans, BL, et al.; Neuromodulation by implant for treating lower urinary tract symptoms and dysfunction; Eur Urol; 1999; 81-91; 36;Abstract. |
Beneton, C, et al.; [The medical treatment of overactive bladder]; Neurochirurgie; 2003; 369-376; 49;Abstract. |
Benson, JT, et al.; Pudendal neuralgia, a severe pain syndrome; Am J Obstet Gynecol; 2005; 1663-1668; 192. |
Benson, JT; New therapeutic options for urge incontinence; Curr Womens Health Rep; 2001; 61 -66; 1;Abstract. |
Benson-Cooper, S, et al.; Introduction of sacral neuromodulation for the treatment of faecal incontinence; N Z Med J; 2013; 47-53; 126. |
Xiao, Z, et al.; Somatic modulation of spinal reflex bladder activity mediated by nociceptive bladder afferent nerve fibers in cats; Am J Physiol Renal Physiol; 2014; F673-679; 307. |
Yamanishi, T, et al.; Neuromodulation for the Treatment of Lower Urinary Tract Symptoms; Low Urin Tract Symptoms; 2015; 121-132; 7. |
Yamanouchi, M, et al.; Integrative control of rectoanal reflex in guinea pigs through lumbar colonic nerves; Am J Physiol Gastrointest Liver Physiol; 2002; G148-156; 283. |
Yang, G, et al.; Pudendal nerve stimulation and block by a wireless-controlled implantable stimulator in cats; Neuromodulation; 2014; 490-496; discussion 496; 17. |
Yazdany, T, et al.; Determining outcomes, adverse events, and predictors of success after sacral neuromodulation for lower urinary disorders in women; Int Urogynecol J; 2011; 1549-1554; 22. |
Yih, JM, et al.; Changes in sexual functioning in women after neuromodulation for voiding dysfunction; J Sex Med; 2013; 2477-2483; 10. |
Yoong, W, et al.; Neuromodulative treatment with percutaneous tibial nerve stimulation for intractable detrusor instability: outcomes following a shortened 6-week protocol; BJU Int; 2010; 1673-1676; 106. |
Yun, AJ, et al.; Opening the floodgates: benign prostatic hyperplasia may represent another disease in the compendium of ailments caused by the global sympathetic bias that emerges with aging; Med Hypotheses; 2006; 392-394; 67. |
Zabihi, N, et al.; Short-term results of bilateral S2-S4 sacral neuromodulation for the treatment of refractory interstitial cystitis, painful bladder syndrome, and chronic pelvic pain; Int Urogynecol J Pelvic Floor Dysfunct; 2008; 553-557; 19. |
Zariffa, J, et al.; A Phase-Based Electrical Plethysmography Approach to Bladder Volume Measurement; Ann Biomed Eng; 2015. |
Zecca, C, et al.; Motor and sensory responses after percutaneous tibial nerve stimulation in multiple sclerosis patients with lower urinary tract symptoms treated in daily practice; Eur J Neurol; 2014; 506-511; 21. |
Zecca, C, et al.; Posterior tibial nerve stimulation in the management of lower urinary tract symptoms in patients with multiple sclerosis; Int Urogynecol J; 2015. |
Zempleni, MZ, et al.; Cortical substrate of bladder control in SCI and the effect of peripheral pudendal stimulation Neuroimage; 2010; 2983-2994; 49. |
Zhang, F, et al.; Inhibition of bladder overactivity by a combination of tibial neuromodulation and tramadol treatment in cats; Am J Physiol Renal Physiol; 2012; F1576-1582; 302. |
Zhang, F, et al.; Neural pathways involved in sacral neuromodulation of reflex bladder activity in cats; Am J Physiol Renal Physiol; 2013; F710-717; 304. |
Zhang, N, et al.; Transcutaneous Neuromodulation at Posterior Tibial Nerve and ST36 for Chronic Constipation; Evid Based Complement Alternat Med; 2014; 560802; 2014. |
Zhao, X, et al.; Diffused and sustained inhibitory effects of intestinal electrical stimulation on intestinal motility mediated via sympathetic pathway; Neuromodulation; 2014; 373-379; discussion 380; 17. |
Zheng, J, et al.; [Sacral neuromodulation in the treatment of intractable constipation]; Zhonghua Wei Chang Wai Ke Za Zhi; 2014; 1175-1178; 17;Abstract. |
Zhou, Y, et al.; Change of vanilloid receptor 1 following neuromodulation in rats with spinal cord injury; J Surg Res 2002; 140-144; 107. |
Zullo, MA, et al.; Sacral neuromodulation after stabilization of L2-S1 vertebrae with metallic fixation devices: is it feasible?; Int Urogynecol J; 2011; 373-375; 22. |
Zvara, P, et al.; An animal model for the neuromodulation of neurogenic bladder dysfunction; Br J Urol; 1998; 267-271; 82. |
Roth, TM; Sacral neuromodulation and cardiac pacemakers; Int Urogynecol J; 2010; 1035-1037; 21. |
Roth, TM; Safe Simultaneous Use of Sacral Neuromodulation and Vagal Nerve Stimulation; Female Pelvic Med Reconstr Surg; 2016; e1-2; 22;Abstract. |
Roth, TM; Subcapsular relocation for sacral neuromodulation pulse generator implant revision; Neuromodulation 2010; 145-146; 13. |
Rouprei, M, et al.; Sacral neuromodulation for refractory detrusor overactivity in women with an artificial urinary sphincter; J Urol; 2004; 236-239; 172. |
Rovner, ES; Treatment of urinary incontinence; Curr Urol Rep; 2000; 235-244; 1. |
Ruhhion, A, et al.; [Sacral root neuromodulation for the treatment of urinary incontinence reported to detrusor hyperactivity]; Neurochirurgie; 2003; 377-382; 49;Abstract. |
Ruhhion, A, et al.; [Two indications for bilateral neuromodulation]; Prog Urol; 2003; 1394-1396; 13;Abstract. |
Saber-Khalaf, M, et al.; Sacral neuromodulation outcomes in male patients with chronic urinary retention; Neuromodulation; 2015; 329-334; discussion 334; 18. |
Sadiq, A, et al.; Management of neurogenic lower urinary tract dysfunction in multiple sclerosis patients; Curr Urol Rep; 2015; 44; 16. |
Sahai, A, et al.; Neurogenic detrusor overactivity in patients with spinal cord injury: evaluation and management; Curr Urol Rep; 2011; 404-412; 12. |
Sajadi, KP, et al.; Bladder augmentation and urinary diversion for neurogenic LUTS: current indications; Curr Urol Rep; 2012; 389-393; 13. |
Sajadi, KP, et al.; Overactive bladder after sling surgery; Curr Urol Rep; 2010; 366-371; 11. |
Sakas, DE, et al.; An introduction to operative neuromodulation and functional neuroprosthetics, the new frontiers of clinical neuroscience and biotechnology; Acta Neurochir Suppl; 2007; 42439; 97;Abstract. |
Sancaktar, M, et al.; The outcome of adding peripheral neuromodulation (Stoller afferent neuro-stimulation) to anti-muscarinic therapy in women with severe overactive bladder; Gynecol Endocrinol; 2010; 729-732; 26. |
Sanford, MT, et al.; Neuromodulation in neurogenic bladder; Transl Androl Urol; 2016; 117-126; 5. |
Scaglia, M, et al.; Fecal incontinence treated with acupuncture—a pilot study; Auton Neurosci; 2009; 89-92; 145. |
Scheepens, WA, et al.; [Neuromodulation and neurostimulation in urology]; Ned Tijdschr Geneeskd; 2001 1730-1734; 145; Abstract. |
Scheepens, WA, et al.; Predictive factors for sacral neuromodulation in chronic lower urinary tract dysfunction Urology; 2002; 598-602; 60. |
Scheepens, WA, et al.; Unilateral versus bilateral sacral neuromodulation in patients with chronic voiding dysfunction; J Urol; 2002; 2046-2050; 168. |
Scheepens, WA, et al.; Urodynamic results of sacral neuromodulation correlate with subjective improvement in patients with an overactive bladder; Eur Urol; 2003; 282-287; 43. |
Scheiner, DA, et al.; [Interstitial cystitis/bladder pain syndrome (IC/BPS)]; Praxis (Bern 1994); 2015; 909-918; 104. |
Schijns, O, et al.; Development and characterization of [123l]iodotiagabine for in-vivo GABA-transporter imaging Nucl Med Commun; 2013; 175-179; 34;Abstract. |
Schmidt, RA, et al.; Neurostimulation and neuromodulation: a guide to selecting the right urologic patient; Eur Urol; 1998; 23-26; 34 Suppl 1;Abstract. |
Schneider, MP, et al.; Tibial Nerve Stimulation for Treating Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review; Eur Urol; 2015; 859-867; 68. |
Schonberger, B; [Bladder dysfunction and surgery in the small pelvis. Therapeutic possibilities]; Urologe A; 2003; 1569-1575; 42. |
Schreiber, KL, et al.; Evidence for neuromodulation of enteropathogen invasion in the intestinal mucosa; J Neuroimmune Pharmacol; 2007; 329-337; 2. |
Schultz-Lampel, D, et al.; Experimental results on mechanisms of action of electrical neuromodulation in chronic urinary retention; World J Urol; 1998; 301-304; 16. |
Schurch, B, et al.; Dysfunction of lower urinary tract in patients with spinal cord injury; Handb Clin Neurol; 2015; 247-267; 130. |
Schurch, B, et al.; Electrophysiological recordings during the peripheral nerve evaluation (PNE) test in complete spinal cord injury patients; World J Urol; 2003; 319-322; 20. |
Schwalenberg, T, et al.; [Sacral neuromodulation in urology—development and current status]; Aktuelle Urol 2012; 39-48; 43;Abstract. |
Schwen, Z, et al.; Combination of foot stimulation and tolterodine treatment eliminates bladder overactivity in cats Neurourol Urodyn; 2014; 1266-1271; 33. |
Schwen, Z, et al.; Inhibition of bladder overactivity by duloxetine in combination with foot stimulation or WAY-100635 treatment in cats; Am J Physiol Renal Physiol; 2013; F1663-1668; 305. |
Schwen, Z, et al.; Involvement of 5-HT3 receptors in pudendal inhibition of bladder overactivity in cats; Am J Physiol Renal Physiol; 2013; F663-671; 305. |
Seif, C, et al.; [Pudendal nerve stimulation therapy of the overactive bladder—an alternative to sacral neuromodulation?]; Aktuelle Urol; 2005; 234-238; 36;Abstract. |
Seif, C, et al.; [Use of permanent electrodes in the peripheral nerve evaluation test (PNE-Test) in comparison to conventional wire electrodes]; Aktuelle Urol; 2006; 277-280; 37;Abstract. |
Seif, C, et al.; Findings with Bilateral Sacral Neurostimulation: Sixty-two PNE-Tests in Patients with Neurogenic and Idiopathic Bladder Dysfunctions; Neuromodulation; 2004; 141-145; 7. |
Seif, C, et al.; Improved sacral neuromodulation in the treatment of the hyperactive detrusor: signal modification in an animal model; BJU Int; 2003; 711-715; 91. |
Seih, A, et al.; What's new in the diagnosis and management of painful bladder syndromelinterstitial cystitis?; Curr Urol Rep; 2008; 349-357; 9. |
Sevcencu, C; A review of electrical stimulation to treat motility dysfunctions in the digestive tract: effects and stimulation patterns; Neuromodulation; 2007; 85-99; 10. |
Sevcencu, C; Gastrointestinal mechanisms activated by electrical stimulation to treat motility dysfunctions in the digestive tract: a review; Neuromodulation; 2007; 100-112; 10. |
Shafik, A, et al.; Percutaneous peripheral neuromodulation in the treatment of fecal incontinence; Eur Surg Res; 2003; 103-107; 35. |
Shah, P, et al.; Unique spatiotemporal neuromodulation of the lumbosacral circuitry shapes locomotor success after spinal cord injury; J Neurotrauma; 2016;Abstract. |
Shaker, H, et al.; Role of C-afferent fibres in the mechanism of action of sacral nerve root neuromodulation in chronic spinal cord injury; BJU Int; 2000; 905-910; 85. |
Shaker, H, et al.; Sacral root neuromodulation in the treatment of various voiding and storage problems; Int Urogynecol J Pelvic Floor Dysfunct; 1999; 336-343; 10;Abstract. |
Shaker, HS, et al.; Sacral nerve root neuromodulation: an effective treatment for refractory urge incontinence; J Urol; 1998; 1516-1519; 159. |
Shaker, HS, et al.; Sacral root neuromodulation in idiopathic nonobstructive chronic urinary retention; J Urol; 1998; 1476-1478; 159. |
Shalom, DF, et al.; Sacral nerve stimulation reduces elevated urinary nerve growth factor levels in women with symptomatic detrusor overactivity; Am J Obstet Gynecol; 2014; 561.e561-565; 211. |
Shamliyan, T, et al.; Prevention of urinary and fecal incontinence in adults; Evid Rep Technol Assess (Full Rep); 2007; 1-379; ;Abstract. |
Sharma, A, et al.; Review of sacral neuromodulation for management of constipation; Surg Innov; 2013; 614-624; 20. |
Sharma, A, et al.; Sacral neuromodulation for the management of severe constipation: development of a constipation treatment protocol; Int J Colorectal Dis; 2011; 1583-1587; 26. |
Van Koeveringe, GA, et al.; Detrusor underactivity: a plea for new approaches to a common bladder dysfunction; Neurourol Urodyn; 2011; 723-728; 30. |
Van Ophoven, A, et al.; [The future of invasive neuromodulation: new techniques and expanded indications]; Urologe A; 2012; 212-216; 51. |
Van Voskuilen, AC, et al.; Long term results of neuromodulation by sacral nerve stimulation for lower urinary tract symptoms: a retrospective single center study; Eur Urol; 2006; 366-372; 49. |
Van Voskuilen, AC, et al.; Medium-term experience of sacral neuromodulation by tined lead implantation; BJU Int; 2007; 107-110; 99. |
Van Wunnik, BP, et al.; Cost-effectiveness analysis of sacral neuromodulation for faecal incontinence in The Netherlands; Colorectal Dis; 2012; e807-814; 14. |
Van Wunnik, BP, et al.; Neuromodulation for constipation: sacral and transcutaneous stimulation; Best Pract Res Clin Gastroenterol; 2011; 181-191; 25. |
Van Wunnik, BP, et al.; Patient experience and satisfaction with sacral neuromodulation: results of a single-center sample survey; Dis Colon Rectum; 2011; 95-100; 54. |
Van Wunnik, BP, et al.; Sacral neuromodulation therapy: a promising treatment for adolescents with refractory functional constipation; Dis Colon Rectum; 2012; 278-285; 55. |
Vasavada, SP, et al.; Neuromodulation techniques: a comparison of available and new therapies; Curr Urol Rep; 2007; 455-460; 8. |
Vasdev, N, et al.; The surgical management of the refractory overactive bladder; Indian J Urol; 2010; 263-269; 26. |
Veeratterapillay, R, et al.; Augmentation cystoplasty: Contemporary indications, techniques and complications; Indian J Urol; 2013; 322-327; 29. |
Veit-Rubin, N, et al.; [Overactive bladder syndrome—a public health challenge]; Rev Med Suisse; 2015; 2016-2021; 11;Abstract. |
Vigil, HR, et al.; Urinary tract infection in the neurogenic bladder; Transl Androl Urol; 2016; 72-87; 5. |
Vignes, JR, et al.; Animal models of sacral neuromodulation for detrusor overactivity; Neurourol Urodyn; 2009; 42594; 28. |
Vignes, JR, et al.; Sacral neuromodulation as a functional treatment of bladder overactivity; Acta Neurochir Suppl; 2007; 315-322; 97;Abstract. |
Vignes, JR, et al.; Sacral neuromodulation in lower urinary tract dysfunction; Adv Tech Stand Neurosurg; 2005; 177-224; 30;Abstract. |
Wallace, JL, et al.; Lack of beneficial effect of a tachykinin receptor antagonist in experimental colitis; Regul Pept; 1998; 95-101; 73. |
Walsh, IK, et al.; Non-invasive antidromic neurostimulation: a simple effective method for improving bladder storage; Neurourol Urodyn; 2001; 73-84; 20. |
Walter, S; [Duloxetine. A new preparation for patients with urinary incontinence]; Ugeskr Laeger; 2005; 4553-4555; 167;Abstract. |
Wang, Y, et al.; Neuromodulation reduces c-fos gene expression in spinalized rats: a double-blind randomized study; J Urol; 2000; 1966-1970; 163. |
Wang, Y, et al.; Neuromodulation reduces urinary frequency in rats with hydrochloric acid-induced cystitis; BJU Int; 2000; 726-730; 86. |
Wark, HA, et al.; Restoration from acute urinary dysfunction using Utah electrode arrays implanted into the feline pudendal nerve; Neuromodulation; 2015; 317-323; 18. |
Watanabe, JH, et al.; Cost analysis of interventions for antimuscarinic refractory patients with overactive bladder; Urology; 2010; 835-840; 76. |
Wehbe, SA, et al.; Minimally invasive therapies for chronic pelvic pain syndrome; Curr Urol Rep; 2010; 276-285; 11. |
Wehbe, SA, et al.; Sacral neuromodulations for female lower urinary tract, pelvic floor, and bowel disorders; Curr Opin Obstet Gynecol; 2010; 414-419; 22. |
Weil, EH, et al.; Sacral root neuromodulation in the treatment of refractory urinary urge incontinence: a prospective randomized clinical trial; Eur Urol; 2000; 161-171; 37;Abstract. |
Wein, AJ, et al.; Overactive bladder: a better understanding of pathophysiology, diagnosis and management; J Urol; 2006; S5-10; 175. |
Wein, AJ; Diagnosis and treatment of the overactive bladder; Urology; 2003; 20-27; 62. |
Wein, AJ; Re: inhibition of bladder overactivity by a combination of tibial neuromodulation and tramadol treatment in cats; J Urol; 2014; 868-869; 191. |
Wein, AJ; Re: is on-demand sacral neuromodulation in patients with OAB syndrome a feasible therapy regime?; J Urol; 2013; 610-611; 189. |
Wein, AJ; Re: Results of a Prospective, Randomized, Multicenter Study Evaluating Sacral Neuromodulation with InterStim Therapy Compared to Standard Medical Therapy at 6-Months in Subjects with Mild Symptoms of Overactive Bladder; J Urol; 2015; 1051-1052; 194. |
Wenzler, DL, et al.; Proof of concept trial on changes in current perception threshold after sacral neuromodulation; Neuromodulation; 2015; 228-231; discussion 232; 18. |
Wexner, SD, et al.; Current surgical strategies to treat fecal incontinence; Expert Rev Gastroenterol Hepatol; 2015; 1577-1589; 9;Abstract. |
White, N, et al.; Overactive Bladder; Obstet Gynecol Clin North Am; 2016; 59-68; 43. |
Whitmore, KE; Complementary and alternative therapies as treatment approaches for interstitial cystitis; Rev Urol; 2002; S28-35; 4 Suppl 1. |
Wiklund, CU, et al.; Modulation of cholinergic and substance P-like neurotransmission by nitric oxide in the guinea-pig ileum; Br J Pharmacol; 1993; 833-839; 110. |
Wiklund, NP, et al.; Cholinergic neuromodulation by endothelin in guinea pig ileum; Neurosci Lett; 1989; 342-346; 101. |
Wiklund, NP, et al.; Neuromodulation by adenine nucleotides, as indicated by experiments with inhibitors of nucleotide inactivation; Acta Physiol Scand; 1986; 217-223; 126;Abstract. |
Williams, MJ, et al.; Self-Reported Medication Costs In Patients Receiving Sacral Neuromodulation For Overactive Bladder; Value Health; 2015; A352; 18. |
Withington, J, et al.; The changing face of urinary continence surgery in England: a perspective from the Hospital Episode Statistics database; BJU Int; 2014; 268-277; 114. |
Wolff, K, et al.; Functional outcome and quality of life after stapled transanal rectal resection for obstructed defecation syndrome; Dis Colon Rectum; 2010; 881-888; 53. |
Wood, LN, et al.; Urinary incontinence in women; Bmj; 2014; g4531; 349. |
Wooldridge, LS; Percutaneous tibial nerve stimulation for the treatment of urinary frequency, urinary urgency, and urge incontinence: results from a community-based clinic; Urol Nurs; 2009; 177-185; 29. |
Worsoe, J, et al.; Turning off sacral nerve stimulation does not affect gastric and small intestinal motility in patients treated for faecal incontinence; Colorectal Dis; 2012; e713-720; 14. |
Wosnitzer, MS, et al.; The use of sacral neuromodulation for the treatment of non-obstructive urinary retention secondary to Guillain-Barre syndrome; Int Urogynecol J Pelvic Floor Dysfunct; 2009; 1145-1147; 20. |
Wu, JM, et al.; Patient preferences for different severities of and treatments for overactive bladder; Female Pelvic Med Reconstr Surg; 2011; 184-189; 17;Abstract. |
Wyndaele, JJ, et al.; Conservative treatment of the neuropathic bladder in spinal cord injured patients; Spinal Cord; 2001; 294-300; 39. |
Wyndaele, JJ, et al.; Influence of sacral neuromodulation on electrosensation of the lower urinary tract; J Urol; 2000; 221-224; 163. |
Wyndaele, JJ; Clinical outcome of sacral neuromodulation in incomplete spinal cord injured patients suffering from neurogenic lower urinary tract symptoms; Spinal Cord; 2009; 427; 47. |
Xiao, Z, et al.; Role of spinal GABAA receptors in pudendal inhibition of nociceptive and nonnociceptive bladder reflexes in cats; Am J Physiol Renal Physiol; 2014; F781-789; 306. |
Kovacevic, M, et al.; Reflex neuromodulation of bladder function elicited by posterior tibial nerve stimulation in anesthetized rats; Am J Physiol Renal Physiol; 2015; F320-329; 308. |
Krames, E, et al.; Spinal cord stimulation reverses pain and diarrheal episodes of irritable bowel syndrome: a case report; Neuromodulation; 2004; 82-88; 7. |
Krivoborodov, GG, et al.; [Afferent stimulation of the tibial nerve in patients with hyperactive bladder]; Urologiia; 2002; 36-39; ;Abstract. |
Krivoborodov, GG, et al.; [Tibial neuromodulation in the treatment of neurogenic detrusor hyperactivity in patients with Parkinson's disease]; Urologiia; 2006; 42435; ;Abstract. |
Krolczyk, G, et al.; Effects of continuous microchip (MC) vagal neuromodulation on gastrointestinal function in rats J Physiol Pharmacol; 2001; 705-715; 52. |
Kubota, M, et al.; Effects of neuromodulation with sacral magnetic stimulation for intractable bowel or bladder dysfunction in postoperative patients with anorectal malformation: a preliminary report; Pediatr Surg Int; 2011; 599-603; 27. |
Kumsar, S, et al.; Effects of sacral neuromodulation on isolated urinary bladder function in a rat model of spinal cord injury; Neuromodulation; 2015; 67-74; discussion 74-65; 18. |
Kuo, HC; Recovery of detrusor function after urethral botulinum A toxin injection in patients with idiopathic low detrusor contractility and voiding dysfunction; Urology; 2007; 57-61; discussion 61-52; 69. |
Kuo, TL, et al.; Pelvic floor spasm as a cause of voiding dysfunction; Curr Opin Urol; 2015; 311-316; 25. |
Kurpad, R, et al.; The evaluation and management of refractory neurogenic overactive bladder; Curr Urol Rep; 2014; 444; 15. |
Kutzenberger, J; [Neurogenic urinary incontinence. Value of surgical management]; Urologe A; 2008; 699-706; 47. |
La, TH, et al.; Intermittent sacral neuromodulation for idiopathic urgency urinary incontinence in women; Neurourol Urodyn; 2015;Abstract. |
Laudano, MA, et al.; Disparities in the Use of Sacral Neuromodulation among Medicare Beneficiaries; J Urol; 2015; 449-453; 194. |
Laviana, A, et al.; Sacral neuromodulation for refractory overactive bladder, interstitial cystitis, and painful bladder syndrome; Neurosurg Clin N Am; 2014; 33-46; 25. |
Lay, AH, et al.; The role of neuromodulation in patients with neurogenic overactive bladder; Curr Urol Rep; 2012; 343-347; 13. |
Lazzeri, M, et al.; The challenge of overactive bladder therapy: alternative to antimuscarinic agents; Int Braz J Urol; 2006; 620-630; 32. |
Le, NB, et al.; Expanding the Role of Neuromodulation for Overactive Bladder: New Indications and Alternatives to Delivery; Curr Bladder Dysfunct Rep; 2011; 25-30; 6. |
Leclers, F, et al.; [Cystomanometric study of bladder sensation during sacral neuromodulation test]; Prog Urol; 2005; 238-243; 15;Abstract. |
Lee, YY; What's New in the Toolbox for Constipation and Fecal Incontinence?; Front Med (Lausanne); 2014; 5; 1. |
Leicht, W, et al.; [Botulinum toxin versus sacral neuromodulation for idiopathic detrusor overactivity]; Urologe A; 2012; 348-351; 51. |
Leng, WW, et al.; How sacral nerve stimulation neuromodulation works; Urol Clin North Am; 2005; 42692; 32. |
Leong, FC, et al.; Neuromodulation for the treatment of urinary incontinence; Mo Med; 2007; 435-439; 104;Abstract. |
Leong, RK, et al.; Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin A treatment for patients with idiopathic overactive bladder; BJU Int; 2011; 558-564; 108. |
Leong, RK, et al.; Current information on sacral neuromodulation and botulinum toxin treatment for refractory idiopathic overactive bladder syndrome: a review; Urol Int; 2010; 245-253; 84. |
Leong, RK, et al.; PNE versus 1st stage tined lead procedure: a direct comparison to select the most sensitive test method to identify patients suitable for sacral neuromodulation therapy; Neurourol Urodyn; 2011; 1249-1252; 30. |
Leong, RK, et al.; Satisfaction and patient experience with sacral neuromodulation: results of a single center sample survey; J Urol; 2011; 588-592; 185. |
Levin, PJ, et al.; Psychosocial factors related to the use of InterStim(R) for the treatment of refractory overactive bladder; Female Pelvic Med Reconstr Surg; 2014; 272-275; 20;Abstract. |
Levin, PJ, et al.; The efficacy of posterior tibial nerve stimulation for the treatment of overactive bladder in women: a systematic review; Int Urogynecol J; 2012; 1591-1597; 23. |
Levy, RM; The evolving definition of neuromodulation; Neuromodulation; 2014; 207-210; 17. |
Lewis, JM, et al.; Non-traditional management of the neurogenic bladder: tissue engineering and neuromodulation ScientificWorldJournal; 2007; 1230-1241; 7. |
Liao, KK, et al.; Effect of sacral neuromodulation on the spinal nociceptive reflex of patients with idiopathic overactive bladder; Neuromodulation; 2008; 50-55; 11. |
Liberman, D, et al.; Concerns regarding sacral neuromodulation as a treatment option for medical-refractory overactive bladder; Can Urol Assoc J; 2011; 285-287; 5. |
Lin, YT, et al.; Effects of pudendal neuromodulation on bladder function in chronic spinal cord-injured rats; J Formos Med Assoc; 2015. |
Linares Quevedo, AI, et al.; [Posterior sacral root neuromodulation in the treatment of chronic urinary dysfunction] Actas Urol Esp; 2002; 250-260; 26;Abstract. |
Lippmann, QK, et al.; Successful use of sacral neuromodulation in a 12-year-old with cerebral palsy and neurogenic bladder; Neuromodulation; 2014; 396-398; 17. |
Lombardi, G, et al.; Clinical concomitant benefits on pelvic floor dysfunctions after sacral neuromodulation in patients with incomplete spinal cord injury; Spinal Cord; 2011; 629-636; 49. |
Lombardi, G, et al.; Clinical female sexual outcome after sacral neuromodulation implant for lower urinary tract symptom (LUTS); J Sex Med; 2008; 1411-1417; 5. |
Lombardi, G, et al.; Clinical outcome of sacral neuromodulation in incomplete spinal cord injured patients suffering from neurogenic lower urinary tract symptoms; Spinal Cord; 2009; 486-491; 47. |
Lombardi, G, et al.; Clinical outcome of sacral neuromodulation in incomplete spinal cord-injured patients suffering from neurogenic bowel dysfunctions; Spinal Cord; 2010; 154-159; 48. |
Lombardi, G, et al.; Intravesical electrostimulation versus sacral neuromodulation for incomplete spinal cord patients suffering from neurogenic non-obstructive urinary retention; Spinal Cord; 2013; 571-578; 51. |
Lombardi, G, et al.; Sacral neuromodulation and female sexuality; Int Urogynecol J; 2015; 1751-1757; 26. |
Lombardi, G, et al.; Sacral neuromodulation for lower urinary tract dysfunction and impact on erectile function; J Sex Med; 2008; 2135-2140; 5. |
Lombardi, G, et al.; Sacral neuromodulation for neurogenic non-obstructive urinary retention in incomplete spinal cord patients: a ten-year follow-up single-centre experience; Spinal Cord; 2014; 241-245; 52. |
Lopez-Delgado, A, et al.; Effect on anal pressure of percutaneous posterior tibial nerve stimulation for faecal ncontinence; Colorectal Dis; 2014; 533-537; 16. |
Lowette, K, et al.; Role of corticosterone in the murine enteric nervous system during fasting; Am J Physiol Gastrointest Liver Physiol; 2014; G905-913; 307. |
Lyon, TD, et al.; Pudendal but not tibial nerve stimulation inhibits bladder contractions induced by stimulation of pontine micturition center in cats; Am J Physiol Regul Integr Comp Physiol; 2016; R366-374; 310. |
M. Matsushita et al.; Primary somatosensory evoked magnetic fields elicited by sacralsurface electrical stimulation; Neuroscience Letters; 2008; 77?80; 431. |
Madersbacher, H, et al.; What are the causes and consequences of bladder overdistension? ICI-RS 2011; Neurourol Urodyn; 2012; 317-321; 31. |
Madersbacher, H; Overactive bladder—a practical approach to evaluation and management; J Med Liban; 2004; 220-226; 52;Abstract. |
Maeda, Y, et al.; Sacral nerve stimulation for faecal incontinence and constipation: a European consensus statement; Colorectal Dis; 2015; O74-87; 17. |
Del Popolo, G, et al.; [Standard pharmacological treatment and new therapies for overactive bladder]; Urologia; 2012; 42534; 79. |
Denzinger, S, et al.; Does sacral neuromodulation lead to relevant reduction in the need for intermittent catheterization? A single-center experience on patients with chronic urinary retention; Neuromodulation; 2012; 586-591; discussion 591; 15. |
Desrosiers, L, et al.; Urogynecologic conditions: interstitial cystitis/painful bladder syndrome; FP Essent; 2015; 17-22; 430;Abstract. |
Devane, LA, et al.; Acute lumbosacral nerve stimulation does not affect anorectal motor function in a rodent model Neurogastroenterol Motil; 2016; 358-363; 28. |
Devroede, G, et al.; Quality of life is markedly improved in patients with fecal incontinence after sacral nerve stimulation; Female Pelvic Med Reconstr Surg; 2012; 103-112; 18;Abstract. |
Di Giovangiulio, M, et al.; The Neuromodulation of the Intestinal Immune System and its Relevance in Inflammatory Bowel Disease; Front Immunol; 2015; 590; 6. |
Dijkema, HE, et al.; [Initial experiences with neuromodulation as treatment for incontinence and micturition disorders in The Netherlands]; Ned Tijdschr Geneeskd; 1992; 88-90; 136;Abstract. |
Dijkema, HE, et al.; Neuromodulation of sacral nerves for incontinence and voiding dysfunctions Clinical results and complications; Eur Urol; 1993; 72-76; 24;Abstract. |
Dmochowski, R; Neuromodulation and the urinary tract—are we over the rainbow or have we simply stepped through the looking glass?; J Urol; 2007; 1844-1845; 178. |
Donon, L, et al.; [Sacral neuromodulation: results of a monocentric study of 93 patients]; Prog Urol; 2014; 1120-1131; 24;Abstract. |
Dorflinger, A, et al.; Voiding dysfunction; Curr Opin Obstet Gynecol; 2001; 507-512; 13. |
Doumouchtsis, SK, et al.; Female voiding dysfunction; Obstet Gynecol Surv; 2008; 519-526; 63. |
Drake, MJ; Management and rehabilitation of neurologic patients with lower urinary tract dysfunction; Handb Clin Neurol; 2015; 451-468; 130. |
Drossaerts, J, et al.; Screening for depression and anxiety in patients with storage or voiding dysfunction: A retrospective cohort study predicting outcome of sacral neuromodulation; Neurourol Urodyn; 2015;Abstract. |
Drossaerts, J, et al.; The value of urodynamic tools to guide patient selection in sacral neuromodulation; World J Urol;2015; 1889-1895; 33. |
Dudding, TC, et al.; Sacral nerve stimulation for faecal incontinence: optimizing outcome and managing complications; Colorectal Dis; 2011; e196-202; 13. |
Dudding, TC, et al.; Sacral nerve stimulation for faecal incontinence: patient selection, service provision and operative technique; Colorectal Dis; 2011; e187-195; 13. |
Dudding, TC, et al.; Sacral nerve stimulation: an effective treatment for chronic functional anal pain?; Colorectal Dis; 2013; 1140-1144; 15. |
Dudding, TC; Future indications for sacral nerve stimulation; Colorectal Dis; 2011; 23-28; 13 Suppl 2. |
Duelund-Jakobsen, J, et al.; Baseline factors predictive of patient satisfaction with sacral neuromodulation for idiopathic fecal incontinence; Int J Colorectal Dis; 2014; 793-798; 29. |
Duthie, J, et al.; Botulinum toxin injections for adults with overactive bladder syndrome; Cochrane Database Syst Rev; 2007; Cd005493; ;Abstract. |
Duthie, JB, et al.; Botulinum toxin injections for adults with overactive bladder syndrome; Cochrane Database Syst Rev; 2011; Cd005493. |
Duve, H, et al.; Distribution and functional significance of Leu-callatostatins in the blowfly Calliphora vomitoria; Cell Tissue Res; 1994; 367-379; 276. |
Dwyer, ME, et al.; The dysfunctional elimination syndrome in children—is sacral neuromodulation worth the trouble?;J Urol; 2012; 1076-1077; 188. |
Elkelini, MS, et al.; Mechanism of action of sacral nerve stimulation using a transdermal amplitude-modulated signal in a spinal cord injury rodent model; Can Urol Assoc J; 2012; 227-230; 6. |
Elkelini, MS, et al.; Safety of MRI at 1.51Tesla in patients with implanted sacral nerve neurostimulator; Eur Urol 2006; 311-316; 50. |
Ellsworth, P, et al.; Neurogenic detrusor overactivity: an update on management options; R I Med J (2013); 2013; 38-40; 96. |
Ellsworth, P, et al.; Update on the pharmacologic management of overactive bladder: the present and the future Urol Nurs; 2010; 29-38, 53; 30. |
Elneil, S, et al.; Optimizing the duration of assessment of stage-1 sacral neuromodulation in nonobstructive chronic urinary retention; Neuromodulation; 2014; 66-70; discussion 70-61; 17. |
Elneil, S; Urinary retention in women and sacral neuromodulation; Int Urogynecol J; 2010; S475-483; 21 Suppl 2. |
Elser, DM; Stress urinary incontinence and overactive bladder syndrome: current options and new targets for management; Postgrad Med; 2012; 42-49; 124;Abstract. |
Evans, RJ; Sacral neuromodulation is an effective treatment for interstitial cystitis/bladder pain syndrome: con; J Urol; 2012; 2044-2045; 188. |
Everaert, K, et al.; Sacral nerve stimulation for pelvic floor and bladder dysfunction in adults and children Neuromodulation; 2005; 186-187; 8. |
Everaert, K, et al.; The urodynamic evaluation of neuromodulation in patients with voiding dysfunction; Br J Urol; 1997; 702-707; 79. |
Evers, J, et al.; Effects of stimulation frequency and intensity in sacral neuromodulation on anorectal inputs to the somatosensory cortex in an experimental model; Br J Surg; 2014; 1317-1328; 101. |
Evers, J, et al.; Reversal of sensory deficit through sacral neuromodulation in an animal model of fecal incontinence; Neurogastroenterol Motil; 2016;Abstract. |
Fall, M, et al.; EAU guidelines on chronic pelvic pain; Eur Urol; 2004; 681-689; 46. |
Fall, M, et al.; EAU guidelines on chronic pelvic pain; Eur Urol; 2010; 35-48; 57. |
Falletto, E, et al.; Is sacral nerve stimulation an effective treatment for chronic idiopathic anal pain?; Dis Colon Rectum; 2009; 456-462; 52. |
Falletto, E, et al.; Sacral neuromodulation for bowel dysfunction: a consensus statement from the Italian group; Tech Coloproctol; 2014; 53-64; 18. |
Fang, Q, et al.; [Morphological study on the role of ICC-like cells in detrusor neuro-modulation of rat urinary bladder] Zhonghua Wai Ke Za Zhi; 2008; 1542-1545; 46. |
Fariello, JY, et al.; Sacral neuromodulation stimulation for IC/PBS, chronic pelvic pain, and sexual dysfunction; Int Urogynecol J; 2010; 1553-1558; 21. |
Faucheron, JL, et al.; Sacral neuromodulation for bowel dysfunction; Tech Coloproctol; 2014; 42433; 18. |
Faucheron, JL; [Anal incontinence]; Presse Med; 2008; 1447-1462; 37;Abstract. |
Feler, CA, et al.; Sacral neuromodulation for chronic pain conditions; Anesthesiol Clin North America; 2003; 785-795; 21. |
Felt-Bersma, RJ, et al.; Temperature-controlled radiofrequency energy (SECCA) to the anal canal for the treatment of faecal incontinence offers moderate improvement; Eur J Gastroenterol Hepatol; 2007; 575-580; 19;Abstract. |
Ferhi, K, et al.; [Results of sacral posterior neuromodulation on voiding disorders and impact on sexuality based on a single-center study]; Prog Urol; 2008; 160-166; 18;Abstract. |
Ferroni, MC, et al.; Role of the brain stem in tibial inhibition of the micturition reflex in cats; Am J Physiol Renal Physiol; 2015; F242-250; 309. |
Ferulano, GP, et al.; [Sacral neuromodulation in fecal continence disorders]; Recenti Prog Med; 2002; 403-409; 93;Abstract. |
Finazzi-Agro, E, et al.; Percutaneous tibial nerve stimulation produces effects on brain activity: study on the modifications of the long latency somatosensory evoked potentials; Neurourol Urodyn; 2009; 320-324; 28. |
Shen, B, et al.; Neuromodulation of bladder activity by stimulation of feline pudendal nerve using a transdermal amplitude modulated signal (TAMS); Neurourol Urodyn; 2011; 1686-1694; 30. |
Shepherd, JP, et al.; InterStim Sacral Neuromodulation and Botox Botulinum-A Toxin Intradetrusor Injections for Refractory Urge Urinary Incontinence: A Decision Analysis Comparing Outcomes Including Efficacy and Complications; Female Pelvic Med Reconstr Surg; 2011; 199-203; 17;Abstract. |
Sherif, H, et al.; Posterior tibial nerve stimulation as treatment for the overactive bladder; Arab J Urol; 2013; 131-135; 11. |
Sheriff, MK, et al.; Neuromodulation of detrusor hyper-reflexia by functional magnetic stimulation of the sacral roots; Br J Urol; 1996; 39-46; 78;Abstract. |
Sherman, ND, et al.; Current and future techniques of neuromodulation for bladder dysfunction; Curr Urol Rep; 2007; 448-454; 8. |
Sherman, ND, et al.; Sacral neuromodulation for the treatment of refractory urinary urge incontinence after stress incontinence surgery; Am J Obstet Gynecol; 2005; 2083-2087; 193. |
Sherman, ND, et al.; The current use of neuromodulation for bladder dysfunction; Minerva Ginecol; 2006; 283-293; 58;Abstract. |
Shi, P, et al.; Bladder response to acute sacral neuromodulation while treating rats in different phases of complete spinal cord injury: a preliminary study; Int Braz J Urol; 2015; 1194-1201; 41. |
Shi, P, et al.; Effects of acute sacral neuromodulation on bladder reflex in complete spinal cord injury rats; Neuromodulation; 2013; 583-589; discussion 589; 16. |
Shvarts, PG, et al.; [The modern methods of the electrical stimulation for the management of neurogenic disturbances of urination]; Vopr Kurortol Fizioter Lech Fiz Kult; 2015; 18-21; 92. |
Siegel, S, et al.; Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder, Neurourol Urodyn; 2015; 224-230; 34. |
Sievert, KD, et al.; [Unconventional treatment procedures of the bladder in paraplegia and myelomeningocele]; Urologe A; 2012; 1692-1696; 51. |
Sievert, KD, et al.; Early sacral neuromodulation prevents urinary incontinence after complete spinal cord injury; Ann Neurol; 2010; 74-84; 67. |
Sievert, KD; Neuromodulation; Neurourol Urodyn; 2005; 310; 24. |
Signorello, D, et al.; Impact of sacral neuromodulation on female sexual function and his correlation with clinical outcome and quality of life indexes: a monocentric experience; J Sex Med; 2011; 1147-1155; 8. |
Sillen, U, et al.; Effects of transcutaneous neuromodulation (TENS) on overactive bladder symptoms in children: a randomized controlled trial; J Pediatr Urol; 2014; 1100-1105; 10. |
Silveri, M, et al.; Voiding dysfunction in x-linked adrenoleukodystrophy: symptom score and urodynamic findings; J Urol; 2004; 2651-2653; 171. |
Sivalingam, N, et al.; Concepts in the management of the overactive bladder in women; Med J Malaysia; 2012; 137-141; quiz 142; 67. |
Skobejko-Wlodarska, L; [Non-neurogenic lower urinary tract dysfunction]; Pol Merkur Lekarski; 2008; 131-137; 24 Suppl 4;Abstract. |
Smaldone, MC, et al.; Neuromodulation versus neurotoxin for the treatment of refractory detrusor overactivity: for neurotoxin; Nat Clin Pract Urol; 2008; 120-121; 5. |
Smith, AL, et al.; Contemporary management of overactive bladder; Postgrad Med; 2012; 104-116; 124;Abstract. |
Smits, MA, et al.; [Neuromodulation as a treatment for overactive bladder syndrome]; Ned Tijdschr Geneeskd; 2012; A4135; 156;Abstract. |
Smits, MA, et al.; Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy; J Urol; 2013; 2148-2152; 190. |
Snellings, AE, et al.; Effects of stimulation site and stimulation parameters on bladder inhibition by electrical nerve stimulation; BJU Int; 2012; 136-143; 110. |
South, MM, et al.; Detrusor overactivity does not predict outcome of sacral neuromodulation test stimulation; Int Urogynecol J Pelvic Floor Dysfunct; 2007; 1395-1398; 18. |
Speer, LM, et al.; Chronic Pelvic Pain in Women; Am Fam Physician; 2016; 380-387; 93. |
Spinelli, M, et al.; A new minimally invasive procedure for pudendal nerve stimulation to treat neurogenic bladder description of the method and preliminary data; Neurourol Urodyn; 2005; 305-309; 24. |
Spinelli, M, et al.; Latest technologic and surgical developments in using InterStim Therapy for sacral neuromodulation: impact on treatment success and safety; Eur Urol; 2008; 1287-1296; 54. |
Spinelli, M, et al.; New sacral neuromodulation lead for percutaneous implantation using local anesthesia description and first experience; J Urol; 2003; 1905-1907; 170. |
Srivastava, D; Efficacy of sacral neuromodulation in treating chronic pain related to painful bladder syndrome/interstitial cystitis in adults; J Anaesthesiol Clin Pharmacol; 2012; 428-435; 28. |
Starkman, JS, et al.; Management of refractory urinary urge incontinence following urogynecological surgery with sacral neuromodulation; Neurourol Urodyn; 2007; 29-35; discussion 36; 26. |
Starkman, JS, et al.; Refractory overactive bladder after urethrolysis for bladder outlet obstruction: management with sacral neuromodulation; Int Urogynecol J Pelvic Floor Dysfunct; 2008; 277-282; 19. |
Starkman, JS, et al.; Surgical options for drug-refractory overactive bladder patients; Rev Urol; 2010; e97-e110; 12. |
Starkman, JS, et al.; The evolution of obstruction induced overactive bladder symptoms following urethrolysis for female bladder outlet obstruction; J Urol; 2008; 1018-1023; 179. |
Steanu, ID, et al.; The Place of the Ice Water Test (IWT) in the Evaluation of the Patients with Traumatic Spinal Cord Injury; Maedica (Buchar); 2012; 125-130; 7. |
Stephany, HA, et al.; Prospective evaluation of sacral nerve modulation in children with validated questionnaires; J Urol; 2013; 1516-1522; 190. |
Stoffel, JT; Contemporary management of the neurogenic bladder for multiple sclerosis patients; Urol Clin North Am; 2010; 547-557; 37. |
Su, X, et al.; Comparison of neural targets for neuromodulation of bladder micturition reflex in the rat; Am J Physiol Renal Physiol; 2012; F1196-1206; 303. |
Su, X, et al.; Differentiation and interaction of tibial versus spinal nerve stimulation for micturition control in the rat; Neurourol Urodyn; 2015; 92-97; 34. |
Su, X, et al.; Neuromodulation attenuates bladder hyperactivity in a rat cystitis model; BMC Urol; 2013; 70; 13. |
Su, X, et al.; Neuromodulation in a rat model of the bladder micturition reflex; Am J Physiol Renal Physiol; 2012; F477-486; 302. |
Su, X, et al.; Optimization of Neuromodulation for Bladder Control in a Rat Cystitis Model; Neuromodulation; 2016; 101-107; 19. |
Su, X, et al.; Preclinical assessment of potential interactions between botulinum toxin and neuromodulation for bladder micturition reflex; BMC Urol; 2015; 50; 15. |
Su, X, et al.; Quantification of effectiveness of bilateral and unilateral neuromodulation in the rat bladder rhythmic contraction model; BMC Urol; 2013; 34; 13. |
Su, X, et al.; Role of the endogenous opioid system in modulation of urinary bladder activity by spinal nerve stimulation; Am J Physiol Renal Physiol; 2013; F52-60; 305. |
Sullivan, J, et al.; Overactive detrusor; Curr Opin Urol; 1999; 291-296; 9. |
Sullivan, J, et al.; The overactive bladder: neuropharmacological basis of clinical management; Curr Opin Obstet Gynecol; 1999; 477-483; 11. |
Sun, Y, et al.; Effects of neural blocking agents on motor activity and secretion in the proximal and distal rat colon; evidence of marked segmental differences in nicotinic receptor activity; Scand J Gastroenterol; 2000; 380-388; 35. |
Suskind, AM, et al.; Physician Use of Sacral Neuromodulation Among Medicare Beneficiaries With Overactive Bladder and Urinary Retention; Urology; 2015; 30-34; 86. |
Suskind, AM, et al.; Understanding the dissemination of sacral neuromodulation; Surg Innov; 2013; 625-630; 20. |
Maher, CF, et al.; Percutaneous sacral nerve root neuromodulation for intractable interstitial cystitis; J Urol; 2001; 884-886; 165. |
Maher, RM, et al.; A novel externally applied neuromuscular stimulator for the treatment of stress urinary incontinence in women—a pilot study; Neuromodulation; 2013; 590-594; discussion 594; 16. |
Majerus, SJ, et al.; Low-power wireless micromanometer system for acute and chronic bladder-pressure monitoring; IEEE Trans Biomed Eng; 2011; 763-767; 58. |
Majerus, SJ, et al.; Wireless, Ultra-Low-Power Implantable Sensor for Chronic Bladder Pressure Monitoring; ACM J Emerg Technol Comput Syst; 2012;8. |
Mally, AD, et al.; Role of opioid and metabotropic glutamate 5 receptors in pudendal inhibition of bladder overactivity in cats; J Urol; 2013; 1574-1579; 189. |
Malossi, J, et al.; Sacral neuromodulation for the treatment of bladder dysfunction; Curr Urol Rep; 2002; 61-66; 3. |
Malouf, AJ, et al.; Short-term effects of sacral nerve stimulation for idiopathic slow transit constipation; World J Surg; 2002; 166-170; 26. |
Mamopoulos, A, et al.; Active sacral neuromodulator during pregnancy: a unique case report; Am J Obstet Gynecol; 2014; e4-5; 211. |
Manriquez, V, et al.; Transcutaneous posterior tibial nerve stimulation versus extended release oxybutynin in overactive bladder patients. A prospective randomized trial; Eur J Obstet Gynecol Reprod Biol; 2016; 42531; 196. |
Marcelissen, T, et al.; Is the screening method of sacral neuromodulation a prognostic factor for long-term success?; J Urol; 2011; 583-587; 185. |
Marcelissen, T, et al.; Sacral neuromodulation as a treatment for chronic pelvic pain; J Urol; 2011; 387-393; 186. |
Marcelissen, TA, et al.; Long-term results of sacral neuromodulation with the lined lead procedure; J Urol; 2010; 1997-2000; 184. |
Marcelissen, TA, et al.; Psychological and psychiatric factors as predictors for success in sacral neuromodulation treatment; BJU Int; 2011; 1834-1838; 108. |
Marcelissen, TA, et al.; The effect of pulse rate changes on the clinical outcome of sacral neuromodulation; J Urol; 2011; 1781-1785; 185. |
Marcelissen, TA, et al.; The use of bilateral sacral nerve stimulation in patients with loss of unilateral treatment efficacy; J Urol; 2011; 976-980; 185. |
Marinkovic, SP, et al.; Neuromodulation for Overactive Bladder Symptoms in Women Utilizing Either Motor or Sensory/Motor Provocation With a Minimum Nine-Year Follow-Up; Neuromodulation; 2015; 517-521; discussion 521; 18. |
Martin Braun, P, et al.; [Continuous bilateral sacral neuromodulation as a minimally invasive implantation technique in patients with functional bladder changes]; Arch Esp Urol; 2003; 497-501; 56. |
Martinson, M, et al.; Cost of neuromodulation therapies for overactive bladder: percutaneous tibial nerve stimulation versus sacral nerve stimulation; J Urol; 2013; 210-216; 189. |
Mason, MD, et al.; Prospective Evaluation of Sacral Neuromodulation in Children: Outcomes and Urodynamic Predictors of Success; J Urol; 2016. |
Matsuta, Y, et al.; Contribution of opioid and metabotropic glutamate receptor mechanisms to inhibition of bladder overactivity by tibial nerve stimulation; Am J Physiol Regul Integr Comp Physiol; 2013; R126-133; 305. |
Matsuta, Y, et al.; Effect of methysergide on pudendal inhibition of micturition reflex in cats; Exp Neurol; 2013; 250-258; 247. |
Matsuta, Y, et al.; Poststimulation inhibition of the micturition reflex induced by tibial nerve stimulation in rats Physiol Rep; 2014; e00205; 2. |
Mauroy, B, et al.; [Long-term results of interferential current stimulation in the treatment of bladder instability]; Prog Urol; 2001; 34-39; 11; Abstract. |
Mayer, R; Neuromodulation—who, what, when, where and why?; J Urol; 2010; 17-18; 183. |
Mayr, CA, et al.; Cost-effectiveness of novel therapies for overactive bladder; Expert Rev Pharmacoecon Outcomes Res; 2014; 527-535; 14. |
Mazo, EB, et al.; [Temporary sacral and tibial neuromodulation in treating patients with overactive urinary bladder]; Zh Vopr Neirokhir Im N N Burdenko; 2002; 17-21; ;Abstract. |
Mazo, EB, et al.; [Temporary sacral neuromodulation in patients with urge incontinence]; Urologiia; 2000; 42-46; ;Abstract. |
Mazo, EB, et al.; [The role of somatosensory evoked potentials in prognosis of efficacy of tibial neuromodulation in patients with hyperactive urinary bladder]; Urologiia; 2005; 49-52; ;Abstract. |
Mcachran, SE, et al.; Sacral neuromodulation in the older woman; Clin Obstet Gynecol; 2007; 735-744; 50. |
Mckertich, K; Urinary incontinence-procedural and surgical treatments for women; Aust Fam Physician; 2008; 122-131; 37. |
Mcnevin, MS, et al.; Outcomes associated with Interstim therapy for medically refractory fecal incontinence; Am J Surg; 2014; 735-737; discussion 737-788; 207. |
Mehnert, U, et al.; [Neuro-urological dysfunction of the lower urinary tract in CNS diseases: pathophysiology, epidemiology, and treatment options]; Urologe A; 2012; 189-197; 51. |
Mehnert, U, et al.; The management of urinary incontinence in the male neurological patient; Curr Opin Urol; 2014; 586-592; 24. |
Meissnitzer, T, et al.; CT-Guided Lead Placement for Selective Sacral Neuromodulation to Treat Lower Urinary Tract Dysfunctions; AJR Am J Roentgenol; 2015; 1139-1142; 205. |
Melenhorst, J, et al.; Sacral neuromodulation in patients with faecal incontinence: results of the first 100 permanent implantations; Colorectal Dis; 2007; 725-730; 9. |
Meurette, G, et al.; Sacral nerve stimulation enhances epithelial barrier of the rectum: results from a porcine model; Neurogastroenterol Motil; 2012; 267-273, e110; 24. |
Michael Craggs and Jonathon McFARLANE; Neuromodulation of the lower urinary tract; Experimental Physiology (1999), 84, 149-160. |
Michelsen, HB, et al.; Rectal volume tolerability and anal pressures in patients with fecal incontinence treated with sacral nerve stimulation; Dis Colon Rectum; 2006; 1039-1044; 49. |
Miller, JJ, et al.; Diagnosis and treatment of overactive bladder; Minerva Ginecol; 2005; 501-520; 57;Abstract. |
Milne, JL; Behavioral therapies for overactive bladder: making sense of the evidence; J Wound Ostomy Continence Nurs; 2008; 93-101; quiz 102-103; 35;Abstract. |
Minardi, D, et al.; Activity and expression of nitric oxide synthase in rat bladder after sacral neuromodulation; Int J Immunopathol Pharmacol; 2008; 129-135; 21;Abstract. |
Minardi, D, et al.; Lower urinary tract and bowel disorders and multiple sclerosis: role of sacral neuromodulation: a preliminary report; Neuromodulation; 2005; 176-181; 8. |
Miotla, P, et al.; [Sacral nerve stimulation in the treatment of the lower urinary tract function disorders]; Ginekol Pol; 2011; 851-856; 82. |
Mishra, NN; Clinical presentation and treatment of bladder pain syndrome/interstitial cystitis (BPS/IC) in India; Transl Androl Urol; 2015; 512-523; 4. |
Moon, KH, et al.; Prospective Trial of Sacral Neuromodulation for Refractory Overactive Bladder Syndrome in Korean Patients; Low Urin Tract Symptoms; 2014; 175-179; 6. |
Moutzouris, DA, et al.; Interstitial cystitis: an unsolved enigma; Clin J Am Soc Nephrol; 2009; 1844-1857; 4. |
Murphy, AM, et al.; Treatment of overactive bladder: what is on the horizon?; Int Urogynecol J; 2013; 42503; 24. |
Musco, S, et al.; Percutaneous Tibial Nerve Stimulation Improves Female Sexual Function in Women With Overactive Bladder Syndrome; J Sex Med; 2016. |
N. Patidar et al.; Transcutaneous posterior tibial nerve stimulation in pediatric overactivebladder: A preliminary report; Journal of Pediatric Urology; 2015; 351.e1-351.e6; 11. |
Nakib, N, et al.; Neuromodulation versus neurotoxin for the treatment of refractory detrusor overactivity: for neuromodulation; Nat Clin Pract Urol; 2008; 118-119; 5. |
Sutherland, RS, et al.; Vesicourethral function in mice with genetic disruption of neuronal nitric oxide synthase; J Urol; 1997; 1109-1116; 157. |
Svensson, L, et al.; Neuromodulation of experimental Shigella infection reduces damage to the gut mucosa Microbes Infect; 2004; 256-264; 6. |
Swinn, MJ, et al.; The cause and natural history of isolated urinary retention in young women; J Urol; 2002; 151-156; 167. |
Tai et al., “FootStim: Neuromodulation therapy for overactive bladder”; http://www.engineering.pitt.edu/Sub-Sites/Programs/Coulter/Projects/2013—FootStim/: retrieved on Sep. 26, 2017. |
Tai, C, et al.; Bladder inhibition by intermittent pudendal nerve stimulation in cat using transdermal amplitude-modulated signal (TAMS); Neurourol Urodyn; 2012; 1181-1184; 31. |
Tai, C, et al.; Inhibition of bladder overactivity by stimulation of feline pudendal nerve using transdermal amplitude-modulated signal (TAMS); BJU Int; 2012; 782-787; 109. |
Tai, C, et al.; Irritation induced bladder overactivity is suppressed by tibial nerve stimulation in cats; J Urol; 2011; 326-330; 186. |
Tai, C, et al.; Prolonged poststimulation inhibition of bladder activity induced by tibial nerve stimulation in cats; Am J Physiol Renal Physiol; 2011; F385-392; 300. |
Takahashi, S, et al.; Overactive bladder: magnetic versus electrical stimulation; CurrOpin Obstet Gynecol; 2003; 429-433; 15. |
Tanagho, EA; Concepts of neuromodulation; Neurourol Urodyn; 1993; 487-488; 12. |
Tanagho, EA; Neuromodulation in the management of voiding dysfunction in children; J Urol; 1992; 655-657; 148; Abstract. |
Tang, H, et al.; Combination of sacral neuromodulation and tolterodine for treatment of idiopathic overactive bladder in women: a clinical trial; Urol J; 2014; 1800-1805; 11. |
Taweel, WA, et al.; Neurogenic bladder in spinal cord injury patients; Res Rep Urol; 2015; 85-99; 7. |
Thin, NN, et al.; Randomized clinical trial of sacral versus percutaneous tibial nerve stimulation in patients with faecal incontinence; Br J Surg; 2015; 349-358; 102. |
Thin, NN, et al.; Systematic review of the clinical effectiveness of neuromodulation in the treatment of faecal incontinence; Br J Surg; 2013; 1430-1447; 100. |
Thomas, GP, et al.; A pilot study of transcutaneous sacral nerve stimulation for faecal incontinence; Colorectal Dis; 2013; 1406-1409; 15. |
Thomas, GP, et al.; Sacral nerve stimulation for faecal incontinence secondary to congenital imperforate anus; Tech Coloproctol; 2013; 227-229; 17. |
Thompson, JH, et al.; Sacral neuromodulation: Therapy evolution; Indian J Urol; 2010; 379-384; 26. |
Thoua, NM, et al.; Internal anal sphincter atrophy in patients with systemic sclerosis; Rheumatology (Oxford); 2011; 1596-1602; 50. |
Tian, Y, et al.; Inhibitory Effect and Possible Mechanism of Intraurethral Stimulation on Overactive Bladder in Female Rats; Int Neurourol J; 2015; 151-157; 19. |
Tirlapur, SA, et al.; Nerve stimulation for chronic pelvic pain and bladder pain syndrome: a systematic review; Acta Obstet Gynecol Scand; 2013; 881-887; 92. |
Tjandra, JJ, et al.; Sacral nerve stimulation is more effective than optimal medical therapy for severe fecal incontinence: a randomized, controlled study; Dis Colon Rectum; 2008; 494-502; 51. |
Tomonori Yamanishi et al.; Neuromodulation for the Treatment of Lower Urinary TractSymptoms; Low Urin Tract Symptoms; 2015; 121-132; 7. |
Traynor, TR, et al.; Neuromodulation of ion transport in porcine distal colon: NPY reduces secretory actions of leukotrienes; Am J Physiol; 1995; R426-431; 269;Abstract. |
Trevizol, AP, et al.; Trigeminal Nerve Stimulation (TNS) for the Treatment of Irritable Bowel Syndrome in an Elderly Patient with Major Depressive Disorder: A Case Study; Brain Stimul; 2015; 1235-1236; 8. |
Turner, WH, et al.; Smooth muscle of the bladder in the normal and the diseased state: pathophysiology, diagnosis and treatment; Pharmacol Ther; 1997; 77-110; 75. |
Ullah, S, et al.; Temporary gastric neuromodulation for intractable nausea and vomiting; Ann R Coll Surg Engl; 2011; 624-628; 93. |
Uludag, O, et al.; [Sacral neuromodulation is effective in the treatment of fecal incontinence with intact sphincter muscles; a prospective study]; Ned Tijdschr Geneeskd; 2002; 989-993; 146;Abstract. |
Uludag, O, et al.; Sacral neuromodulation in patients with fecal incontinence: a single-center study; Dis Colon Rectum; 2004; 1350-1357; 47. |
Uludag, O, et al.; Sacral neuromodulation: does it affect the rectoanal angle in patients with fecal incontinence? World J Surg; 2010; 1109-1114; 34. |
Uludag, O, et al.; Sacral neuromodulation: long-term outcome and quality of life in patients with faecal incontinence Colorectal Dis; 2011; 1162-1166; 13. |
Uludag, O, et al.; Sacral neuromodulation; does it affect colonic transit time in patients with faecal incontinence? Colorectal Dis; 2006; 318-322; 8. |
Unger, CA, et al.; Fecal incontinence: the role of the urologist; Curr Urol Rep; 2014; 388; 15. |
Unwala, DJ, et al.; Repeated botulinum toxin injection for idiopathic overactive bladder: will chemodenervation become a long-term solution?; Curr Urol Rep; 2007; 419-424; 8. |
Uranga, A, et al.; An integrated implantable electrical sacral root stimulator for bladder control; Neuromodulation; 2002; 238-247; 5. |
Vaarala, MH, et al.; Sacral neuromodulation in urological indications: the Finnish experience; Scand J Urol Nephrol; 2011; 46-51; 45. |
Vaizey, CJ, et al.; Effects of short term sacral nerve stimulation on anal and rectal function in patients with anal incontinence; Gut; 1999; 407-412; 44. |
Vallet, C, et al.; Sacral nerve stimulation for faecal incontinence: response rate, satisfaction and the value of preoperative investigation in patient selection; Colorectal Dis; 2010; 247-253; 12. |
Van Balken, MR, et al.; Prognostic factors for successful percutaneous tibial nerve stimulation; Eur Urol; 2006; 360-365; 49. |
Van Balken, MR, et al.; Sexual functioning in patients with lower urinary tract dysfunction improves after percutaneous tibial nerve stimulation; Int J Impot Res; 2006; 470-475; discussion 476; 18. |
Van Balken, MR, et al.; The use of electrical devices for the treatment of bladder dysfunction: a review of methods; J Urol; 2004; 846-851; 172. |
Van Balken, MR; Percutaneous tibial nerve stimulation: the Urgent PC device; Expert Rev Med Devices; 2007; 693-698; 4. |
Van Der AA, HE, et al.; Sacral anterior root stimulation for bladder control: clinical results; Arch Physiol Biochem; 1999; 248-256; 107. |
Van Der Pal, F, et al.; Current opinion on the working mechanisms of neuromodulation in the treatment of lower urinary tract dysfunction; Curr Opin Urol; 2006; 261-267; 16. |
Van Der Pal, F, et al.; Implant-Driven Tibial Nerve Stimulation in the Treatment of Refractory Overactive Bladder Syndrome: 12-Month Follow-up; Neuromodulation; 2006; 163-171; 9. |
Van Kerrebroeck, P; Editorial comment re: Killinger et al. “Secondary changes in bowel function after successful treatment of voiding symptoms with neuromodulation”; Neurourol Urodyn; 2011; 1403; 30. |
Van Kerrebroeck, PE, et al.; Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study; J Urol; 2007; 2029-2034; 178. |
Van Kerrebroeck, PE; Advances in the role of sacral nerve neuromodulation in lower urinary tract symptoms; Int Urogynecol J; 2010; S467-474; 21 Suppl 2. |
Van Kerrebroeck, PE; Neuromodulation and other electrostimulatory techniques; Scand J Urol Nephrol Suppl; 2002; 82-86. |
Van Kerrebroeck, PE; The role of electrical stimulation in voiding dysfunction; Eur Urol; 1998; 27-30; 34 Suppl 1; Abstract. |
Peters, KM, et al.; Effect of Sacral Neuromodulation on Outcome Measures and Urine Chemokines in Interstitial Cystitis/Painful Bladder Syndrome Patients; Low Urin Tract Symptoms; 2015; 77-83; 7. |
Peters, KM, et al.; Effect of Sacral Neuromodulation Rate on Overactive Bladder Symptoms: A Randomized Crossover Feasibility Study; Low Urin Tract Symptoms; 2013; 129-133; 5. |
Peters, KM, et al.; Is sensory testing during lead placement crucial for achieving positive outcomes after sacral neuromodulation?; Neurourol Urodyn; 2011; 1489-1492; 30. |
Peters, KM, et al.; Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study; J Urol; 2013; 2194-2201; 189. |
Peters, KM, et al.; Predictors of reoperation after sacral neuromodulation: A single institution evaluation of over 400 patients; Neurourol Urodyn; 2015;Abstract. |
Peters, KM, et al.; Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial; J Urol; 2010; 1438-1443; 183. |
Peters, KM; Alternative approaches to sacral nerve stimulation; Int Urogynecol J; 2010; 1559-1563; 21. |
Peters, KM; Sacral neuromodulation is an effective treatment for interstitial cystitis/bladder pain syndrome: pro; J Urol; 2012; 2043-2044; 188. |
Pettit, PD, et al.; Sacral neuromodulation: new applications in the treatment of female pelvic floor dysfunction; Curr Opin Obstet Gynecol; 2002; 521-525; 14. |
Peyronnet, B, et al.; [Management of overactive bladder in women]; Prog Urol; 2015; 877-883; 25;Abstract. |
Phe, V, et al.; How to define a refractory idiopathic overactive bladder?; Neurourol Urodyn; 2015; 42411; 34. |
Possover, M, et al.; Neuromodulation of the superior hypogastric plexus: a new option to treat bladder atonia secondary to radical pelvic surgery?; Surg Neurol; 2009; 573-576; 72. |
Possover, M, et al.; Risks, symptoms, and management of pelvic nerve damage secondary to surgery for pelvic organ prolapse: a report of 95 cases; Int Urogynecol J; 2011; 1485-1490; 22. |
Possover, M; A novel implantation technique for pudendal nerve stimulation for treatment of overactive bladder and urgency incontinence; J Minim Invasive Gynecol; 2014; 888-892; 21. |
Possover, M; Laparoscopic management of endopelvic etiologies of pudendal pain in 134 consecutive patients; J Urol; 2009; 1732-1736; 181. |
Possover, M; The laparoscopic implantation of neuroprothesis to the sacral plexus for therapy of neurogenic bladder dysfunctions after failure of percutaneous sacral nerve stimulation; Neuromodulation; 2010; 141-144; 13. |
Possover, M; The sacral Lion procedure for recovery of bladder/rectum/sexual functions in paraplegic patients after explantation of a previous Finetech-Brindley controller; J Minim Invasive Gynecol; 2009; 98-101; 16. |
Powell, CR, et al.; Long-term outcomes of urgency-frequency syndrome due to painful bladder syndrome treated with sacral neuromodulation and analysis of failures; J Urol; 2010; 173-176; 183. |
Pucciani, F; A review on functional results of sphincter-saving surgery for rectal cancer: the anterior resection syndrome; Updates Surg; 2013; 257-263; 65. |
Puccini, F, et al.; Sacral neuromodulation: an effective treatment for lower urinary tract symptoms in multiple sclerosis; Int Urogynecol J; 2016; 347-354; 27. |
Qin, C, et al.; Is constant current or constant voltage spinal cord stimulation superior for the suppression of nociceptive visceral and somatic stimuli? A rat model; Neuromodulation; 2012; 132-142; discussion 143; 15. |
Rahnama'l, MS, et al.; Evidence for prostaglandin E2 receptor expression in the intramural ganglia of the guinea pig urinary bladder; J Chem Neuroanat; 2015; 43-47; 64-65. |
Rai, BP, et al.; Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults; Cochrane Database Syst Rev; 2012; Cd003193; 12;Abstract. |
Ramage, L, et al.; A systematic review of sacral nerve stimulation for low anterior resection syndrome; Colorectal Dis; 2015; 762-771; 17. |
Ramundo, JM, et al.; State of the science: pathology and management of the patient with overactive bladder Ostomy Wound Manage; 2002; 22-27; 48. |
Rana, MV, et al.; Tripolar spinal cord stimulation for the treatment of abdominal pain associated with irritable bowel syndrome; Neuromodulation; 2013; 73-77; discussion 77; 16. |
Rashid, TG, et al.; Male incontinence: onabotulinum toxin A and sacral nerve stimulation; CurrOpin Urol; 2013; 545-551; 23. |
Rasmussen, NT, et al.; Successful use of sacral neuromodulation after failed bladder augmentation; Can Urol Assoc J; 2009; E49-50; 3. |
Ratto, C, et al.; Minimally invasive sacral neuromodulation implant technique: modifications to the conventional procedure; Dis Colon Rectum; 2003; 414-417; 46. |
Ratto, C, et al.; Sacral neuromodulation in the treatment of defecation disorders; Acta Neurochir Suppl; 2007; 341-350; 97;Abstract. |
Rawashdeh, YF, et al.; International Children's Continence Society's recommendations for therapeutic intervention in congenital neuropathic bladder and bowel dysfunction in children; Neurourol Urodyn; 2012; 615-620; 31. |
Reese, JN, et al.; Role of spinal metabotropic glutamate receptor 5 in pudendal inhibition of the nociceptive bladder reflex in cats; Am J Physiol Renal Physiol; 2015; F832-838; 308. |
Reitz, A, et al.; Topographic anatomy of a new posterior approach to the pudendal nerve for stimulation; Eur Urol 2007; 1350-1355; discussion 1355-1356; 51. |
Reyblat, P, et al.; Augmentation enterocystoplasty in overactive bladder: is there still a role?; Curr Urol Rep; 2010; 432-439; 11. |
Riazimand, SH, et al.; A rat model for studying effects of sacral neuromodulation on the contractile activity of a chronically inflamed bladder; BJU Int; 2004; 158-163; 94. |
Riazimand, SH, et al.; Interaction between neurotransmitter antagonists and effects of sacral neuromodulation in rats with chronically hyperactive bladder; BJU Int; 2005; 900-908; 96. |
Richter, EO, et al.; Percutaneous cephalocaudal implantation of epidural stimulation electrodes over sacral nerve roots-a technical note on the importance of the lateral approach; Neuromodulation; 2011; 62-67; discussion 67; 14. |
Ridout, AE, et al.; Tibial nerve stimulation for overactive bladder syndrome unresponsive to medical therapy; J Obstet Gynaecol; 2010; 111-114; 30. |
Rigaud, J, et al.; [Specific treatments for painful bladder syndrome]; Prog Urol; 2010; 1044-1053; 20;Abstract. |
Rimmer, CJ, et al.; Short-term Outcomes of a Randomized Pilot Trial of 2 Treatment Regimens of Transcutaneous Tibial Nerve Stimulation for Fecal Incontinence; Dis Colon Rectum; 2015; 974-982; 58. |
Ripetti, V, et al.; Sacral nerve neuromodulation improves physical, psychological and social quality of life in patients with fecal incontinence; Tech Coloproctol; 2002; 147-152; 6. |
Rittenmeyer, H; Sacral nerve neuromodulation (InterStim). Part I: Review of the InterStim system; Urol Nurs; 2008; 15-20; 28. |
Robaina Padron, FJ; [Surgical neuromodulation: new frontiers in neurosurgery]; Neurocirugia (Astur); 2008; 143-155; 19;Abstract. |
Robinson, D, et al.; Overactive bladder: diagnosis and management; Maturitas; 2012; 188-193; 71. |
Robinson, D, et al.; The management of overactive bladder refractory to medical therapy; Maturitas; 2013; 101-104; 75. |
Robinson, D, et al.; The medical management of refractory overactive bladder; Maturitas; 2013; 386-390; 74. |
Rogers, MJ, et al.; Propranolol, but not naloxone, enhances spinal reflex bladder activity and reduces pudendal inhibition in cats; Am J Physiol Regul Integr Comp Physiol; 2015; R42-49; 308. |
Rogers, MJ, et al.; Role of glycine in nociceptive and non-nociceptive bladder reflexes and pudendal afferent inhibition of these reflexes in cats; Neurourol Urodyn; 2015;Abstract. |
Romero Maroto, J, et al.; [Techniques and current practice of urodynamics. Problems and traps]; Actas Urol Esp; 2003; 75-91; 27;Abstract. |
Roth, TM; Blunt trauma leading to delayed extrusion of sacral nerve implant; Int Urogynecol J Pelvic Floor Dysfunct; 2009; 735-737; 20. |
Canbaz Kabay, S, et al.; Long term sustained therapeutic effects of percutaneous posterior tibial nerve stimulation treatment of neurogenic overactive bladder in multiple sclerosis patients: 12-months results; Neurourol Urodyn; 2015; Abstract. |
Cardarelli, S, et al.; Efficacy of sacral neuromodulation on urological diseases: a multicentric research project; Urologia; 2012; 90-96; 79. |
Cardot, V, et al.; [Guidelines for the treatment of urinary incontinence in women with reftactory idiopathic vesical hyperactivity using sacral neuromodulation]; Prog Urol; 2010; S161-169; 20 Suppl 2;Abstract. |
Carey, HV, et al.; Neuromodulation of intestinal transport in the suckling mouse; Am J Physiol; 1989; R481-486; 256; Abstract. |
Carey, M, et al.; Sacral nerve root stimulation for lower urinary tract dysfunction: overcoming the problem of lead migration; BJU Int; 2001; 15-18; 87. |
Carlson, JJ, et al.; Estimating the cost-effectiveness of onabotulinumtoxinA for neurogenic detrusor overactivity in the United States; Clin Ther; 2013; 414-424; 35. |
Carlucci, L, et al.; Functional variability of sacral roots in bladder control; J Neurosurg Spine; 2014; 961-965; 21. |
Carr, MC; Conservative nonsurgical management of spina bifida; Curr Urol Rep; 2010; 109-113; 11. |
Carrington, EV, et al.; A systematic review of sacral nerve stimulation mechanisms in the treatment of fecal incontinence and constipation; Neurogastroenterol Motil; 2014; 1222-1237; 26. |
Chaabane, W, et al.; Sacral neuromodulation for treating neurogenic bladder dysfunction: clinical and urodynamic study; Neurourol Urodyn; 2011; 547-550; 30. |
Chan, DK, et al.; Effective treatment of dyssynergic defecation using sacral neuromodulation in a patient with cerebral palsy; Female Pelvic Med Reconstr Surg; 2015; e27-29; 21;Abstract. |
Chancellor, MB, et al.; Principles of Sacral Nerve Stimulation (SNS) for the Treatment of Bladder and Urethral Sphincter Dysfunctions; Neuromodulation; 2000; 16-26; 3. |
Chandra, A, et al.; Neuromodulation of perineally transposed antropylorus with pudendal nerve anastomosis following total anorectal reconstruction in humans; Neurogastroenterol Motil; 2014; 1342-1348; 26. |
Chapple, C, et al.; The second-line management of idiopathic overactive bladder: what is the place of sacral neuromodulation and botulinum toxin-A in contemporary practice?; BJU Int; 2009; 1188-1190; 104. |
Chapple, CR, et al.; Surgery for detrusor overactivity; World J Urol; 1998; 268-273; 16. |
Chartier-Kastler, E, et al.; [Sacral neuromodulation with InterStim system: Results from the French national register]; Prog Urol; 2011; 209-217; 21;Abstract. |
Chartier-Kastler, E, et al.; [Update on the second line management of idiopathic overactive bladder]; Prog Urol; 2009; 530-537; 19;Abstract. |
Chartier-Kastler, E; Sacral neuromodulation for treating the symptoms of overactive bladder syndrome and non-obstructive urinary retention: >10 years of clinical experience; BJU Int; 2008; 417-423; 101. |
Chatoor, D, et al.; Constipation and evacuation disorders; Best Pract Res Clin Gastroenterol; 2009; 517-530; 23. |
Chen, G, et al.; Sacral neuromodulation for neurogenic bladder and bowel dysfunction with multiple symptoms secondary to spinal cord disease; Spinal Cord; 2014;Abstract. |
Chen, G, et al.; The inhibitory effects of pudendal nerve stimulation on bladder overactivity in spinal cord injury dogs is early stimulation necessary?; Neuromodulation; 2012; 232-237; discussion 237; 15. |
Chen, ML, et al.; Electrical stimulation of somatic afferent nerves in the foot increases bladder capacity in healthy human subjects; J Urol; 2014; 1009-1013; 191. |
Chen, SC, et al.; Pudendal neuromodulation improves voiding efficiency in diabetic rats; Neurourol Urodyn; 2013; 293-300; 32. |
Chiarioni, G, et al.; Neuromodulation for fecal incontinence: an effective surgical intervention; World J Gastroenterol; 2013; 7048-7054; 19. |
Choudhary, M, et al.; Inhibitory effects of tibial nerve stimulation on bladder neurophysiology in rats; Springerplus; 2016; 35; 5. |
Christopher J. Chermansky et al., “MP68-15 Electrical Stimulation of Afferent Nerves in the Foot Nith Transcutaneous Adhesive Pad Electrodes Improves Overactive Bladder Symptoms in Women”, The Journal of Urology, vol. 195, No. 4S, Supplement, Monday, May 9, 2016, 2 pages. |
Christopher J. Chermansky, “Foot/Hand Neuromodulation for Overactive Bladder (OAB) (FootStim)”; First Posted: Oct. 30, 2013; http://clinicaltrials.govict2/show/NCT01972061; pp. 1-5. |
Colaco, M, et al.; Current guidelines in the management of interstitial cystitis; Transl Androl Urol; 2015; 677-683; 4. |
Collins, SM; Is the irritable gut an inflamed gut?; Scand J Gastroenterol Suppl; 1992; 102-105; 192;Abstract. |
Comiter, CV; Conscious Neuromodulation of the Bladder before Clinical Use; J Urol; 2015; 16-17; 194. |
Comiter, CV; Sacral neuromodulation for the symptomatic treatment of refractory interstitial cystitis: a prospective study; J Urol; 2003; 1369-1373; 169. |
Corcos, J, et al.; Canadian Urological Association guidelines on urinary incontinence; Can J Urol; 2006; 3127-3138; 13;Abstract. |
Cornu, JN; Actual treatment of overactive bladder and urge urinary incontinence; Minerva Urol Nefrol; 2013; 21-35; 65;Abstract. |
Costa, JA, et al.; Spinal cord neuromodulation for voiding dysfunction; Clin Obstet Gynecol; 2000; 676-688; 43. |
Craggs, M, et al.; Neuromodulation of the lower urinary tract; Exp Physiol; 1999; 149-160; 84. |
Craggs, MD; Objective measurement of bladder sensation: use of a new patient-activated device and response to neuromodulation; BJU Int; 2005; 29-36; 96 Suppl 1. |
Crock, LW, et al.; Central amygdala metabotropic glutamate receptor 5 in the modulation of visceral pain; J Neurosci; 2012; 14217-14226; 32. |
Dahms, SE, et al.; Sacral neurostimulation and neuromodulation in urological practice; Curr Opin Urol; 2000; 329-335; 10. |
Daneshgari, F, et al.; Future directions in pelvic neuromodulation; Urol Clin North Am; 2005; 113-115, viii; 32. |
Daneshgari, F; Applications of neuromodulation of the lower urinary tract in female urology; Int Braz J Urol; 2006; 262-272; 32. |
Daniels, DH, et al.; Sacral neuromodulation in diabetic patients: success and complications in the treatment of voiding dysfunction; Neurourol Urodyn; 2010; 578-581; 29. |
Dasgupta, R, et al.; Changes in brain activity following sacral neuromodulation for urinary retention; J Urol; 2005; 2268-2272; 174. |
Dasgupta, R, et al.; The management of female voiding dysfunction: Fowler's syndrome—a contemporary update Curr Opin Urol; 2003; 293-299; 13. |
Davis, T, et al.; Sacral neuromodulation outcomes for the treatment of refractory idiopathic detrusor overactivity stratified by indication: Lack of anticholinergic efficacy versus intolerability; Can Urol Assoc J; 2013; 176-178; 7. |
De Boer, TA, et al.; [Male urinary incontinence]; Ned Tijdschr Geneeskd; 2008; 797-802; 152;Abstract. |
De Gennaro, M, et al.; Current state of nerve stimulation technique for lower urinary tract dysfunction in children; J Urol; 2011; 1571-1577; 185. |
De Gennaro, M, et al.; Percutaneous tibial nerve neuromodulation is well tolerated in children and effective for treating refractory vesical dysfunction; J Urol; 2004; 1911-1913; 171. |
De Groat, WC, et al.; Impact of Bioelectronic Medicine on the Neural Regulation of Pelvic Visceral Function; Bioelectron Med; 2015; 25-36; 2015. |
De Seze, M, et al.; [Peripheral electrical stimulation in neurogenic bladder]; Ann Readapt Med Phys; 2008; 473-478; 51;Abstract. |
Deffieux, X, et al.; [Voiding dysfunction after surgical resection of deeply infiltrating endometriosis: pathophysiology and management]; Gynecol Obstet Fertil; 2007; S8-13; 35 Suppl 1;Abstract. |
Aksu et al.; State dependent excitability changes of spinal flexor reflex in patients with restless legs syndrome secondary to chronic renal failure; Sleep Medicine; 2002; 3(5); 427-430. |
Bucher, SF, et al.; Reflex studies and MRI in the restless legs syndrome; Acta Neurologica Scandinavica; 1996; 94 2); 145-150. |
Cogiamanian et al.; Transcutaneous spinal cord direct current stimulation inhibits the lower limb nociceptive iexion reflex in human beings; Pain; 2011; 152(2); 370-375. |
Dafkin, C, et al.; Circadian variation of flexor withdrawal and crossed extensor reflexes in patients with restless legs syndrome; Journal of Sleep Research; 2018; 27(5); 1-7. |
Entezari-Taher, M, et al.; Changes in excitability of motor cortical circuitry in primary restless legs syndrome Neurology; 1999; 53(6); 1201-1205. |
Garrison, MK, et al.; Flexor reflex decreases during sympathetic stimulation in chronic human spinal cord injury Experimental Neurology; 2009; 219(2); 507-515. |
Gemignani, F; Restless legs syndrome from the spinal cord perspective: A flexor reflex circuitopathy?; Journal of Sleep Research; 2018; 27(5); 1-2. |
Gregori; Suppression of flexor reflex by transcutaneous electrical nerve stimulation in spinal cord injured patients; Muscle and Nerve; 1998; 21(2); 166-172. |
Guo, S, et al.; Restless legs syndrome: From pathophysiology to clinical diagnosis and management; Frontiers in Aging Neuroscience; 2017; 9(JUN); 1-14. |
Heide, AC, et al.; Effects of transcutaneous spinal direct current stimulation in idiopathic restless legs patients; Brain Stimulation; 2014; 7(5); 636-642. |
Karatas, M; Restless legs syndrome and periodic limb movements during sleep: Diagnosis and treatment; Neurologist; 2007; 13(5); 294-301. |
Koo, BB, et al.; Restless Legs Syndrome: Current Concepts about Disease Pathophysiology; Tremor and other Hyperkinetic Movements; 2016; 6(0); 401. |
Krueger; Restless Legs Syndrome and Periodic Movements of Sleep; Mayo Clinic Proceedings; 1990; 65(7); ?99-1006. |
Merkl, et al.; Vagus nerve stimulation improves restless legs syndrome associated with major depression: A case eport [3]; Journal of Clinical Psychiatry; 2007; 68 (4); 635-636. |
Ninos et al.; Restless Legs Syndrome Fact Sheet Restless Legs Syndrome Fact Sheet What is restless legs syndrome; 2019; 1-8. |
Ristanovi et al.; Nonpharmacologic treatment of periodic leg movements in sleep; Archives of Physical Medicine and Rehabilitation; 1991; 72(6); 385-389. |
Rizzo, V, et al.; Dopamine agonists restore cortical plasticity in patients with idiopathic restless legs syndrome Movement Disorders; 2009; 24(5); 710-715. |
Roby-Brami, A, et al.; Inhibitory effects on flexor reflexes in patients with a complete spinal cord lesion; ExperimentalBrain Research; 1992; 90(1); 201-208. |
Rozeman, AD, et al.; Effect of sensory stimuli on restless legs syndrome: A randomized crossover study; Journal of Clinical Sleep Medicine; 2014; 10(8); 893-896. |
Sharon, D, et al.; Restless Legs Syndrome and Periodic Limb Movement Disorder in Children; Journal of Child Science; 2019; 9(1); E38-E49. |
Yam, MF, et al.; General pathways of pain sensation and the major neurotransmitters involved in pain regulation; International Journal of Molecular Sciences; 2018; 19(8). |
Yogi A. Patel; Kilohertz Electrical Stimulation Nerve Conduction Block: Effects of Electrode Surface Area; IEEET-Ransactions on Neural Systems and Rehabilitation Engineering, vol. 25, No. 10, Oct. 2017. |
Number | Date | Country | |
---|---|---|---|
20190336763 A1 | Nov 2019 | US |
Number | Date | Country | |
---|---|---|---|
61828981 | May 2013 | US | |
62697692 | Jul 2018 | US | |
62697702 | Jul 2018 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14893946 | US | |
Child | 15650228 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15650228 | Jul 2017 | US |
Child | 16385361 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16385361 | Apr 2019 | US |
Child | 16511390 | US |